This post will describe the conditions that can make ingesting fiber a problem for affected people. I will briefly cover the condition and common symptoms in hopes that anyone not yet diagnosed may recognize them and seek appropriate care. Finally, we will discuss sources of fiber better tolerated by affected people and foods in general that can worsen their digestive symptoms.

When Bacteria Set Up Shop in the Wrong Place

Your digestive tract is not uniform, different sections do different jobs and the populations of microorganisms living in each section are different. Your large intestine (the colon) is home to trillions of bacteria. That is where most fiber fermentation is supposed to happen, and the byproducts of that fermentation, including short-chain fatty acids, are genuinely beneficial.

Your small intestine is different: this is where most nutrient absorption takes place, and under normal conditions it hosts relatively few bacteria. Small intestinal bacterial overgrowth (SIBO) is what happens when bacteria proliferate in the small intestine where they do not belong. These misplaced organisms ferment food before your body has a chance to absorb it, producing gas, pain, and digestive disruption in the wrong location.

Small intestinal fungal overgrowth (SIFO) is the same concept with a different organism: fungal species, most commonly Candida, overgrow in the small intestine. SIBO and SIFO share risk factors, produce overlapping symptoms, and frequently coexist. According to a 2015 review in Current Gastroenterology Reports, SIFO was found in up to 34% of patients who also had SIBO (Erdogan & Rao, 2015). One important distinction: SIBO has a substantially stronger evidence base. SIFO is a real and emerging area of research, but the literature is thinner and no validated non-invasive diagnostic test exists for it.

How Common Is This?

The true prevalence in the general population is unclear. A comprehensive review in Cureus estimated that SIBO has been detected in anywhere from 0 to 20% of healthy controls, depending on the diagnostic method used (Achufusi et al., 2020). That wide range tells as much about the limitations of current testing as it does about the condition itself.

Where the numbers become more clinically relevant is in people with digestive symptoms. A 2020 systematic review and meta-analysis of 25 case-control studies, published in the American Journal of Gastroenterology, found that SIBO was present in approximately 31% of patients with irritable bowel syndrome (IBS), with IBS patients roughly 3.7 times more likely to have SIBO than controls. When the analysis was restricted to the 15 highest-quality studies, that association grew stronger (Shah et al., 2020).

For SIFO, two studies found that roughly one in four patients with unexplained gastrointestinal symptoms had fungal overgrowth on duodenal aspirate culture: 26% in one study (24 of 94 patients) and 25% in a second (38 of 150 patients). The most common organisms were Candida species (Erdogan & Rao, 2015; Jacobs et al., 2013). The findings are preliminary but suggest SIFO is not rare among people with chronic, unexplained digestive symptoms.

A systematic review and meta-analysis in Scientific Reports found that a significant proportion of patients who meet the diagnostic criteria for IBS in specialty care actually have identifiable organic conditions, including SIBO, bile acid diarrhea, and carbohydrate malabsorption (Poon et al., 2022). The overlap between IBS symptoms and SIBO is precisely why SIBO is frequently missed.

Common SIBO/SIFO Symptoms

The symptoms of SIBO and SIFO are nonspecific, which is a large part of the diagnostic challenge. They include:

• Bloating and abdominal distension

• Excessive gas and flatulence

• Abdominal pain

• Diarrhea (more common with hydrogen-dominant SIBO)

• Constipation (more common with methane-dominant SIBO)

• Nausea and belching

Every one of these symptoms also appears in IBS, food intolerances, and a dozen other conditions. A take away point: if you have been diagnosed with IBS and your symptoms are not improving, or if increasing your fiber intake is making you worse, SIBO is worth investigating.

Why This Matters

The risk factors for SIBO are commonly found in people with metabolic syndrome: proton pump inhibitor (PPI) use, diabetes, and conditions that affect gut motility. A 2013 study in Alimentary Pharmacology and Therapeutics found that both PPI use and intestinal dysmotility were independent risk factors for bacterial and fungal overgrowth in the small intestine (Jacobs et al., 2013). The 2020 American College of Gastroenterology (ACG) Clinical Guideline on SIBO identifies diabetic enteropathy as a well-established predisposing factor (Pimentel et al., 2020).

If you are managing metabolic syndrome, you may be taking a PPI for reflux and you may have diabetes or pre-diabetes. Both of those conditions independently raise your risk for SIBO. Prior abdominal surgery, chronic narcotic use, along with age-related decline in gastric acid production and intestinal motility are additional risk factors.

Getting Tested

Breath testing is the most common diagnostic method. Glucose and lactulose hydrogen breath tests measure the gases produced when bacteria ferment carbohydrates. If gas production rises above a threshold within a specific time window, the test is considered positive.

The ACG Clinical Guideline acknowledges that both glucose and lactulose breath tests have significant limitations in sensitivity and specificity, meaning they miss a meaningful number of cases and sometimes produce false positives (Pimentel et al., 2020). The gold standard, jejunal aspirate culture (collecting fluid directly from the small intestine), is invasive and not widely available. For SIFO, no validated non-invasive test exists at all.

If you recognize these symptoms, consult a gastroenterologist. A negative breath test does not definitively rule SIBO out; your physician can interpret the results in the context of your full clinical picture.

Treatment Is Physician-Directed

Treatment for SIBO centers on antibiotics: rifaximin is the most studied option. A 2017 meta-analysis in Alimentary Pharmacology and Therapeutics, covering 32 studies and over 1,300 patients, found an overall eradication rate of approximately 71% (Gatta & Scarpignato, 2017). For methane-dominant cases, rifaximin is sometimes combined with neomycin. SIFO is treated with antifungals, typically fluconazole.

Recurrence is common because the underlying predisposing factors, whether PPI use, diabetes, dysmotility, or structural issues, often persist after treatment. This is not a reason to understand that long-term dietary management matters even after a successful antibiotic course.

The wellness and supplement space around SIBO is heavily marketed. Elemental diets and herbal antimicrobials are promoted aggressively online, sometimes with legitimate preliminary evidence, sometimes without. The evidence base for these alternatives is substantially weaker than for rifaximin. If you are exploring them, do so under medical supervision, not based on an influencer’s protocol.

A Nutritional Red Flag

Severe or longstanding SIBO can impair your body’s ability to absorb certain nutrients. The fat-soluble vitamins (A, D, E, and K), vitamin B12, and iron are the most commonly affected. If you have unexplained deficiencies in any of these nutrients alongside chronic digestive symptoms, raise both issues with your physician, they may be connected. Supplementation decisions should be made in consultation with your treating doctor, not independently.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Why Standard Fiber Advice Backfires

The issue is not fiber itself, is a specific category of carbohydrates called FODMAPs, an acronym for fermentable oligosaccharides, disaccharides, monosaccharides, and polyols. These are short-chain carbohydrates that are poorly absorbed in the small intestine and rapidly fermented by gut bacteria.

In a healthy gut, most FODMAP fermentation happens in the colon, where it produces beneficial compounds. In SIBO, the overgrown bacteria in the small intestine ferment these carbohydrates before your body can absorb them, producing gas, pain, and distension in a location not designed to handle it.

The low-FODMAP diet is the most evidence-based dietary approach for managing these symptoms. It was developed at Monash University in Australia using rigorous laboratory food testing, and systematic reviews support its use for short-term symptom improvement in IBS, with up to 70% of patients experiencing meaningful relief (Whelan & Staudacher, 2022). Evidence for its use specifically in SIBO, as opposed to IBS more broadly, is described in a 2022 review in Current Opinion in Pharmacology as “scant,” meaning the diet has been proposed to help but no studies have confirmed or denied whether it prevents SIBO recurrence (Biesiekierski & Tuck, 2022). The rationale is extrapolated from the strong IBS evidence base, which is reasonable given the symptom overlap.

The Five FODMAP Subgroups

FODMAPs are not a single substance. They are five categories of carbohydrates, each found in different foods:

• Fructans: wheat, rye, barley, onion, garlic, artichokes, inulin, chicory root

• Galacto-oligosaccharides (GOS): legumes, beans, lentils, chickpeas

• Lactose: milk, soft cheeses, yogurt, ice cream

• Excess fructose: apples, pears, mango, watermelon, honey, agave, high-fructose corn syrup

• Polyols: stone fruits (peaches, plums, cherries), mushrooms, cauliflower, sugar alcohols (sorbitol, mannitol, xylitol)

Look at that list carefully: onion, garlic, wheat, legumes, apples, pears, cauliflower. These are foods that appear on every “eat more of this” list ever published, including in this publication. For most people, they are excellent choices. For people with SIBO, they are fuel for the overgrown organisms in the wrong part of the gut.

The Three-Phase Approach

The low-FODMAP diet is not a permanent elimination diet. It is a structured, three-phase clinical tool:

Phase 1, Elimination: Strict reduction of high-FODMAP foods for two to six weeks to establish whether symptoms improve.

Phase 2, Reintroduction: Systematic, one-at-a-time reintroduction of each FODMAP subgroup to identify which specific carbohydrates trigger your symptoms and at what dose.

Phase 3, Personalization: A long-term eating pattern that avoids only your specific triggers at your specific threshold doses, while reincorporating everything else.

This process is best done with the guidance of a dietitian experienced in FODMAP management. There is a practical reason for this beyond general caution: serving size is a critical variable that most internet food lists get wrong. A food can be low-FODMAP at one portion size and high-FODMAP at another. Reliable guidance requires portion-specific information, which is what the Monash University FODMAP app provides based on their laboratory testing.

The Downsides of Prolonged Restriction

Staying in the elimination phase too long has documented downsides. Multiple studies have found consistent reductions in Bifidobacteria abundance during strict FODMAP elimination, along with decreases in butyrate-producing bacteria and mucus-associated bacteria (StatPearls, 2026). There are also potential nutritional gaps in calcium, B vitamins, iron, and folic acid during prolonged restriction. These effects appear to be mitigated when patients move through reintroduction and personalization or use probiotic supplementation. The elimination phase is temporary by design.

What to Reduce Now

If you suspect SIBO is behind your symptoms, the following high-FODMAP foods are the most likely culprits. Reducing them is a reasonable, low-risk first step while you pursue a proper medical evaluation. This is not a substitute for diagnosis, it is something you can do today that may provide symptom relief and useful information for your physician.

• Onion and garlic (among the most potent FODMAP sources, and present in most prepared foods)

• Wheat-based bread, pasta, and cereals

• Legumes: beans, lentils, chickpeas

• Apples, pears, stone fruits, mango, dried fruits

• Mushrooms and cauliflower

• Honey, agave, high-fructose corn syrup

• Sugar alcohols in sugar-free gum, mints, and diet products (sorbitol, mannitol, xylitol)

Better Fiber Choices

Having SIBO does not mean abandoning fiber, it means choosing fiber sources that provide bulk and nutritional benefit without rapidly feeding the overgrown organisms in your small intestine. The following foods are generally well-tolerated at standard serving sizes.

Vegetables (cooked preferred)

Cooking breaks down fiber structure, improving digestibility and reducing fermentability. Cooked vegetables are generally better tolerated than raw in SIBO.

• Carrots: No measurable FODMAPs, one of the safest options.

• Zucchini, spinach, bell peppers, green beans: Well-tolerated at typical serving sizes.

• Eggplant: Tolerated at moderate portions.

• Lettuce and salad greens, tomatoes, cucumber: Generally safe raw or cooked.

• Potatoes: Plain preparation, a reliable, well-tolerated starch.

Fruits (moderate portions)

Choose low-fructose, low-sorbitol options and keep portions moderate.

• Blueberries, strawberries, raspberries: Excellent choices with strong nutritional profiles.

• Oranges, mandarins, kiwi: Well-tolerated citrus and tropical options.

• Pineapple, cantaloupe, grapes: Good variety options.

• Slightly underripe bananas: Better tolerated than fully ripe bananas, which have higher FODMAP content.

Grains and Starches

• White rice (freshly cooked): A note here: cooled rice forms resistant starch that bacteria can ferment, so freshly cooked is better tolerated than leftover rice.

• Quinoa: A complete protein source and generally well-tolerated grain alternative.

• Oats: Tolerated at moderate portions for most people.

Seeds and Supplemental Fiber

• Chia seeds and flaxseeds: Provide fiber and omega-3 fatty acids without high FODMAP content.

• Psyllium husk: A soluble fiber that is generally well-tolerated and has a gentle effect on the digestive system. The ingredient in many OTC fiber products for constipation (Metamicil for example).

A Fiber Supplement Worth Knowing About

Partially hydrolyzed guar gum (PHGG) deserves specific mention because it is the one supplemental fiber with randomized controlled trial (RCT) evidence showing benefit during SIBO treatment. A 2010 RCT published in Alimentary Pharmacology and Therapeutics studied 77 patients with SIBO. Rifaximin combined with PHGG at 5 grams per day achieved an eradication rate of about 87%, compared to about 62% for rifaximin alone, a statistically significant difference. PHGG alone was essentially ineffective, with only about 7% eradication (Furnari et al., 2010).

PHGG is not a standalone therapy, its value is as an adjunct to antibiotic treatment. A separate RCT found that 6 grams per day of PHGG for 12 weeks significantly improved bloating in IBS patients compared to placebo, with no significant side effects (Niv et al., 2016).

Side effects of PHGG are mild and transient: some initial gas and bloating that typically resolve.

Caution if using taking metformin: large doses of guar gum (10 grams or more per day) may reduce metformin absorption. The dose studied in the Furnari trial was 5 grams per day, which is below the interaction threshold. If you are considering PHGG, take it at least two hours apart from metformin and discuss it with your physician.

What You Can Do Today

Understanding which fiber sources to choose while pursuing diagnosis can make a real difference in your daily comfort. Individual variation is real, and systematic reintroduction under professional guidance is how you find what works for your body.

A few principles to carry forward:

Cook your vegetables. Cooking generally improves tolerance by breaking down fiber structure and reducing fermentability.

Watch serving sizes. A food that is safe at a small portion may cause problems at a larger one. The Monash University FODMAP app provides portion-specific guidance and is a practical resource if you are pursuing this path with your provider.

Do not stay in elimination mode permanently. The restriction phase is a diagnostic tool, not a long-term diet. Work with a dietitian to move through reintroduction and personalization.

Get evaluated. If you recognize these symptoms, especially if fiber is making you worse, the first step is a conversation with your doctor or gastroenterologist. This is not a condition you diagnose or treat on your own, your physician can assess the full picture and determine next steps.

It Takes An Active Community

First, I want to thank Mr. Hamilton Creek for bringing this important issue to my attention, his thoughtful comments were the reason for this article.

The main objective of this site is to inform but also to foster a community with open two-way communication. If you have questions or want to learn more about a particular topic, please don’t hesitate to leave me a comment.

Found this article useful? Share your thoughts. Join the conversation below.

Subscribe now

What follows is a category-by-category reference covering every major food group that belongs in a metabolically healthy diet. This is the dietary education that should have been available to you decades ago.

Part Nine will show you how to assemble these building blocks into a personalized, sustainable dietary plan.

Protein, You Cannot Afford to Ignore It

Protein is the only macronutrient the body cannot store, what is not used for structural repair, enzyme synthesis, immune function, and hormone production is either oxidized for energy or converted to glucose or fat. This means protein must be consumed consistently, at adequate amounts, every day.

The federal recommended dietary allowance (RDA) of 0.8 grams per kilogram of body weight per day has anchored dietary guidance for decades. That figure represents the minimum required to prevent deficiency in sedentary healthy adults, not an optimal intake for metabolic health, lean mass preservation, or satiety. A March 2026 Stanford Medicine commentary confirmed that newly revised dietary guidelines now recommend 1.2 to 1.6 grams per kilogram per day for general adults, reflecting a growing consensus that the 0.8g/kg figure represents a survival floor, not a target (Stanford Medicine News, 2026).

Requirements differ further by population. The PROT-AGE Study Group, an international consortium convened by the European Union Geriatric Medicine Society, recommends 1.0 to 1.2 grams per kilogram per day for healthy adults over 65, rising to 1.2 to 1.5 grams per kilogram per day for older adults managing acute or chronic disease, and up to 1.6 grams per kilogram per day for those with sarcopenia, with emphasis on distributing intake across multiple daily meals to maximally stimulate muscle protein synthesis (Bauer et al., JAMDA, 2013; Landi et al., J Gerontol A, 2023).

If you carry excess weight, these calculations should use your target body weight, not your current weight. If you have significant chronic kidney disease (CKD), protein targets require individualized physician guidance and are beyond the scope of this article.

Protein also has the highest thermic effect of any macronutrient: approximately 20 to 30 percent of its caloric value is expended in digestion and processing. This means protein delivers fewer net calories per gram than the label suggests, while simultaneously producing the most sustained satiety response per calorie of any macronutrient.

Practical protein sources: Eggs, poultry, fish and shellfish, lean red meat, Greek yogurt, cottage cheese, legumes (lentils, chickpeas, black beans), tofu and tempeh, edamame, and dairy. Variety across these sources ensures complementary amino acid profiles and avoids the micronutrient gaps that come with excessive reliance on any single source.

A Word On Eggs

A 2025 umbrella review in Nutrition, Metabolism and Cardiovascular Diseases concluded that the longtime restriction on egg consumption has been progressively mitigated as higher-quality studies have consistently failed to demonstrate strong cardiovascular outcome associations (Carter et al., 2025). A systematic review of 23 randomized controlled trials (RCTs) found nonsignificant effects of increasing egg consumption on cardiovascular disease risk markers. The 2015 to 2020 US Dietary Guidelines removed the previous 300mg per day dietary cholesterol restriction entirely. A 2025 RCT in the American Journal of Clinical Nutrition confirmed that saturated fat has a greater independent impact on low-density lipoprotein (LDL) cholesterol than dietary cholesterol from eggs: eggs contain minimal saturated fat per egg, making them nutritionally distinct from other high-cholesterol foods (AJCN, 2025).

Current evidence supports up to one egg per day as safe for the general healthy population. Evidence above that threshold is limited and heterogeneous: a reasonable position is that moderate consumption beyond one per day is not associated with clear harm in most populations, but the evidence is sparse here. One egg per day is the well-supported recommendation.

Fats, Quality Over Quantity

The dietary position that fat intake drives cardiovascular disease dominated nutrition policy for four decades. It was not entirely wrong but was incomplete, and the incompleteness caused real harm.

The De Novo Lipogenesis Correction

The liver synthesizes 70 to 80 percent of circulating cholesterol endogenously from acetyl-CoA, a substrate derived primarily from excess carbohydrate metabolism and caloric overconsumption, not from dietary fat intake (Endotext, NIH Bookshelf, 2026). This process is called de novo lipogenesis (DNL), one of the most important and least understood pieces of metabolic biology.

When you consume more carbohydrates than your body can use for immediate energy or glycogen storage, the liver converts the surplus to fat. High-carbohydrate diets raise serum triglycerides by 30 to 40 percent through carbohydrate-induced hypertriglyceridemia, an effect observable within five days of high carbohydrate intake (JCI, 1999).

The practical implication: reducing caloric overconsumption and excess refined carbohydrate intake is a more powerful and direct target for dyslipidemia management than dietary fat restriction alone.

Saturated Fat, The Exception

Saturated fat is a genuine independent contributor to LDL elevation and should be moderated. The evidence for this is solid. The error was not in implicating saturated fat, it was ignoring the carbohydrate-driven pathway that accounts for most of the liver’s cholesterol and triglyceride output.

Extra-Virgin Olive Oil: The Evidence-Based Standard

Extra-virgin olive oil (EVOO) is produced through mechanical cold pressing without chemical treatment, preserving its full complement of bioactive phenolics alongside approximately 75 percent oleic acid content. These compounds provide anti-inflammatory, antioxidant, insulin-sensitizing, cardioprotective, and antiatherogenic activity that refined olive oils cannot replicate. Refined olive oil and olive oil blends undergo processing that destroys polyphenol content. Only extra-virgin olive oil delivers the full benefits.

The PREDIMED trial of 7,477 high cardiovascular risk individuals found that a Mediterranean diet supplemented with EVOO produced significantly lower incidence of major cardiovascular events including stroke, myocardial infarction, and cardiovascular mortality compared to a reduced-fat control diet (JACC, 2020). A large US prospective cohort study found that replacing other types of fat with olive oil was associated with lower risk of total cardiovascular disease and coronary heart disease.

Use EVOO for cooking and as a finishing oil on vegetables, salads, and grains. The evidence for its benefit is among the strongest in the dietary literature.

Vegetables and Fruits, The Foundation

No dietary pattern with a strong evidence base omits vegetables and fruits. There is no credible metabolic health argument for reducing them.

A 2024 study in Nutrients found that daily intake of two or more servings of vegetables is associated with lower prevalence of metabolic syndrome in older adults (Cubas-Basterrechea et al.). Systematic reviews confirm the role of vegetables, fruits, and berries in reducing risk of cardiovascular disease, gastric and lung cancer, and all-cause mortality with evidence graded as strong for these specific outcomes (Food and Nutrition Research, 2024; Critical Reviews in Food Science and Nutrition, 2019).

Flavonoids, particularly anthocyanins found in berries, red and purple produce, are associated with reduced cardiovascular disease risk, reduced all-cause mortality, and direct effects on glucose metabolism and LDL cholesterol in RCT data. Carotenoids provide anti-inflammatory and antioxidant effects independent of their pro-vitamin A activity. Fiber and polyphenols slow gastric emptying, blunt postprandial glucose excursions, and feed the gut microbiome.

One practical point worth emphasizing: the peel of edible-skinned fruits and vegetables contains substantially more fiber and polyphenol content than the flesh beneath it. Apple peel provides approximately twice the fiber content of peeled apple per equivalent weight. Eat the peel wherever it is practical and safe to do so. Wash produce thoroughly, for thin-skinned, high-pesticide-residue fruits and vegetables choosing organic is a reasonable consideration.

Aim for variety across colors. Different pigments reflect different phytochemical families. A plate that looks the same every day is a plate that delivers the same narrow subset of the available benefit.

Starches and Grains Are Energy, Not Enemies

Carbohydrates became dietary villains by association with sugar and refined grains, which leads people to eliminate legitimate whole food sources of energy.

Starches and whole grains are important dietary energy sources. Their metabolic impact depends almost entirely on the degree of processing and preparation. Whole grains retain the fiber, vitamins, minerals, and phytochemicals stripped during refinement. A 2-serving-per-day increment in whole grain consumption is associated with a 21 percent reduction in type 2 diabetes risk in epidemiological data, a magnitude consistent across multiple large cohort studies (StatPearls, 2025).

The real bread versus industrial bread distinction is the clearest illustration of this principle. Real bread, a baguette or sourdough crusty bread, is a minimally processed whole food. Industrial sandwich bread is an ultraprocessed food (UPF) product: it contains emulsifiers, dough conditioners, preservatives, added sugars, and industrial fats that categorically separate it from its whole food counterpart.

Cooking and cooling starchy foods converts a portion of digestible starch to resistant starch, which behaves metabolically more like fiber: it resists digestion in the small intestine, reaches the colon intact, and serves as a prebiotic substrate. The full discussion of this mechanism and how to apply it practically is covered in the dietary hacks article published separately in this series.

Practical whole grain and starch sources: Oats, barley, quinoa, brown and wild rice, whole grain pasta, farro, buckwheat, whole grain bread made from whole flour, potatoes and sweet potatoes with skin, legumes.

Nuts, A Handful That Earns Its Place

The evidence for daily nut consumption is among the most consistent and robust in the dietary literature. An umbrella review of 89 articles found that 28 grams per day of nuts, approximately one small closed handful, compared with eating no nuts was associated with a 21 percent reduction in cardiovascular disease risk, a 22 percent reduction in all-cause mortality, and an 11 percent reduction in cancer mortality (Balakrishna et al., Adv Nutr, 2022). The PREDIMED trial confirmed cardiovascular protection from daily nut consumption equivalent in magnitude to the EVOO supplementation arm compared to the low-fat control.

Walnuts and almonds have the strongest individual evidence bases. Walnuts carry a European Union-approved health claim for improvement of endothelium-dependent vasodilation, supported by their polyunsaturated fatty acid and plant-based omega-3 fatty acid content. Almonds dose-dependently reduce LDL cholesterol through their monounsaturated fat, phytosterol, fiber, and vitamin E content, and improve fasting and postprandial glucose and insulin resistance markers (J Am Heart Assoc, 2015). A 2025 RCT in adults with metabolic syndrome found that whole dry-roasted almonds consumed as snacks produced beneficial changes in total cholesterol, LDL, intestinal inflammation biomarkers, and vitamin E status (ScienceDirect, 2025). The US Food and Drug Administration (FDA) has issued a qualified health claim for nut consumption and reduced coronary artery disease risk.

The 28-gram portion is the evidence-supported quantity. The evidence applies to plain, raw, or dry-roasted nuts with minimal salt. Honey-roasted, flavored, and commercially seasoned nut products are UPF products, the metabolic benefit documented in the literature does not extend to them.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Fiber, The Missing Dietary Link

Only 5 percent of Americans meet the fiber recommended dietary allowance. The World Health Organization (WHO) recommends 25 to 30 grams per day. The average American consumes approximately 15 grams (StatPearls, 2025; Front Nutr, 2024).

Fiber has documented roles in postprandial glucose regulation, LDL cholesterol reduction, gut microbiome support, satiety, and long-term diabetes and cardiovascular disease risk reduction. Chronic fiber deficiency is a chronic metabolic liability.

Fiber exists in two forms with distinct mechanisms.

Soluble fiber: beta-glucan in oats and barley, pectin in apples and citrus fruits, forms a viscous gel in the gut that slows gastric emptying, blunts postprandial glucose excursions, and binds bile acids in the small intestine. Bile acid binding forces the liver to synthesize new bile acids from circulating cholesterol, lowering serum LDL. Soluble fiber also serves as a prebiotic substrate: gut bacteria ferment it into short-chain fatty acids (SCFAs) including butyrate, which reduce colonic inflammation and support the intestinal barrier.

Insoluble fiber: cellulose, lignin, and hemicellulose in whole grains and vegetables, does not dissolve and produces the strongest long-term diabetes risk reduction in epidemiological data. The 21 percent reduction in diabetes risk per 2-serving-per-day increment in whole grain consumption cited in the grains section is driven substantially by this insoluble fiber content.

Consolidated fiber sources across food categories:

• Soluble: oats, barley, apples, pears, citrus fruits, legumes (lentils, chickpeas, black beans), psyllium husk, flaxseed

• Insoluble: whole wheat products, brown rice, quinoa, vegetables (broccoli, carrots, leafy greens), nuts and seeds, potato and fruit skins

One important instruction: increase fiber intake gradually. Rapid increases can cause gastrointestinal discomfort, bloating, gas, cramping, entirely avoidable with a measured approach. Add one to two servings of high-fiber food per week and increase water intake concurrently, increase gradually as tolerated.

Sugars, Different Sources

Table sugar (sucrose) at moderate intake is not an independent cause of metabolic disease. The metabolic harm attributed to sugar derives overwhelmingly from the quantities in which it appears in UPF and sugar-sweetened beverages, not from a teaspoon in coffee or modest use in home cooking. The WHO recommendation is to keep free sugars below 10 percent of total daily caloric intake, with additional benefit observed below 5 percent (WHO, 2015). A moderate quantity of table sugar used thoughtfully in the context of an otherwise whole-food diet is not what is driving the metabolic disease epidemic.

Brown sugar and raw sugar: are compositionally 88 to 97 percent sucrose. They offer no meaningful nutritional or metabolic advantage over white sugar at equivalent quantities, despite their premium price and implicit health positioning. While the difference in processing is real, the difference in metabolic impact at the quantities used is negligible.

The natural sweetener: Agave nectar marketed as a low-glycemic natural alternative to sugar, contains 70 percent or more fructose, higher than high-fructose corn syrup. Its low glycemic index (GI) reflects the fact that fructose does not acutely raise blood glucose the way glucose does. Fructose drives hepatic DNL directly raising triglycerides, promoting insulin resistance, and contributing to non-alcoholic fatty liver disease (NAFLD). Agave is potentially the worst available sweetener choice, despite its health marketing.

Honey: contains approximately 40 percent fructose, 30 percent glucose, and 20 percent water alongside approximately 181 bioactive compounds including polyphenols. Some controlled trials suggest modestly smaller postprandial glucose excursions and marginal lipid benefits for raw unprocessed varieties. Honey remains predominantly sugar and should be consumed in equivalent moderation. The marginal benefit is real but modest.

Real maple syrup: is 97 percent sucrose equivalent to table sugar. It is also a single-ingredient minimally processed whole food, and it is categorically superior to artificial pancake syrup, which is a UPF product containing high-fructose corn syrup, caramel color, artificial flavors, and preservatives, despite similar caloric content per serving.

Artificial sweeteners are addressed in the Diet Soda article published separately in this series.

High Potassium Foods

Potassium is one of the most recommended dietary targets in international cardiovascular and metabolic guidelines, and one of the most consistently underconsumed minerals in the Western diet. Most Western populations currently consume approximately twice as much sodium as potassium. The WHO recommends reversing that ratio: less than 2,300mg of sodium per day and at least 3,500mg of potassium per day (WHO Guideline).

Potassium reduces blood pressure through renal mechanisms, modulating sodium reabsorption in the distal tubule and promoting sodium excretion. A 2025 dose-response meta-analysis of RCTs confirmed a significant dose-dependent relationship between increased potassium intake and blood pressure reduction, particularly meaningful in established hypertension (Clin Kidney J, 2025). Potassium intake between 3,000 and 5,000mg per day is associated with slowed development of type 2 diabetes and favorable effects on insulin sensitivity in observational data.

The practical good news: a diet naturally rich in vegetables, fruits, and legumes is automatically a high-potassium diet.

High potassium food sources:

• Vegetables: spinach, Swiss chard, kale, beet greens, sweet potato, potato with skin, winter squash, tomatoes, broccoli, Brussels sprouts, avocado

• Fruits: banana, orange, cantaloupe, honeydew, dried apricots, prunes, pomegranate

• Legumes: lentils, black beans, kidney beans, edamame, white beans

• Other: salmon, plain yogurt, whole milk, nuts and seeds

Mandatory caveat: Patients with significant chronic kidney disease cannot adequately excrete potassium and face serious hyperkalemia risk with unrestricted high-potassium intake. If you have CKD, potassium management requires individualized physician guidance. This section’s general targets do not apply to you.

High Vitamin K Foods

Vitamin K exists in two biologically distinct forms with different food sources, different functions, and different clinical considerations.

Vitamin K1 (phylloquinone) is found predominantly in green leafy vegetables and certain plant oils. It is the primary dietary form in most Western diets and is essential for hepatic synthesis of clotting factors II, VII, IX, and X. A single half-cup serving of cooked kale or spinach meets or exceeds the daily requirement of 90mcg for women and 120mcg for men entirely (NIH Office of Dietary Supplements, 2024). K1 bioavailability from plant sources is significantly lower than from plant oils and is meaningfully improved by consuming alongside dietary fat.

Vitamin K2 (menaquinones) is produced by bacteria, including gut microbiome bacteria, and is found in fermented foods as well as certain animal products including aged cheeses and egg yolks. K2’s role in bone health and vascular calcification prevention is an active and developing area of research beyond its coagulation function.

High vitamin K food sources:

• K1: kale, spinach, collard greens, Swiss chard, beet greens, broccoli, Brussels sprouts, cabbage, lettuce, parsley, green onions, plant oils (soybean, canola)

• K2: natto, aged hard cheeses (Gouda, Brie), egg yolks, chicken liver, fermented foods

For patients on warfarin: Warfarin works by competitive inhibition of vitamin K-dependent clotting factor synthesis. Stable daily vitamin K intake allows your warfarin dose to be calibrated and maintained accurately. If you plan to significantly increase your intake of green leafy vegetables, implement the change gradually and inform your physician so your international normalized ratio (INR) can be monitored appropriately during the transition.

Beverages

Water

Water is the only beverage the body requires. Pre-meal consumption of 500ml is associated with reduced food intake at the subsequent meal across multiple RCTs, through gastric volume contribution to early satiety; a modest effect with zero cost and zero risk.

Tea

Unsweetened naturally brewed tea provides polyphenols including epigallocatechin gallate (EGCG) with documented antioxidant, anti-inflammatory, and metabolic benefits in large prospective cohort studies. Regular green tea consumption is associated with improved insulin sensitivity, modest LDL reduction, and reduced cardiovascular risk. Commercially bottled teas are predominantly sugar-sweetened beverages and are not the product the evidence supports.

Coffee

Moderate consumption of one to three cups per day is associated with reduced risk of type 2 diabetes, metabolic syndrome, and all-cause mortality across multiple large meta-analyses (Ding et al., Diabetes Care, 2014). The benefit derives from chlorogenic acids and polyphenols. Decaffeinated coffee shows similar metabolic associations, confirming that caffeine is not the active component.

The problem is what most people put into it. Sugar, flavored syrups, and high-calorie creamers transform a metabolically beneficial beverage into a dessert. Black coffee, or coffee with a small amount of whole milk, is the evidence-supported version.

Smoothies and Fruit Juice

A homemade whole fruit smoothie retains the complete fiber content of intact fruit. Blending disrupts the physical food matrix structure but does not destroy fiber. The glycemic response to a whole fruit smoothie is significantly more favorable than equivalent fruit juice, where fiber has been removed. Commercial smoothies are typically made with fruit juice rather than whole fruit, contain added sugars and other industrial ingredients, and are metabolically equivalent to sugar-sweetened beverages despite the health marketing on their labels.

Fruit juice removes the structural fiber matrix regardless of pulp addition. Pulp adds approximately 0.5 grams of fiber per cup compared to 3 to 4 grams in equivalent whole fruit. The result is a significantly faster postprandial glucose excursion than whole fruit produces.

The Complete Dietary Toolkit

The pattern that emerges across all twelve categories is consistent. Whole, minimally processed foods deliver their nutrients in a biological context that refined and ultraprocessed products cannot replicate.

Part Nine will show you how to assemble these components into a personalized, sustainable dietary plan using the proven principles of Mediterranean, DASH, and Volumetric eating applied to foods you already know, understand, and can access.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

The Metabolic Archives is for educational and informational purposes only, and is not intended as medical advice, diagnosis, or treatment, and does not constitute a doctor-patient relationship. Do not adopt any recommendation discussed in any article or guides published here, make changes or abandon any prescribed medical treatment without prior consultation with your physician. Always seek the advice of your physician or other qualified health provider for any questions regarding your medical condition and recommended treatment options.

By reading this post, you acknowledge that you have read and agree to the Terms of Service of The Metabolic Archives, which govern all use of this content including restrictions on reproduction.

© 2026 The Metabolic Archives. All rights reserved.

On July 24, 2026, Reuters reported that Nestle has been lobbying U.S. regulators, including officials in Health and Human Services Secretary Robert F. Kennedy Jr.’s team, to allow “common names” instead of technical names on ingredient labels (originally reported by Reuters, reporting by Richa Naidu; accessible reprint available at BNN Bloomberg). This lobbying effort had not been previously reported before the Reuters exclusive.

The examples Nestle leads with sound reasonable. Replace “ascorbic acid” with “vitamin C.” Replace “beta-carotene” with “vitamin A.” A former senior Nestle executive told Reuters the current system makes products sound like “Frankenstein food” when the ingredients are actually natural and have common-language equivalents. Nestle’s technology chief, Stefan Palzer, confirmed the company is engaged in lobbying via trade associations to make labels less complex.

The Coalition Behind It

Nestle is not acting alone. The company is part of Americans for Ingredient Transparency (AFIT), a 501(c)(4) nonprofit launched in October 2025. AFIT’s membership includes Nestle, Coca-Cola, PepsiCo, Kraft Heinz, General Mills, Tyson Foods, Cargill, and more than a dozen food industry trade associations.

The coalition is also pushing for federal legislation that would preempt state-level ingredient laws, creating a single national standard that would override stricter protections individual states have already enacted. Consumer advocacy groups, including Consumer Reports and the Environmental Working Group, have criticized AFIT as an industry effort to block more protective state food safety laws under the banner of “transparency.”

According to a June 2026 investigation by NOTUS, organizations lobbying specifically on reform of the Generally Recognized as Safe (GRAS) process nearly tripled from 12 in the first quarter of 2025 to 35 in the first quarter of 2026. AFIT alone spent $240,000 on lobbying between August 2025 and March 2026. Four companies that publicly committed to removing artificial food dyes, Nestle, PepsiCo, Coca-Cola, and Keurig Dr Pepper, met individually with Food and Drug Administration (FDA) officials to lobby on GRAS reforms, according to meeting records reported by NOTUS. Around the same time, the FDA quietly updated its website to extend the compliance deadline for the industry’s voluntary dye removal commitment by a full year, from the end of 2026 to the end of 2027.

Several of the same companies publicly pledging to remove ingredients from their products are simultaneously lobbying to rename the ingredients they intend to keep. Nestle itself pledged in early 2015 to remove artificial flavors and colors from its products by the end of that year. As the Associated Press reported in June 2025, that promise did not hold. As of mid-2025, Nestle said roughly 90% of its U.S. portfolio no longer contained synthetic dyes and made a new pledge for elimination by mid-2026. That second promise was eventually fulfilled.

The Data They Cite and the One They Don’t

Nestle’s proposal leans on a report by Innova Market Insights (an industry aligned market research company) finding that about 75% of North American consumers reconsider purchases because of ingredient lists. The industry reads this as evidence that technical names are scaring consumers away from safe products.

The same research organization during the same period, published findings that tell a different story. In a July 2025 press release ahead of the Institute of Food Technologists (IFT) first conference in Chicago, Innova reported that only 36% of North American consumers describe their approach to healthy eating as actively limiting ingredients they consider harmful. Lu Ann Williams, Innova’s Global Insights Director, stated that affordability and enjoyment remain the dominant drivers of food choice, while “demonized ingredients are not a major concern for most consumers.”

The 75% number most likely reflects a general unease at encountering unfamiliar terms on a label, not a sophisticated ingredient-by-ingredient evaluation. The industry’s response to that unease is to make the terms less unfamiliar. The consumer-protective response would be to help people understand what those terms actually mean.

The EU Comparison They Cherry-Picked

The Reuters article frames European labeling as more flexible and consumer-friendly, noting that in Europe, ascorbic acid can appear on labels as “vitamin C.” That is true.

But the article omits that under EU Regulation (EC) No 1333/2008 on food additives, every food additive that appears on an ingredient list must be preceded by the name of its functional category: antioxidant, emulsifier, preservative, stabilizer, and so on. A European label does not just say “vitamin C.” It says “antioxidant: vitamin C” or “antioxidant: ascorbic acid” or “antioxidant: E300.” The consumer sees both what the ingredient is and why it is there.

Nestle is citing the part of the EU system that makes labels look simpler while ignoring the functional-category disclosure that makes the EU system more transparent, not less. If the U.S. adopted the full EU approach, consumers would actually get more information than they have now.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

The Identifying Markers of Ultra-Processed Food

The technical names on ingredient lists are not obstacles to understanding. They are the tools that allow you to identify ultra-processed food (UPF).

The NOVA classification system, increasingly the global standard for categorizing food by degree of processing, identifies UPF (Group 4) by the presence of specific marker ingredients. A 2023 study published in Public Health Nutrition by Neumann, Eichner, and Fasshauer analyzed 2,146 commercial products from the UK market and found that just three categories of markers (flavourings, emulsifiers, and colourants) detected about four out of five UPF products. When the researchers expanded to six marker categories total, the detection rate climbed to nearly nine out of ten.

Those markers are visible to consumers only because ingredient lists currently use specific, regulated terminology.

Modified Starches

Your current ingredient label might read “modified corn starch” or “modified food starch.” The word “modified” distinguishes an industrially processed additive from ordinary cornstarch, the kind you might keep in your pantry. Under current U.S. regulations, these must be labeled as “modified food starch” or “modified [source] starch.” Under NOVA, they are classified as a marker of ultra-processing.

If “modified corn starch” becomes simply “cornstarch,” the single word that tells you this ingredient was industrially processed vanishes. The additive and the pantry staple become indistinguishable on the label.

Protein Isolates

“Soy protein isolate” becoming “soy protein” erases the word that identifies the industrial fractionation process. Products made with protein isolates are classified as UPF under NOVA specifically because of this fractionation. As noted in a 2022 perspective published in Advances in Nutrition by Messina et al., soy-based products containing these isolates meet the NOVA Group 4 classification regardless of their nutritional profile.

Drop the word “isolate,” and you can no longer tell from the label whether a product contains a whole-food soy ingredient or an industrially fractionated one.

Maltodextrin

Maltodextrin is the strongest single illustration of how naming conventions already exploit the gap between regulatory definitions and metabolic reality. It already appears under multiple alternative names, including modified cornstarch, modified food starch, glucose polymer, and dextrin.

Its glycemic index ranges from 85 to 105, depending on processing method and starch source. For comparison, table sugar (sucrose) has a glycemic index of approximately 65; maltodextrin spikes your blood sugar faster than the sugar in your sugar bowl!

Because maltodextrin is classified as a polysaccharide (a complex carbohydrate) rather than a mono- or disaccharide (a simple sugar), products containing it can legally carry “No Added Sugar” claims under current U.S. labeling rules. A fiber supplement labeled “SUGAR-FREE” can contain maltodextrin with a glycemic index higher than table sugar. The metabolic reality is the opposite of what the consumer is led to believe.

The High-Fructose Corn Syrup Precedent

In 2010, the Corn Refiners Association petitioned the FDA to rename high-fructose corn syrup (HFCS) “corn sugar.” The FDA denied the petition on May 30, 2012, in a letter authored by Michael M. Landa, then Director of the FDA’s Center for Food Safety and Applied Nutrition. The FDA’s reasoning was threefold.

First, the term “sugar” describes a solid, dried, crystallized food, and HFCS is a syrup, so the name would not accurately describe the product’s basic nature. Second, “corn sugar” had been used for over 30 years as an alternate name for dextrose, and consumers would confuse the two. Third, individuals with hereditary fructose intolerance had learned to identify HFCS by its current name, and changing it could endanger their health.

The FDA’s reasoning applies directly to the current proposal. When consumers learn to identify a specific ingredient by its regulated name, renaming it means the removal of a tool the consumer has already learned to use.

The Problem With No Common Name

Emulsifiers are the second most frequent UPF marker, appearing in about 36% of all ultra-processed products according to the Neumann et al. (2023) analysis. The names are immediately recognizable to anyone who has started reading labels: polysorbate 80, carboxymethylcellulose, mono- and diglycerides of fatty acids.

There is no common-language equivalent for polysorbate 80, because nothing in a home kitchen does what polysorbate 80 does.

Either the “common name” principle does not apply to emulsifiers, meaning labels would still contain unfamiliar technical names and the stated rationale for the proposal collapses. Or the proposal would require inventing euphemisms for ingredients that have no natural-language equivalent, which is worse than the status quo because it would actively mislead.

The EU Comparison Nestle Doesn’t Want You to See

Under EU rules, if a product contains polysorbate 80, the label must read “emulsifier: polysorbate 80” or “emulsifier: E433.” The consumer knows both what the ingredient is and what it does in the product.

Nestle cites the “vitamin C” part of EU labeling as a model for the U.S. while ignoring the functional-category disclosure requirement that makes the EU system more informative. If transparency were truly the goal, the proposal would advocate for adopting the EU’s functional-category requirement alongside any name simplification. But it doesn’t.

What This Means for You

If you have learned to scan ingredient labels for the markers of ultra-processing, modified starches, protein isolates, emulsifiers, maltodextrin, and other technical terms, this proposal would make it harder for you.

The ingredient list is the last point at which you have full access to what is actually in a packaged food product. The ingredient list, because it is regulated, is the one place where the manufacturer has to tell the truth in specific terms.

The argument this proposal makes is that the ingredient list is too confusing for consumers. The argument the evidence actually supports is that most consumers do not yet use ingredient lists effectively, not because the names are too technical, but because they have not been given the tools to understand them. The response to that gap should be education, not erasure.

Relabel vs. Reformulate

The Reuters article quotes Aldi eliminating dozens of ingredients from its products and Nestle lobbying to rename ingredients it intends to keep. These are presented as if they are part of the same trajectory toward cleaner food.

Aldi’s approach is reformulation: actually changing what is in the product. Nestle’s proposal is relabeling: changing what the consumer sees on the package while the product inside stays the same.

The ingredient label is not the problem to be solved, it is the tool that tells you what the problem is. This proposal treats your ability to identify what is in your food as the obstacle, rather than the right to be protected.

Found this article useful? Share your thoughts. Join the conversation below.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

This installment covers three dimensions of that architecture: sequence, speed, and timing.

Sequencing Is A Metabolic Strategy

In a pilot randomized controlled trial of overweight adults with type 2 diabetes consuming a standard Western meal, the incremental area under the glucose curve over 120 minutes was 73% lower when vegetables and protein were consumed before carbohydrates compared to the reverse sequence (Shukla et al., Diabetes Care, 2015). Postprandial glucose levels were reduced by 28.6% at 30 minutes, 36.7% at 60 minutes, and 16.8% at 120 minutes. Postprandial insulin levels at 60 and 120 minutes were also significantly lower.

Japanese patients with type 2 diabetes and normal glucose tolerance, healthy adults in the United Arab Emirates in a randomized crossover trial, healthy Chinese adults across five different eating sequences in the PATTERN study, and women with gestational diabetes in a 2024 Frontiers in Nutrition randomized controlled trial, all showed significant reductions in postprandial glucose and insulin when vegetables and protein were consumed before carbohydrates (Imai et al., Diabet Med, 2013; Shukla et al., BMJ Open Diabetes Res Care, 2017; Tan et al., Clin Nutr, 2020; Al Khatib et al., 2024; Front Nutr, 2024). A 2025 study in Diabetes Care confirmed that sustained carbohydrates-last food order improved time in range and reduced glycemic variability in type 2 diabetes over extended follow-up (Shukla et al., 2025).

Fiber consumed first slows gastric emptying and buffers subsequent carbohydrate absorption. Protein consumed early stimulates incretin responses before the carbohydrate load arrives. Fat consumed before carbohydrates further delays gastric emptying. These effects are cumulative.

The take away point is simple enough: at every meal, eat vegetables first, follow by protein, and eat carbohydrates last. A meal with separately served rice or bread is immediately actionable: eat the protein and vegetables first, then the starch, and only if still hungry. Mixed dishes that do not permit easy separation are not a problem. Apply the sequence consistently where the structure allows, and do not stress where it does not. Even partial consistent application captures meaningful benefit. The barrier to implementation couldn’t be lower.

Ready, Set, Slow Down

A systematic review and meta-analysis published in Frontiers in Nutrition found that eating faster was associated with a 54% higher risk of metabolic syndrome and a higher risk of central obesity compared to eating slowly (Feng et al., 2021). A separate three-year prospective cohort study in a large Japanese population found that fast eaters had a 30% higher risk of developing metabolic syndrome, a 35% higher risk of central obesity, and a 37% higher risk of low high-density lipoprotein (HDL) cholesterol compared to non-fast eaters (Nagahama et al., 2015). A 2024 multicenter cross-sectional study and meta-analysis extended this picture further, finding a significant association between fast eating and metabolic dysfunction-associated steatotic liver disease (MASLD), a condition on the rise around the world (Nutr Diabetes, 2024).

The gut hormones that register fullness require time to rise in response to food entering the gastrointestinal tract. The conventional estimate is approximately 20 minutes between the start of eating and the meaningful arrival of satiety signals at the hypothalamus. Eating slowly allows satiety signaling to engage while food is still on the plate.

A randomized controlled crossover study in healthy young women found that eating vegetables first produced significant reductions in postprandial glucose and insulin regardless of eating speed, fast eating with vegetables first outperformed slow eating with carbohydrates first on both measures (Imai et al., Nutrients, 2023). Eating order is the more powerful of the two interventions when they compete.

The eating speed evidence is predominantly observational. Large randomized controlled trials isolating eating speed as a single variable against long-term metabolic outcomes have not been conducted. However, there are no observed adverse consequences associated to slow eating so for now this remains a reasonable and easy to implement recommendation.

The Clock Your Body Actually Runs On

The breakfast-lunch-dinner construct is a social and industrial artifact. It was not designed around human metabolic biology and the evidence shows it.

The human body operates on a sophisticated internal timing system that governs hunger, satiety, metabolic rate, hormone secretion, and fuel utilization across a 24-hour cycle. Multiple metabolic hormones have diurnal variations. Eating when the clock says noon rather than when genuine hunger is present means consuming calories uncoupled from actual metabolic need; this is an independent driver of caloric overconsumption.

Diet-induced thermogenesis, the energy the body expends processing a meal, is higher after a morning meal than after an evening meal (PMC7997809; Nutrients, 2025). The body burns more calories processing the same food eaten in the morning than in the evening. The Western convention of the large evening meal is directly misaligned with this biology.

A 20-week weight loss trial found that participants whose food intake was weighted toward later in the day lost less weight and experienced slower weight loss despite identical caloric intake, identical energy expenditure, and identical sleep duration (Garaulet et al., Int J Obes, 2013). A separate randomized controlled trial comparing a large breakfast group to a large dinner group with identical total caloric intake, found that the large breakfast group lost significantly more weight and more waist circumference. It also showed greater decreases in fasting glucose, insulin, and insulin resistance, while reporting greater satiety, lower hunger, and lower ghrelin levels (Jakubowicz et al., Obesity, 2013).

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

A Protein-Rich Breakfast

Caloric intake should be weighted toward the earlier part of the day and the evidence is specific about what that meal should look like.

A randomized controlled trial of breakfast identified a meal protein threshold of approximately 30 grams to achieve consistent and superior satiety effects compared to lower protein breakfasts (Kamer et al., J Dairy Sci, 2024). At this threshold, the area under the curve for satiety, fullness, and satisfaction across the three hours following breakfast was significantly higher than carbohydrate-matched controls, while hunger, desire to eat, and prospective eating were significantly lower. Below this threshold, the satiety benefit of protein at breakfast is inconsistent across studies. A separate randomized crossover study comparing 30 grams of protein from plant-based versus animal-based breakfast sources found significant satiety hormone responses from both sources at equivalent protein content (Nyambe-Silavwe et al., PMC12612008).

Dietary protein stimulates the release of GLP-1, PYY, and CCK, gut hormones that suppress appetite, while simultaneously decreasing ghrelin (Kim et al., J Obes Metab Syndr, 2020). Protein also carries a greater thermic effect than carbohydrates or fat, meaning the body expends more energy processing it. The consequence of a protein-rich breakfast is reduced caloric intake not just at lunch but across the remainder of the day.

The typical American breakfast (cereal, toast, pastries, juice, sweetened yogurt) is carbohydrate-dominant, protein-poor, and engineered for palatability rather than satiety. It produces a rapid postprandial glucose excursion, a corresponding insulin response, and a return of hunger within two to three hours. Replacing it with a protein-rich meal reaching 25 to 30 grams requires no exotic ingredients: eggs, Greek yogurt, cottage cheese, smoked salmon, and legumes all qualify, individually or in combination.

Lunch, Supper, and the Architecture of the Day

The evidence supports a large lunch as the primary caloric event of the day weighted toward the midpoint of the active day rather than the end. This runs counter to the pattern most working adults practice: a handheld meal at a desk, food consumed in a car, or lunch skipped in favor of late-day snacking. Even a partial shift, a larger lunch and a lighter supper, moves you in the right direction.

The evening meal should be the lightest of the day, consumed at least three hours before the expected sleep time. This serves two purposes simultaneously: it aligns caloric intake with the period of declining metabolic efficiency and establishes the starting point of the overnight physiological fast.

Sleep Is the Fast

The overnight period between a properly timed light supper and the next morning’s breakfast is an active metabolic state; the fasting period the human body was designed to use.

During the overnight fast insulin falls to baseline allowing fat oxidation to predominate over glucose oxidation. Growth hormone rises during deep sleep, supporting tissue repair and lean mass maintenance. Autophagy, the cellular process that clears damaged proteins and organelles, activates in the fasting state. Peripheral circadian clocks in metabolic tissues reset in the suprachiasmatic nucleus (Shkorfu et al., Food Sci Nutr, 2025; Nutrients, 2025; J Umm Al-Qura Univ Med Sci, 2025).

A randomized controlled trial in 39 overweight and obese participants found that extending overnight fasting duration by three hours, specifically ensuring the last meal was consumed at least three hours before habitual sleep time, producing a 13 to 16 hour overnight fast, significantly improved nighttime autonomic balance. It decreased blood pressure, increased blood pressure dipping, and enhanced glucose regulation compared to control participants maintaining habitual eating patterns (Arteriosclerosis, Thrombosis, and Vascular Biology, 2025).

Many people attempting intermittent fasting time their fasting window to coincide with the morning skipping breakfast to extend the fast into the late morning or early afternoon. This inverts the biological logic entirely, eliminates breakfast and displacing eating time into the afternoon and evening when metabolic efficiency is declining.

If you wish to practice intermittent fasting, the most cited schedule suggests 8 hour window to eat with 16 hour fast until the next day; is backed by science as beneficial for weight loss and metabolic health, particularly when caloric intake happens between the hours of 7:00 am and 3:00 pm.

The Complete Architecture

This is the right architecture is now clear.

A protein-rich breakfast consumed within a reasonable time after waking. A substantial, sit-down lunch as the primary caloric event of the day. A light early supper consumed at least three hours before sleep. An overnight fast that resets the metabolic and circadian systems in preparation for the next morning. Within each meal: vegetables first, protein second, carbohydrates last, and eaten at a slower pace that allows proper satiety signaling.

No new foods, calorie counting, apps, or supplements. It requires only that you eat the right things in the right order at the right time and that you take long enough to finish so your body can tell you when it is done.

Part Eight discuss the individual food components of the meal itself.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

On July 23, 2026, a Food and Drug Administration (FDA) advisory panel voted 8 to 6 to recommend that compounding pharmacies be allowed to produce and dispense a substance called BPC-157, one of the most popular peptides in the wellness industry. One panel member abstained. An identical 8-6 vote followed for a second peptide, KPV. Votes on two more peptides are expected this afternoon, with three additional substances scheduled for Friday.

The FDA’s own career scientists reviewed the evidence on all seven peptides and recommended against every one of them; the panel voted yes anyway. I addressed the science behind most common peptides here: The Evidence Gap the Peptide Industry Doesn’t Want You to Think About.

These substances will soon be available by prescription at compounding pharmacies across the country. You will hear about them. You may already have heard about them. And the single most important thing you need to understand is this: a prescription for a compounded peptide will look identical to any other prescription you have ever received. But the scientific foundation behind it is not remotely comparable to what stands behind other medications.

What “Cleared for Compounding” Means

When a pharmaceutical company develops a new drug, it spends years conducting clinical trials. The FDA then reviews all of that data before granting approval; that is what FDA Approved means.

Being placed on the FDA’s 503A compounding list is a different thing entirely; it means pharmacies are permitted to mix and dispense a substance. It is a regulatory permission, not a scientific validation. The FDA did not determine that it works or is even safe.

What the FDA’s Own Scientists Found

The agency’s career scientists reviewed the available evidence on all seven peptides under consideration and concluded that none met the criteria for inclusion on the compounding list (FDA briefing documents, July 2026).

For BPC-157, the most popular peptide in the wellness space, here is what the total published human evidence looks like:

Fewer than 30 total human subjects across all published studies. These include a 2024 interstitial cystitis pilot study with 12 patients, a 2021 knee pain study with 16 patients, and a 2025 intravenous safety pilot involving 2 healthy adults. The largest planned Phase I trial, registered in December 2015, was canceled without publishing results. The first properly designed RCT, a double-blind, placebo-controlled Phase 2 study of 120 participants for hamstring strain, began recruiting in February 2026 and has not yet reported results (ClinicalTrials.gov, NCT07437547).

For context, NYU Langone endocrinologist Dr. Rachel Pessah-Pollack noted that BPC-157 has been tested in roughly 30 humans, compared to the hundreds of thousands of subjects studied in the clinical trials that led to the approval of GLP-1 drugs like Ozempic and Wegovy (CBS News, July 23, 2026).

Russell Wesdyk, an associate director in the FDA’s drug center, raised a concern during the meeting that goes beyond the limited evidence. He stated that the name “BPC-157” has no standardized pharmaceutical definition. There is no way to guarantee that what a compounding pharmacy mixes under that name is the same substance studied in those few small trials (Associated Press, July 23, 2026). The FDA staff also raised concerns about contamination risks, allergic reactions, and quality control problems.

Both BPC-157 and TB-500, another peptide under review, are classified as prohibited substances by the World Anti-Doping Agency (WADA) under the 2026 Prohibited List (WADA 2026 Prohibited List; USADA).

The Off-Label Prescribing Gap

The Pharmacy Compounding Advisory Committee (PCAC) reviewed BPC-157 in the context of specific conditions, including ulcerative colitis and gut healing. But once a substance is cleared for compounding, clinicians have broad discretion to prescribe it for any condition. That is how off-label prescribing works across medicine.

What this means: you may be offered these peptides for knee pain, muscle recovery, anti-aging, longevity, and conditions that were never evaluated in the review process. Telehealth platforms and online wellness services are already positioned to begin offering compounded peptides as soon as the FDA clears them (STAT News, July 23, 2026).

The Advisory Panel Reconstitution

The PCAC was originally created under the FDA Modernization Act (FDAMA) of 1997 and re-established in 2012 under the Drug Quality and Security Act (DQSA) of 2013. That legislation was passed in direct response to a catastrophe: the 2012 New England Compounding Center (NECC) fungal meningitis outbreak, which killed more than 60 people and infected over 750 patients across 20 states from contaminated compounded injectable drugs (FDA Human Drug Compounding Progress Report, January 2017). The PCAC’s charter specifies membership from organizations including the National Association of Boards of Pharmacy and the United States Pharmacopeia, along with pharmacists, physicians, and patient advocacy representatives.

For over a decade, spanning multiple administrations, the panel was composed of independent academic experts from institutions including Duke, Harvard, and Johns Hopkins. Those panels repeatedly voted against allowing peptide compounding, finding the substances too risky and the evidence too thin.

In June 2026, the panel was reconstituted, eight of twelve members were newly appointed on June 29, less than a month before the vote. All but one of the new appointees had financial ties to businesses that sell or administer peptides (Associated Press, June 29, 2026; U.S. News/HealthDay, July 1, 2026). The panel now included wellness clinic owners who prescribe peptides, pharmacists who compound them, and consultants who promote them online. The Associated Press identified members including a doctor who runs clinics selling peptide, testosterone, and weight-loss injections and another who charges $500 for peptide consultations and promotes BPC-157 online.

Days before the meeting, apparently in response to criticism, the FDA added a handful of academic temporary voting members but it did not change the outcome.

The result: the same peptides, reviewed by a reconstituted panel, produced the opposite outcome of a decade of prior votes. The 8-6 vote split perfectly along the line between industry-connected and non-industry members, every industry-connected member voted yes.

Dr. Peter Lurie, a former FDA associate commissioner who now serves as president of the Center for Science in the Public Interest (CSPI), stated that a reputable panel would typically exclude members with a financial interest in the outcome of a vote (U.S. News/HealthDay, July 1, 2026). In April, he told CBS News that he did not believe the process represented an honest investigation, and characterized the situation as a “profound threat” to the FDA’s decades-old system for vetting drugs (CBS News, April 16, 2026).

Kennedy himself has publicly acknowledged that expanding access to peptides and experimental therapies means “you’re going to get a lot of charlatans” (CSPI statement citing Kennedy’s remarks, April 16, 2026).

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

The Harshbarger Narrative

One member of the reconstituted panel illustrates the depth and interconnectedness of the conflicts at play. What follows is a chronological sequence of verified facts.

Robert Harshbarger Jr., a licensed pharmacist from Kingsport, Tennessee, doing business as American Inhalation Medication Specialists, Inc., pleaded guilty on May 21, 2013 to one count of distributing a misbranded drug and one count of health care fraud. He admitted purchasing iron sucrose from Chinese companies and substituting it for FDA-approved Venofer, the only iron sucrose drug approved for kidney dialysis patients, in sales to Kansas Dialysis Services from 2004 to 2009. He was sentenced to 48 months in federal prison, ordered to pay restitution of $848,504 and a $25,000 criminal fine, and forfeited $425,000 in cash. His pharmacy license was revoked (U.S. Department of Justice, District of Kansas, May 21, 2013; November 4, 2013).

His wife, Diana Harshbarger, is also a licensed pharmacist who operates Premier Pharmacy, a compounding pharmacy in Kingsport, and a former board member of the International Academy of Compounding Pharmacists. She was first elected to Congress in 2020 representing Tennessee’s 1st District, running on a platform that included criticizing reliance on Chinese pharmaceuticals as a national security concern (WJHL, May 13, 2020).

On November 3, 2025, President Trump endorsed Diana Harshbarger for reelection. On November 7, Trump signed a pardon for Robert Harshbarger Jr. A White House official defended the pardon by characterizing the crime as “a common practice among pharmacists known as ‘compounding,’ in which unapproved drugs are provided to patients” (Associated Press, November 11, 2025).

On November 10, 2025, three days after the pardon, Diana Harshbarger sent a letter to Health and Human Services (HHS) Secretary Kennedy urging the FDA to exercise enforcement discretion with respect to compounding of certain peptides, specifically naming BPC-157, CJC-1295, Ipamorelin, Thymosin alpha-1, TB-500, and GHK-Cu. The letter explicitly requested that the FDA assess these substances based on their safety profile and suitability for compounding rather than on whether a manufacturer has pursued traditional pharmaceutical approval (Diana Harshbarger letter to HHS Secretary Kennedy, November 10, 2025; hosted by the Alliance for Pharmacy Compounding).

On June 29, 2026, their son Bobby Harshbarger, a Tennessee State Senator and a pharmacist at the family’s Premier Pharmacy, which sells compounded medications for weight loss, longevity, pain, and other conditions, was appointed to the PCAC (STAT News, June 29, 2026). On July 23, 2026, he voted as part of the 8-6 majority recommending BPC-157 for compounding.

The Supply Chain Problem

The most commonly offered argument in favor of clearing peptides for compounding is a practical one: moving these substances into licensed pharmacies will steer people away from unvetted gray-market products sold online, often sourced from overseas with no quality controls.

There is a legitimate core to that argument: people are already using these peptides, the gray market is real, and it is dangerous.

But the argument has a gap. The bulk peptide powder that compounding pharmacies will use has to be sourced somewhere, and the supply chain for these raw materials is largely unregulated. A June 2026 investigation by the blockchain analytics firm Chainalysis, subsequently reported by Axios on July 7, 2026, found that crypto payments to gray-market peptide vendors rose from $12 million to $32 million in a single quarter, a 159% increase, pushing the sector past a $100 million annual run rate. The investigation found proceeds from U.S. online peptide sales flowing to China-based manufacturers of chemicals used to produce synthetic opioids like fentanyl.

Chainalysis identified specific companies: one, Shanghai Sigma Audley, had operated as a fentanyl precursor supplier with documented links to darknet vendors before rebranding into weight-loss peptides. Another, Bigreat Technology, a supplier of precursors for fentanyl and synthetic amphetamines, created a shell company called Zhengzhou DEPU Technology to sell peptides directly to Western buyers, using the same laboratory (Chainalysis, June 2026; Axios, July 7, 2026). The Partnership for Safe Medicines raised these supply-chain concerns in its opposition to the compounding recommendation.

The Enforcement Irony

Until this vote, distributing these same peptides was a criminal offense. Tailor Made Compounding LLC, a Kentucky pharmacy, pleaded guilty to distributing unapproved new drugs including BPC-157 from October 2018 through April 2020 and forfeited $1,788,906.82 (U.S. Department of Justice, Eastern District of Kentucky, October 2020). The FDA issued more than 50 warning letters to compounders, online sellers, and clinics in 2024 and 2025.

What was a federal crime is about to become a prescription, only because the political environment changed and the advisory panel was deliberately stacked in favor of the industry.

What This Means for You

If your doctor writes you a prescription for BPC-157 next year, that prescription will look and feel identical to any other prescription you have received. Everything about the experience will communicate that this is a vetted, evidence-based medical product.

It is not! And here is what you need to know before you fill it.

The absence of evidence of harm is not evidence of safety. It means the studies that would detect harm have not been conducted.

Anecdotes are not data, social media testimonials cannot account for placebo effects, natural healing, concurrent treatments, or the fact that people who saw no benefit or were harmed rarely post about it.

Your doctor may not know much more than you do, the clinical data that would otherwise inform prescribing decisions does not yet exist. Physicians will be making clinical judgments with the same limited evidence base available to anyone who reads the FDA briefing documents.

The Bottom Line

Of 24 speakers who offered public comment on BPC-157 at today’s meeting, four were scientists who argued against broader access. The remaining 20 were doctors, chemists, and peptide business owners who favored it, relying on personal and patient anecdotes (CBS News, July 23, 2026). One industry-connected panel member, David Pope, chief pharmacy officer of Xifin Pharmacy Solutions, stated: “I voted yes because it’s time to put this decision back in the hands of the patient, the physician and the pharmacist” (Associated Press, July 23, 2026). That framing, patient autonomy and physician discretion, sounds reasonable until you recognize that neither the patient nor the physician has access to the clinical data that would make such decisions informed.

The PCAC’s recommendation is non-binding, the FDA must still decide whether to accept it, publish a proposed rule, accept public comments, and issue a final rule, a process that typically takes 12 to 24 months.

If the science eventually supports these peptides, that would be welcome. But the science needs to be done first, not assumed on the basis of popularity and political enthusiasm.

Found this article useful? Share your thoughts. Join the conversation below.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

What CoQ10 Is and Where It Came From

CoQ10 was isolated in 1957 by Frederick Crane at the University of Wisconsin, extracted from beef heart mitochondria (Crane et al., Biochim Biophys Acta, 1957). Karl Folkers at Merck worked out the chemical structure the following year. Peter Mitchell’s chemiosmotic theory, which earned him the Nobel Prize in 1978, clarified what CoQ10 actually does: it is the mobile electron carrier that shuttles electrons between Complexes I and II and Complex III in the mitochondrial respiratory chain. Every cell that produces adenosine triphosphate (ATP) through oxidative phosphorylation depends on it. CoQ10 also serves a second role as a lipid-soluble antioxidant in cell membranes and lipoproteins.

Your body makes CoQ10: the synthesis starts from the amino acid tyrosine and runs through a long biochemical pathway. The early steps of that pathway are shared with cholesterol synthesis, specifically the mevalonate pathway. This shared origin is the entire biochemical basis of the statin-CoQ10 narrative that comes later. Tissue levels of CoQ10 decline with age in some tissues but not others, and the clinical significance of that decline is far less established than supplement marketing suggests.

Dietary intake in a typical Western diet adds 3 to 6 milligrams per day on average (López-Lluch et al., Antioxidants, 2019). The richest sources are organ meats (beef heart, liver, and kidney at roughly 3 to 12 milligrams per 100 grams), fatty fish (sardines, mackerel, salmon at 2 to 6 milligrams per 100 grams), other meats, nuts, seeds, and some vegetable oils. Healthy adults with adequate nutrition meet their physiologic needs through endogenous synthesis plus diet.

The Japanese Regulatory History

In 1974, Japan approved CoQ10 as a prescription drug for congestive heart failure. This is unusual in the supplement landscape and partly explains why CoQ10 carries more medical credibility than other dietary supplements. Most physicians who recommend it are responding, at least in part, to that regulatory pedigree and to the early enthusiasm it generated in the cardiology literature of the 1980s and 1990s. Worth knowing as you weigh the recommendations you have received.

Ubiquinol Versus Ubiquinone

Two oxidation states of CoQ10 are sold commercially: ubiquinone (the oxidized form) and ubiquinol (the reduced form). The supplement industry has built a substantial premium on the claim that ubiquinol is 2 to 3 times more bioavailable and the only worthwhile form to take. The independent evidence does not support this unequivocally.

Some studies show modestly higher plasma levels with ubiquinol (Langsjoen and Langsjoen, Clin Pharmacol Drug Dev, 2014, though that author has commercial ties to ubiquinol products). Other studies show no meaningful difference when the carrier oil is matched between formulations. The independent reviews converge on a different conclusion: what drives bioavailability is the formulation itself, specifically oil-based softgels with appropriate lipid carriers, more than the redox state of the molecule (López-Lluch et al., Nutrition, 2019).

The single largest positive clinical trial in CoQ10’s entire history, the Q-SYMBIO trial in heart failure, used ubiquinone, not ubiquinol. No head-to-head clinical outcome trial has shown ubiquinol superiority on any meaningful endpoint. The premium price for ubiquinol products is not supported by outcome data.

The Statin Question

Statins work by inhibiting hydroxymethylglutaryl-coenzyme A reductase (HMG-CoA reductase), which reduces flux through the mevalonate pathway, which in turn reduces endogenous CoQ10 synthesis. Plasma CoQ10 levels fall measurably during statin therapy. From this established biochemistry, the leap was made that statin-related muscle symptoms are caused by CoQ10 depletion, and that supplementation can prevent or treat them. However the trial evidence is genuinely mixed.

Multiple meta-analyses of small open-label trials have reported symptomatic benefit. The 2018 meta-analysis by Qu and colleagues pooled 12 randomized controlled trials (RCTs) with 575 patients and reported reductions in muscle pain, weakness, cramps, and tiredness (Qu et al., J Am Heart Assoc, 2018). The same analysis found no reduction in creatine kinase (CK), the blood marker of muscle injury. Whatever symptomatic improvement was being reported was not reflecting reduced muscle damage.

Kennedy and colleagues, working from a similar trial base in 2020, came to the opposite conclusion: no significant benefit on statin-associated muscle symptoms (Kennedy et al., Atherosclerosis, 2020). A 2025 meta-analysis from Kovacic and colleagues in the Journal of Nutritional Science found the picture more nuanced still (Kovacic et al., J Nutr Sci, 2025). When the authors separated trials that enrolled patients with confirmed statin-associated muscle symptoms from trials that did not, the trials with confirmed symptoms showed no significant pain reduction, while trials without that inclusion criterion did. Translation: when you select patients whose muscle symptoms are actually verified as statin-related, CoQ10 fails to help.

The decisive trial in this space is Taylor and colleagues’ 2015 study in Atherosclerosis. The investigators first used a blinded crossover design to confirm whether patients who reported statin myalgia actually had reproducible symptoms when rechallenged with statin versus placebo. Only 36 percent of patients with reported statin myalgia had reproducible symptoms on blinded crossover. In that subset, the patients with confirmed, verified statin-induced muscle pain, CoQ10 produced no benefit on pain, strength, or exercise performance (Taylor et al., Atherosclerosis, 2015).

Now consider this: in Taylor’s study, if only 36 percent of reported statin myalgia is real, what is the other 64 percent?

The SAMSON trial (Howard et al., J Am Coll Cardiol, 2021) used an elegant crossover design, alternating statin, placebo, and no-treatment months in the same patients. The result: 90 percent of the symptom burden patients attributed to statins was reproduced by placebo. The StatinWISE trial (Herrett et al., BMJ, 2021) reached the same conclusion: no difference in muscle symptoms between statin and placebo periods. The Cholesterol Treatment Trialists’ Collaboration meta-analysis (Lancet, 2022) pooled blinded RCT data from approximately 120,000 patients and found that the true excess of muscle pain on statins, over what occurs on placebo, is less than 1 percentage point in the first year of therapy, with no excess after the first year. Confirmed, clinically significant statin myopathy (the rare condition with elevated CK and genuine muscle injury) occurs in well under 0.1 percent of statin users per year.

Across my forty years of medical practice, the great majority of patients started on statins tolerated them without muscle complaints. Of the patients who did complain of muscle pain, most had normal CK and the symptoms typically resolved over time. The patients who were actually taken off statins for muscle injury, the ones with elevated CK and muscle tenderness on examination, were a small handful across four decades. This pattern is exactly what the blinded RCT evidence predicts and is fundamentally incompatible with the supplement industry’s framing of statin myalgia as a widespread epidemic requiring routine CoQ10 supplementation.

The premise that 20 percent or more of statin users have CoQ10-depletion-driven muscle injury is itself overstated. Most reported statin intolerance is a nocebo response, the appearance of symptoms when a patient expects them, not an actual pharmacologic injury. When open-label CoQ10 trials enroll such patients, any plausible-sounding intervention will appear to work. When blinded trials enroll patients with confirmed, reproducible muscle symptoms, CoQ10 does not help and does not reduce CK.

The evidence of CoQ10 efficacy is mixed; the practice of routinely pairing CoQ10 with every statin prescription is not as well-supported as commonly believed. A patient with new muscle symptoms on a statin is better served by first confirming whether those symptoms are actually statin-related, ideally by withdrawal and rechallenge, since the nocebo response rate is high. For a patient with confirmed, persistent statin-related muscle symptoms, a trial of CoQ10 is a defensible thing to consider given the supplement’s excellent safety profile.

The physicians who recommended CoQ10 to statin patients, including cardiologists, generally did so in good faith. The early cardiology literature was enthusiastic, mechanism-based reasoning was compelling, and small positive trials were available. The Japanese regulatory pedigree alone carried significant weight. A recommendation pattern formed in the 1990s and 2000s, and was passed to patients with the full weight of medical authority.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Heart Failure

The Q-SYMBIO trial (Mortensen et al., JACC Heart Fail, 2014) randomized 420 patients with New York Heart Association (NYHA) Class III and IV heart failure to CoQ10 300 milligrams per day versus placebo on top of standard therapy. At two years, the active arm had reduced major adverse cardiovascular events (15 percent versus 26 percent in the placebo arm) and reduced cardiovascular mortality. This is the strongest single piece of CoQ10 evidence in any indication.

The trial had short-term endpoint failures at 16 weeks: no improvement in NYHA functional class, no improvement in 6-minute walk distance, no reduction in N-terminal pro-brain natriuretic peptide (NT-proBNP). There was significant regional outcome heterogeneity, with the benefit substantially larger at non-European sites.

The trial has never been replicated. Background heart failure therapy has advanced dramatically since 2014, with sodium-glucose cotransporter-2 (SGLT2) inhibitors, sacubitril/valsartan, and optimized mineralocorticoid receptor antagonist (MRA) use all becoming standard. No trial has tested CoQ10 on top of contemporary guideline-directed medical therapy. Neither the American Heart Association/American College of Cardiology nor the European Society of Cardiology heart failure guidelines recommend CoQ10.

The KiSel-10 trial (Alehagen et al., Int J Cardiol, 2013) randomized 443 elderly Swedes aged 70 to 88 to a combination of selenium 200 micrograms plus CoQ10 200 milligrams daily versus placebo for 4 years. Cardiovascular mortality was 5.9 percent in the active arm versus 12.6 percent in placebo at 5 years. The mortality difference persisted at 12-year follow-up, the longest-duration positive finding in the CoQ10 literature.

This was a combination intervention in a known selenium-deficient population. Sweden has low soil selenium and consequently low population selenium status. The trial cannot determine whether the benefit came from CoQ10, from selenium, or from the combination, and the results cannot be generalized to populations with adequate selenium intake.

Primary CoQ10 Deficiency

Primary CoQ10 deficiency syndromes are rare genetic disorders caused by mutations in CoQ10 biosynthetic genes, these patients cannot make adequate CoQ10. If supplementation were going to work robustly in any indication, this would be the one.

The 2022 systematic review by Wang and Hekimi (J Cell Mol Med) examined 89 cases of primary CoQ10 deficiency. Only 27 percent of patients with confirmed primary CoQ10 deficiency showed clinical improvement on supplementation. Even in the disease where supplementation has the strongest possible justification (the body genuinely cannot make enough CoQ10), the clinical response rate is below one in three.

This is the most sobering single data point in the literature, because it sheds real doubt on the broader industry premise that supplementation reliably corrects presumed CoQ10 “deficiency” in any population.

Migraine Prophylaxis

The American Academy of Neurology and American Headache Society guidelines give CoQ10 a Level C recommendation (”possibly effective”) for migraine prevention, placed alongside magnesium and feverfew. Two small RCTs (Sándor et al., Neurology, 2005; Dahri et al., Nutr Neurosci, 2019) showed reduced attack frequency. The 2021 meta-analysis by Sazali and colleagues (BMJ Open) pooled 6 RCTs with 371 patients and found reduced attack frequency and duration but not severity. A pediatric crossover trial was negative (Slater et al., Cephalalgia, 2011).

The evidence base is small and modest in quality but reasonably consistent in adults. The biological premise (mitochondrial dysfunction contributing to migraine pathophysiology) has independent support from neurologic research. For an adult with episodic migraine who is not getting adequate prophylaxis from first-line options, or cannot tolerate them, a trial of CoQ10 is a reasonable alternative.

Claims That Are Weaker, Equivocal, or Refuted

Hypertension

The 2007 meta-analysis by Rosenfeldt and colleagues claimed blood pressure reductions of 16 millimeters of mercury (mmHg) systolic and 8 mmHg diastolic. This figure, inflated by the inclusion of open-label trials, is still cited in supplement marketing nearly two decades later.

The 2016 Cochrane review by Ho and colleagues, restricted to RCTs only, found no significant effect on blood pressure. The most recent and largest pooled analysis (Karimi et al., Int J Cardiol Cardiovasc Risk Prev, 2025) included 45 RCTs and reported a 3.44 mmHg reduction in systolic blood pressure with no significant effect on diastolic pressure. Worth noting that the 2025 analysis detected significant publication bias by Egger’s test and showed very high statistical heterogeneity, both of which the authors acknowledge should temper interpretation.

Parkinson’s Disease

The QE3 trial (Beal et al., JAMA Neurol, 2014) randomized 600 patients with early Parkinson’s disease to CoQ10 1200 milligrams per day, 2400 milligrams per day, or placebo. The trial was terminated early for futility. Both active arms trended slightly worse than placebo on the primary endpoint. The earlier German trial by Storch and colleagues (Arch Neurol, 2007) was also negative. QE3 is the largest and best-designed CoQ10 trial in any neurodegenerative disease. The earlier Phase II suggestion of benefit was definitively refuted. Anyone still recommending CoQ10 for Parkinson’s disease is not engaging the current evidence.

Male Infertility

Multiple meta-analyses report that CoQ10 supplementation improves sperm concentration, motility, and morphology in men with idiopathic infertility. The 2013 meta-analysis by Lafuente and colleagues (J Assist Reprod Genet) found improved sperm surrogate markers but no evidence of increased pregnancy rates and no live birth data. A 2025 meta-analysis (Bakri et al., World J Mens Health) pooled 9 trials with 781 participants and claimed a clinical pregnancy rate benefit, but the included trials are small, heterogeneous, and largely unblinded, and live birth was not reported.

This is a textbook surrogate-versus-hard-endpoint disconnect: the numbers on the semen analysis improve, but whether that reliably translates to actual births remains unproven.

“Energy,” Anti-Aging, Cognition, Skin, Longevity

There is no meaningful clinical evidence in healthy adults for these claims.

The reasoning offered (”CoQ10 is in mitochondria, mitochondria make energy, therefore CoQ10 boosts energy”) is biologically illiterate as applied. These claims represent marketing extrapolation from biochemistry to clinical benefit with no controlled trial support.

Cancer Prevention or Treatment

Despite a long history of claims and early case series, modern controlled trials have not supported any role.

Safety

CoQ10 has an excellent safety profile across the entire dosing range studied in trials, from 60 to 3600 milligrams per day. The most common adverse effects are mild gastrointestinal symptoms (nausea, epigastric discomfort, diarrhea) at less than 1 percent incidence, with no clear dose-response relationship. Occasional reports of headache, insomnia (which is worse with evening dosing), and rare rashes round out the adverse event profile. Hathcock and Shao’s 2006 risk assessment derived an observed safe level of 1200 milligrams per day (Regul Toxicol Pharmacol). The 2008 Japanese safety assessment by Hidaka and colleagues derived an acceptable daily intake of 12 milligrams per kilogram per day (Biofactors). For an average 70-kilogram adult, that corresponds to about 840 milligrams per day with a wide safety margin.

Drug Interactions

The structural similarity between CoQ10 and vitamin K provides biological plausibility for a reduction in international normalized ratio (INR). Several case reports document INR decreases requiring warfarin dose adjustment after starting CoQ10. One small RCT in stable warfarin patients found no significant effect (Engelsen et al., Thromb Haemost, 2003, n=24). The interaction is real but probably uncommon and modest in magnitude. Patients on warfarin who start or stop CoQ10 should consult with their physician for additional surveillance.

There is no documented clinically significant interaction with the direct oral anticoagulants (DOACs): apixaban, rivaroxaban, edoxaban, or dabigatran.

What to Take Away

CoQ10 is biochemically real, physiologically essential, and produced by your body in adequate amounts under normal circumstances. The supplement’s safety profile is favorable, for patients who choose to take it the downside risk is low.

If you are currently taking CoQ10 because a physician recommended it when you were started on a statin, you now have the information to discuss the recommendation. A thoughtful conversation with your physician, armed with this information, is more useful than continuing supplementation on autopilot.

If you are considering CoQ10 for one of the better-supported indications (advanced heart failure, migraine prophylaxis), you can weigh the evidence as it actually stands rather than as it is marketed. If you are considering it for “energy,” anti-aging, cognition, or general wellness, the evidence does not support the expectation that you will get what you are paying for.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

Almost every reader has dieted, most have dieted more than once, the majority did not achieve lasting results and almost none were ever told why. This piece explains what’s the cause of conventional dieting failures and how repeated diet cycles may leave you in a worse metabolic position each time.

Understanding these mechanism is the first step toward escaping it.

Why Your Body Treats Every Diet Like a Famine

When the human body detects caloric intake dropping below weight maintenance needs, it reacts with a predictable compensatory mechanisms to protect against weight loss. Is a basic survival mechanisms rooted in human evolutionary history. In a modern food environment where caloric restriction is voluntary and food is available around the corner, it works against you.

Within days of beginning a caloric restriction diet, a coordinated hormonal counter-response activates across multiple simultaneous pathways.

Leptin falls. Leptin is a hormone produced directly by fat cells, in proportion to how much fat those cells contain. As fat is lost during restriction, fat cells shrink, and leptin production falls with them. The hypothalamus interpret falling leptin as a starvation signal. Its response is to downregulate your metabolism: reducing sympathetic nervous system output, suppressing the hypothalamic-pituitary-thyroid (HPT) axis, and driving down production of triiodothyronine (T3), the active thyroid hormone that governs thermogenesis and metabolic rate. Your body is literally turning down to conserve fuel.

Ghrelin rises. Ghrelin is produced primarily by the stomach and is the most potent hunger-stimulating hormone known. During caloric restriction, ghrelin levels rise and act on the arcuate nucleus of the hypothalamus to powerfully upregulate appetite and food-seeking behavior. You are hungry because this hormonal system is telling your brain to find food.

Non-exercise activity thermogenesis (NEAT) drops. This is the component of daily energy expenditure that most people are unaware of: the calories burned through all movement that is not formal exercise. Under caloric restriction, NEAT drops without conscious awareness. You take the elevator instead of the stairs, sit when you would have stood, stop fidgeting. Studies quantify this reduction at an additional 200 to 400 calories per day beyond the hormonal effects, a meaningful portion of any dietary deficit.

The net result: a body using fewer calories and demanding more food favoring the conditions required to end the diet and restore energy reserves.

The Adaptations That Outlast the Diet

These hormonal and metabolic adaptations do not normalize when the diet ends. A human randomized controlled trial (RCT) documented this: participants who achieved significant weight loss of 13.8 kilograms showed a reduction in resting metabolic rate of 291 kilocalories per day, with an additional adaptive thermogenesis component of 150 kilocalories per day, a total metabolic suppression of approximately 440 kilocalories per day beyond (Thom G et al., Eur J Clin Nutr. 2020). Leptin and glucagon-like peptide-1 (GLP-1) remained reduced, Ghrelin remained significantly elevated. Between six and twenty-four months of follow-up, participants regained an average of 6.1 kilograms despite not reporting increased conscious hunger.

That last point is important: the hormonal drive toward regain was operating below the level of conscious awareness. Participants were not overeating in ways they recognized, they were responding to a biological pressure and regaining weight anyway.

The persistence of elevated ghrelin is documented for up to one year after the end of active weight loss (Thom G, et al., Eur J Clin Nutr. 2020). The person who finishes a diet is operating on a suppressed metabolism with an up-regulated hunger drive, the worst possible conditions for maintaining the weight they just lost.

What Returns Is Not What Left

During caloric restriction, approximately 25% of weight lost comes from lean mass: muscle and other metabolically active tissue, alongside fat. During weight regain, the returning weight is predominantly fat, with only partial lean mass recovery. This asymmetry has been documented in human data. In a five-month nutritional trial of women with obesity aged 50 to 70, for every kilogram of fat lost during the intervention, 0.26 kilograms of lean tissue was simultaneously lost. For every kilogram of fat regained during the following year, only 0.12 kilograms of lean tissue was recovered (Zamboni M, et. al., Rev Endocr Metab Disord. 2025;26).

The person who returns to their starting weight after a failed diet is carrying more fat and less muscle than before they began. Their resting metabolic rate is lower. Their body now requires fewer calories to maintain its current weight than it did before the diet started.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

The Compounding Effect: Why Each Cycle Is Harder

A 2024 systematic review by Sanaya, Janusaite, Dalamaga, and Magkos at the University of Copenhagen, published in Current Obesity Reports, evaluated 23 studies and concluded that the overwhelming majority of evidence does not associate weight cycling with adverse effects on body composition or metabolic rate. This conclusion has received significant attention and criticism from the scientific community. The majority of included studies used inadequate follow-up durations, most relied on self-reported weight history rather than validated body composition measurement, the analysis did not stratify by number of cycling episodes, a critical omission if a dose-response relationship exists. Older populations, in whom the body composition consequences are most pronounced, were substantially underrepresented.

The studies that do use validated body composition methods, longer follow-up periods, and older populations tell a more consistent and concerning story. Weight cycling is associated with progressive central fat deposition, enhanced inflammatory response in adipose tissue, with macrophage infiltration and increased production of pro-inflammatory mediators. Repeated glucose fluctuation and hyperinsulinemia place escalating burden on pancreatic beta cells and increasing cardiovascular risk across cycles (Dulloo AG, Rev Endocr Metab Disord. 2025;26). In older populations specifically, weight cycling is associated with acceleration of age-related lean mass loss, and with sarcopenia and sarcopenic obesity when evaluated using validated strength and body composition measures.

A Special Note for Patients With Significant Obesity

Everything described above scales with the severity of restriction required to produce meaningful weight loss. For patients who need to lose large amounts of weight, the gap between current maintenance calories and target weight maintenance calories may be large enough that dietary modification alone triggers a biological response too powerful to overcome through behavioral change alone.

If you have significant weight to lose, unsupervised caloric restriction is not the right starting point. The appropriate strategy is professional medical supervision to define individual caloric targets based on your specific metabolic situation, and to evaluate whether adjuvant pharmacological or surgical intervention is indicated alongside the lifestyle foundation.

Calculating Your Target: One Tool Worth Using Correctly

Before Part Seven builds the practical framework for what to eat, one foundational concept belongs here.

Most people who attempt caloric restriction calculate their daily needs using their current weight. This produces the caloric intake required to sustain current weight not for weight loss The correct approach is to calculate daily caloric needs at your target weight.

The most validated tool available for this calculation is the Mifflin-St Jeor equation for resting metabolic rate (RMR). Across multiple independent validation studies, Mifflin-St Jeor consistently outperforms competing equations including Harris-Benedict and the World Health Organization (WHO) formula in accuracy against gold-standard indirect calorimetry, correctly predicting RMR within 10% of measured values in 82% of subjects (Frankenfield D, et al., J Am Diet Assoc. 2005 and Rocha KF, et al., Medicine. 2024).

The formula:

For men: RMR = (10 x weight in kg) + (6.25 x height in cm) - (5 x age in years) + 5

For women: RMR = (10 x weight in kg) + (6.25 x height in cm) - (5 x age in years) - 161

Use your target weight in kilograms, not your current weight, in this calculation.

The result is your resting metabolic rate: the calories your body requires at complete rest. To estimate total daily energy expenditure (TDEE), multiply by the activity factor that best reflects your typical day:

• Sedentary (desk work, minimal movement): RMR x 1.2

• Lightly active (light exercise 1-3 days per week): RMR x 1.375

• Moderately active (moderate exercise 3-5 days per week): RMR x 1.55

• Very active (hard exercise 6-7 days per week): RMR x 1.725

The number you arrive at is your daily caloric target: the intake required to achieve your target weight. Keeping daily caloric limit at, or below, this number from the outset creates the required caloric deficit needed for gradual weight loss.

Keep in mind the limitations: accuracy is lower in individuals with obesity (approximately 75% versus 87% in non-obese individuals) meaning the equation performs less precisely in the population most likely to be using it. Also the activity multiplier is itself an estimation, adding a second layer of approximation to the calculation. The result is a useful, evidence-based starting point, but not precise.

For anyone who needs greater precision, indirect calorimetry is the gold standard for RMR assessment and is available through clinical weight management programs. If you are working with a medical team, it is worth asking whether it is available to you.

The US National Institutes of Health clinical guidelines on obesity recommend a safe rate of weight loss of approximately 1–2 pounds per week.

The Exit Is Not Another Diet

The biological picture is now complete.

Part Seven introduces the actual diet footprint. Not a meal plan you will follow for six weeks and abandon, but a structure for making food choices you can sustain indefinitely: gives you the tools to build a way of eating that belongs to you.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

I was recently asked by a dear friend my opinion on turmeric supplements and all multiple health claims around it. This post is a careful look at what the evidence actually shows, what it does not show, and how to think about turmeric and the entire category of supplements that promise to do many things at once.

Turmeric the spice is not curcumin the supplement

Turmeric is the dried, ground rhizome of Curcuma longa, a plant in the ginger family that has been used in South Asian cooking and traditional medicine for thousands of years. The yellow color comes from a family of compounds called curcuminoids, of which the most studied is curcumin.

Whole turmeric rhizome contains only 2 to 7 percent curcuminoids by weight, of which curcumin itself represents about 75 to 90 percent (Anand et al., Mol Pharm 2007). A teaspoon of turmeric in your curry is not a curcumin supplement. A curcumin supplement is a concentrated extract, often combined with additives designed to improve intestinal absorption, that bears little resemblance to the spice in your kitchen. Nearly all the clinical research on “turmeric” is actually research on these concentrated, engineered extracts.

Cooking with turmeric at culinary doses has no documented pattern of liver injury when the spice itself is not contaminated. The concerns in this post are about supplements, not about cuisine.

The bioavailability problem

Native curcumin is poorly soluble in water, unstable at the pH of the intestine, rapidly metabolized in the liver, and rapidly excreted. The oral bioavailability of unmodified curcumin is less than 1 percent (Anand et al., Mol Pharm 2007). In plain terms: more than 99 percent of the curcumin you swallow never makes it into your bloodstream in its active form.

The supplement industry workarounds for this problem include combining curcumin with piperine, the active alkaloid from black pepper, which inhibits the enzymes that break curcumin down. Other approaches include phytosome complexes that bind curcumin to phospholipids, liposomal preparations that package it in fatty droplets, nanoparticle formulations, and liquid micelles that suspend it in detergent-like carriers.

A 2025 study published in iScience by an Amsterdam-based research group tested three commercial bioavailability-enhanced formulations, AOV, Longvida, and NovaSOL, in healthy volunteers (Kroon et al., iScience 2025). Plasma levels of unconjugated curcumin, the form that would actually be biologically active, remained below 2 nanomolar for most formulations. NovaSOL, the best performer, produced peak levels between 6.7 and 38 nanomolar at thirty minutes, but these levels fell quickly. Adding piperine provided no measurable benefit in this study.

To put those numbers in context: laboratory studies showing biological effects of curcumin typically use concentrations in the range of 1 to 50 micromolar, which is roughly 100 to 1000 times higher than what these formulations actually achieve in the bloodstream of a person who has just swallowed them. The translation from cell culture to human body has not happened, even with the best engineering the industry has produced.

Why curcumin appears to do everything

In 2017, a team of medicinal chemists published a paper in the Journal of Medicinal Chemistry titled “The Essential Medicinal Chemistry of Curcumin” (Nelson et al., J Med Chem 2017). The paper formally classified curcumin as both a Pan-Assay Interference Compound (PAINS) and an Improbable Metabolic Panacea (IMP).

A PAINS compound is one that produces apparent activity in many different laboratory tests, not because it acts on the biological targets being studied, but because it physically and chemically interferes with the testing methods themselves. The compound generates false positives. Curcumin exhibits every known PAINS behavior: it covalently attaches to proteins in non-specific ways, it chelates metals that the tests depend on, it has redox reactivity that confuses redox-based assays, it aggregates into colloids that disrupt protein interactions, it disrupts cell membranes, it fluoresces and interferes with fluorescence-based readouts, and it chemically decomposes into other reactive products during testing.

An IMP is a compound that has been claimed to act on many different unrelated biological targets, in ways that, taken together, are biologically implausible. The implausibility is itself a clue that what is being measured is not real, target-specific biology.

The reason curcumin appears to act against multiple conditions in laboratory studies is not because it has some miraculous biology that conventional medicine has overlooked, is because compounds with PAINS behavior generate apparent activity across many different testing systems for reasons that have nothing to do with the disease being modeled. The supplement industry reads the wide range of laboratory hits as evidence of a wonder drug.

The Nelson 2017 paper noted that despite more than 120 clinical trials of curcuminoids conducted at the time, no double-blind, placebo-controlled trial of curcumin had been clearly successful. Subsequent trials have produced modest positive findings in some conditions.

What the human trials actually show

Fatty liver disease

Non-alcoholic fatty liver disease, now more commonly called metabolic dysfunction-associated steatotic liver disease (MASLD), is a condition in which fat accumulates in the liver in people who do not drink heavily. It affects roughly one in three American adults and is closely tied to obesity and insulin resistance.

Multiple meta-analyses report that curcumin supplementation produces modest reductions in liver enzymes and small improvements in liver fat measured by ultrasound. A 2023 umbrella review found very high overlap among the available systematic reviews, meaning the same small group of underlying trials keeps getting reanalyzed and republished in new reviews, which makes the evidence base look larger than it actually is.

The longest available trial randomized 78 Thai adults with type 2 diabetes and MASLD to 1500 mg per day of curcumin or placebo for 12 months, on a background of metformin (Yaikwawong et al., Curr Issues Mol Biol 2025). The curcumin group showed statistically significant improvements in liver fat by imaging, in hemoglobin A1c (HbA1c), and in fasting glucose. The improvements were real but modest, in a single small trial at a single site.

None of the available evidence supports curcumin as a primary treatment for fatty liver disease. The cornerstone of management remains weight loss through dietary change and exercise.

Blood sugar

For type 2 diabetes and prediabetes, the most rigorous available meta-analysis pooled 18 randomized trials including 1,382 patients and reported an average HbA1c reduction of 0.54 percent and a fasting glucose reduction of about 11.5 mg/dL with curcumin supplementation (Mokgalaboni et al., Nutrients 2024).

That sounds meaningful until you compare it to a real medication. Metformin, the first-line treatment for type 2 diabetes, typically lowers HbA1c by 0.5 to 1.0 percent and is one of the best-characterized drugs in modern medicine.

Cholesterol, inflammation, and metabolic syndrome

For systemic inflammation measured by C-reactive protein (CRP), a 2025 dose-response meta-analysis in prediabetes and type 2 diabetes reported significant reductions in CRP, tumor necrosis factor alpha (TNF-α), and interleukin-6 (IL-6) (Naghibi et al., Diabetol Metab Syndr 2025). The authors detected publication bias for CRP and rated the overall certainty of evidence as low for all inflammatory biomarkers using the GRADE assessment framework. In plain language, curcumin supplements do appear to lower markers of inflammation in the blood, but the evidence quality is poor and there are signs that negative studies are not being published.

For metabolic syndrome as a whole, a meta-analysis of 13 trials reported modest improvements (Hejazi et al., Front Nutr 2023). Ten of the 13 trials came from Iran: the geographic concentration is a quality-of-evidence concern, not because Iranian research is intrinsically suspect, but because reproducibility across independent research traditions is one of the strongest tests of any finding.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Knee osteoarthritis

The most rigorous independent trial was published in the Annals of Internal Medicine in 2020 (Wang et al., Ann Intern Med 2020). Seventy participants with symptomatic knee osteoarthritis and ultrasound-confirmed knee inflammation were randomized to a Curcuma longa extract at 1000 mg per day or placebo for 12 weeks. Pain improved by 9.1 mm on a 100 mm visual analog scale, just at the edge of what is considered a minimum clinically important difference. There was no change in inflammation measured by MRI, no change in cartilage quality measured by MRI, and no change in any inflammatory blood marker including TNF-α, IL-6, hsCRP, or MMP-3 (Wang et al., Phytomedicine 2023).

For comparison, acetaminophen, an over-the-counter analgesic that we have collectively decided is not a particularly impressive arthritis treatment, produces pain reductions in the same approximate range in osteoarthritis trials.

The broader meta-analytic literature on curcumin for knee osteoarthritis includes many trials of proprietary formulations conducted with industry involvement, predominantly in Asia. Across this body of work, curcumin produces modest pain relief comparable to or somewhat less than non-steroidal anti-inflammatory drugs (NSAIDs) in short-term studies, with fewer gastrointestinal side effects. This is genuinely useful information for some patients, but hardly a major therapeutic advance.

Globally, osteoarthritis affected approximately 595 million people in 2020, about 7.6 percent of the world population, with a 132 percent increase since 1990 and substantial further increases projected through 2050 (GBD 2021 Osteoarthritis Collaborators, Lancet Rheumatol 2023). The condition is enormous in scale and our pharmacological options for it remain inadequate. The foundation of management remains weight loss, exercise, physical therapy, and judicious use of analgesics. Curcumin is not better than acetaminophen, but acetaminophen is not a great answer either.

The safety story almost no one taking turmeric has heard

Liver injury

Turmeric supplements are now formally listed in the LiverTox database, maintained by the National Institute of Diabetes and Digestive and Kidney Diseases of the National Institutes of Health, as a known cause of drug-induced liver injury (LiverTox: Turmeric, NIH, updated 2025).

The most carefully characterized series comes from the Drug-Induced Liver Injury Network (DILIN), a prospective surveillance system that adjudicates suspected cases of medication-related liver injury at academic centers across the United States. In 2023, the DILIN group published 10 cases of turmeric-associated liver injury, all enrolled since 2011, with 6 since 2017 (Halegoua-DeMarzio et al., Am J Med 2023). Liver injury was hepatocellular in 9 of 10, which is the pattern that carries the highest risk of progression to liver failure. Five patients required hospitalization, one patient died of acute liver failure. Chemical analysis confirmed turmeric in all 7 products tested; 3 also contained piperine.

The DILIN investigators went further and looked at the human leukocyte antigen (HLA) genotypes of the affected patients. Seven of the 10 cases carried the HLA-B*35:01 allele, with two of them homozygous. The carrier frequency in cases was 70 percent, compared with approximately 6 percent in the general United States population (Halegoua-DeMarzio et al., Am J Med 2023). Subsequent case reports have confirmed the association.

While HLA-B*35:01 is the strongest known risk factor for turmeric-associated liver injury, testing is not part of any routine clinical workup. People who carry the allele have no way of knowing they carry it before liver injury happens. On the other hand, three of the 10 DILIN cases occurred in people who did not carry the genetic marker, including the fatal case. So the susceptibility marker identifies the highest-risk subgroup, but it does not identify everyone at risk.

Drug interactions

Curcumin inhibits multiple cytochrome P450 enzymes, the family of liver enzymes responsible for metabolizing the majority of prescription drugs in use today, including warfarin, clopidogrel, statins, certain antiepileptics, and many antidepressants (Bahramsoltani et al., J Ethnopharmacol 2017).

The interaction problem is compounded by piperine, the bioavailability enhancer added to many turmeric supplements. Piperine is itself a potent inhibitor of cytochrome P450 3A4 (CYP3A4), the most important drug-metabolizing enzyme in the body. A 2024 study in the International Journal of Molecular Sciences used physiologically based pharmacokinetic (PBPK) modeling to predict drug interactions for piperine at 20 mg per day, a typical supplement dose taken for 7 days (Lin et al., Int J Mol Sci 2024).

The predicted increases in blood drug exposure were substantial: simvastatin by 59 percent, alfentanil by 39 percent, triazolam by 36 percent, cyclosporine by 35 percent, nifedipine by 34 percent, and ritonavir by 31 percent.

These are common drugs used in cardiology (simvastatin, nifedipine), transplant medicine (cyclosporine), anesthesia (alfentanil), psychiatry (triazolam), and HIV care (ritonavir). A patient on any of these who takes a turmeric-plus-piperine supplement may be experiencing a significant change in drug exposure that neither they nor their prescribing physician has been told about.

Iron, gallbladder, and the supply chain

Whole turmeric inhibits iron absorption by 20 to 90 percent in a dose-dependent manner (Tuntipopipat et al., Int J Food Sci Nutr 2009). This matters for menstruating women, vegetarians, patients with inflammatory bowel disease, and anyone with marginal iron status.

Concentrated curcumin is also relatively contraindicated in patients with active gallbladder disease because it stimulates gallbladder contraction, which can precipitate symptoms in someone with gallstones.

And then there is the lead. Systematic sampling of turmeric across India, Pakistan, Sri Lanka, and Nepal found that 14 percent of 356 samples contained detectable lead above 2 micrograms per gram, with some samples exceeding 1,000 micrograms per gram (Forsyth et al., Sci Total Environ 2024). The source was identified as lead chromate, a yellow pigment that some processors add to enhance the color of turmeric powder. Bangladesh successfully eliminated this adulteration between 2019 and 2021 through coordinated regulatory action, with market sample contamination dropping from 47 percent to zero (Forsyth et al., Environ Res 2023).

There is no safe level of lead exposure, the lead problem is largely separate from the curcumin question, but for any reader thinking about turmeric in either spice or supplement form, sourcing matters.

What is actually in the bottle

Researchers from the National Institutes of Health Dietary Supplement Ingredient Database program analyzed 54 commercially available turmeric supplements (Saldanha et al., J Food Composition Analysis 2021). Among products labeled to contain 500 mg of turmeric, the actual measured curcuminoid content ranged from 16 mg to 554 mg. That is a 35-fold range in the amount of active ingredient at the same label dose. Two bottles on the same shelf can contain wildly different amounts of the compound you are supposedly purchasing.

This is what supplement regulation under the Dietary Supplement Health and Education Act (DSHEA) looks like in practice. There is no premarket approval requirement for efficacy or safety or no enforced standardization of active ingredient content. The label tells you very little about what is in the capsule.

How to think about turmeric, and supplements like it

In my opinion turmeric is a wonderful spice I use on several of my favorite dishes, but the evidence to date supporting its use as a health supplement is thin to none existent and the potential for liver toxicity too severe to ignore.

Some readers will look at the evidence presented here and conclude that a small benefit at unknown risk is not a trade they want to make. Some will conclude that they have taken turmeric for years without incident and will continue. Others using cardiac or other medications will to talk to their doctor before changing anything.

The information covered here summarizes the evidence we have to this date, backed by empiric science and free of any marketing influence.

Now, only you can decide what to do with it.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

The metabolic consequences of that mismatch are directly relevant to your health.

Two Systems, One Cascade

The first is the sympathetic-adrenomedullary (SAM) axis, which is fast. Within seconds of perceiving a threat, it releases epinephrine and norepinephrine from the adrenal medulla, producing the classic fight-or-flight response: elevated heart rate, dilated pupils, mobilized glucose, heightened alertness. This response peaks quickly and, under normal circumstances, resolves quickly.

The second is the hypothalamus-pituitary-adrenal (HPA) axis, which is slower but more consequential. Threat perception triggers the hypothalamus to release corticotropin-releasing hormone (CRH), which signals the pituitary to release adrenocorticotropic hormone (ACTH), which drives the adrenal cortex to produce cortisol. This cascade takes minutes but produces effects that last hours. Cortisol is the molecule that keeps the biological alarm running after the initial burst, sustaining the metabolic mobilization until the threat passes and the system returns to baseline.

In acute stress cortisol mobilizes glucose, suppresses non-essential functions like digestion and reproduction, and keeps you alert and responsive. When the threat resolves, cortisol drops, the inhibitory feedback loop kicks in, and the system resets.

Chronic stress prevents that reset. According to a 2023 narrative review in Frontiers in Endocrinology, the nervous system recalibrates around sustained activation, and the biological motor keeps running at a level it was never designed to sustain indefinitely.

The Cumulative Price of Never Coming Down

Allostatic load is the term introduced by McEwen and Stellar in their landmark 1993 paper in Archives of Internal Medicine to describe the cumulative biological wear produced by repeated or prolonged stress responses that never fully resolve. It is a measurable composite score incorporating neuroendocrine, immune, metabolic, and cardiovascular biomarkers, and it predicts morbidity and mortality better than any single biomarker tested in isolation (Juster, McEwen, and Lupien, Neuroscience and Biobehavioral Reviews, 2010).

A 2025 analysis of 205,504 adults from the UK Biobank found that individuals with the highest allostatic load scores carried more than double the cardiovascular disease risk of those with the lowest scores. Allostatic load is produced by the interaction between chronic HPA activation and the behavioral patterns that chronic stress drives. Each of these behaviors amplifies the biological cost of the others.

What Is Actually Causing Your Chronic Stress

Work stress and burnout. Occupational stress is the most prevalent chronic psychosocial stressor in the adult population. Chronic job stress is associated with approximately 120,000 deaths per year in the United States, primarily through cardiovascular disease (Wellhub 2025 Workplace Stress Report). In 2025, 85% of workers reported burnout or exhaustion. The World Health Organization formally recognizes burnout as an occupational phenomenon. A 2025 systematic review confirmed associations between job strain, long working hours, shift work, and cardiometabolic risk factors including hypertension, impaired glucose metabolism, and obesity. Burnout independently predicts hypercholesterolemia, type 2 diabetes, and coronary heart disease.

Relationship and family stress. Interpersonal conflict, marital discord, family dysfunction, and caregiver burden all activate the HPA axis through the same threat appraisal pathway. Human social bonding is neurobiologically linked to safety, which means that disruption of close relationships registers as a genuine biological threat. A 2025 review in the American Journal of Medicine confirmed interpersonal psychological stress as a primary contributor to chronic HPA dysregulation. For the many adults in the 30 to 70 age range simultaneously managing aging parents and dependent children, caregiver stress represents a chronic stressor that rarely resolves on a defined timeline.

Financial stress. Voluntary overconsumption driven by social comparison and lifestyle inflation, particularly as amplified by influencer culture, is a modifiable stressor with behavioral solutions. Genuine financial distress from inability to meet basic necessities is a problem where individual behavioral intervention has limited reach. Both activate the same cortisol cascade.

Social isolation and loneliness. The absence of social connection functions as a chronic biological stressor. A 2025 review in the journal Stress confirmed that loneliness activates the HPA axis and sympathetic nervous system, producing sustained cortisol and catecholamine elevation, glucocorticoid resistance, and metabolic dysregulation. Studies consistently find higher cortisol awakening responses and flattened diurnal cortisol rhythms in lonely individuals. The US Surgeon General declared loneliness a public health epidemic in 2023, with the WHO estimating that approximately one in three older adults in the United States experiences it.

Online social interaction does not produce the neuroendocrine attenuation that in-person contact provides. Digital connection activates the social cognition network without delivering the oxytocin release and parasympathetic regulation that physical presence generates.

Social media and news consumption. A 2025 nationally representative study of 1,512 US adults aged 30 to 70 found both the time and frequency of social media use independently and linearly associated with loneliness. More directly, a controlled study demonstrated that social media use immediately following an acute stressor impaired cortisol recovery, sustaining elevated salivary cortisol compared to controls. Social media does not necessarily spike cortisol in the moment, it prevents the HPA axis from returning to baseline after stress activation.

Chronic news consumption: repeated exposure to conflict, disaster, and unresolved uncertainty maintains a sustained threat appraisal state. A 2023 study in Health Psychology confirmed that problematic news consumption was independently associated with stress, anxiety, and impaired functioning in a US adult sample.

What Chronic Stress Is Doing to Your Metabolism

Insulin resistance. Chronic cortisol elevation stimulates hepatic gluconeogenesis while simultaneously reducing peripheral insulin sensitivity. A study in a Chinese population directly measured chronic stress scores against homeostatic model assessment of insulin resistance (HOMA-IR) and found a statistically significant independent association. One randomized controlled trial found that controlling for cortisol and testosterone eliminated 50% of stress-induced insulin resistance, directly implicating cortisol as a primary mechanism rather than a byproduct of the same underlying state.

The stress-diet interaction. Chronically stressed individuals show increased consumption of hyperpalatable, energy-dense foods through cortisol-driven reward pathway sensitization. The combination of chronic stress and a high-fat, high-sugar diet produces greater visceral adiposity than either factor alone, documented in a human case-control study.

Visceral fat. Cortisol preferentially drives fat deposition to visceral compartments rather than subcutaneous depots. Visceral adipose tissue is pro-inflammatory, metabolically active in harmful ways, and directly associated with insulin resistance, dyslipidemia, and cardiovascular disease in ways that subcutaneous fat is not. A 2025 comprehensive review in Clinical Obesity confirmed chronic cortisol exposure as a driver of obesity through visceral fat accumulation. The Yale Epel study demonstrated excess abdominal fat in non-overweight women with high stress reactivity, linking stress biology to visceral adiposity independent of overall body weight.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Cardiovascular disease. A 2025 review confirmed a cascade involving neuroendocrine, immune, and inflammatory systems leading to endothelial damage, atherosclerosis progression, and microvascular dysfunction in chronically stressed individuals. A 2024 narrative review in Heart and Mind confirmed cortisol-driven tumor necrosis factor-alpha (TNF-alpha) secretion produces endothelial dysfunction and plaque progression with increasing effect as stress duration extends. For postmenopausal women specifically, the estrogen-mediated endothelial protection that blunted this pathway during reproductive years is no longer present, making older women with chronic stress exposure particularly vulnerable to stress-mediated cardiovascular disease.

Systemic inflammation. Chronic HPA activation produces glucocorticoid receptor resistance over time. The anti-inflammatory signaling function of cortisol, one of its primary physiological roles, becomes less effective as receptors downregulate in response to chronic exposure. The result is simultaneous hypercortisolism and impaired glucocorticoid anti-inflammatory function. A 2025 MDPI review confirmed this produces a pro-inflammatory state that drives metabolic and autoimmune consequences across multiple organ systems. Systemic inflammation is the convergent pathway connecting chronic stress to insulin resistance, cardiovascular disease, and neurodegeneration.

The mortality evidence. An American Journal of Preventive Medicine systematic review and meta-analysis confirmed high allostatic load independently associated with significantly increased all-cause and cardiovascular disease mortality. A 2022 Lancet Regional Health Europe population-based cohort study confirmed stress-related disorders independently associated with increased all-cause mortality, controlling for familial confounding through sibling comparison. A 2024 PLOS ONE analysis of the Midlife in the United States (MIDUS) cohort of 2,915 adults found daily stressor exposure associated with 20% higher mortality risk per standard deviation increase at age 50. A 2025 JMIR Aging study found high social stress associated with 28% higher all-cause mortality compared to low social stress. Stress-related mental health disorders reduce life expectancy by 10 to 20 years, primarily through cardiovascular disease, with depression associated with a 72% higher cardiovascular disease risk and post-traumatic stress disorder (PTSD) with a 61% higher risk (Chan et al., World Psychiatry, 2025).

Chronic Stress Undermines Every Other Intervention

The 2023 Nature Reviews Endocrinology review confirmed that life stress operates on metabolic disorders through both direct neuroendocrine pathways and indirect behavioral pathways, with sleep disturbance identified as the key mediating pathway. Cortisol drives hyperpalatable food consumption through reward pathway sensitization, directly undermining dietary changes. Chronic stress reduces exercise adherence through fatigue, motivational depletion, and the preferential activation of sedentary reward-seeking behavior. And the relationship between HPA activation and sleep is bidirectional: stress disrupts sleep, disrupted sleep elevates cortisol, and elevated cortisol further disrupts sleep.

Taking Back Control: What the Evidence Supports

Stress management interventions work through two mechanisms: reducing or resolving the stressor itself, and modifying the physiological response to it.

Cognitive behavioral therapy. Cognitive behavioral therapy (CBT) is the most evidence-supported psychological intervention for chronic stress. CBT directly targets the cognitive component identified as the trigger of the physiological stress response. By modifying dysfunctional thought patterns, catastrophic predictions, and maladaptive coping strategies, CBT reduces the perception of threat. A 2024 systematic review confirmed that successful CBT normalizes the HPA system by reducing acute cortisol responses to stress stimuli and normalizing basal cortisol levels. A randomized controlled trial (ScienceDirect 2019, n=138) found CBT produced greater HPA axis habituation, including pre-stressor measurements, indicating that CBT reduces the anticipatory cortisol response operating earlier in the stress cascade. A 2024 comprehensive review of 16 behavioral stress reduction programs across more than 200 studies confirmed CBT-based programs produce measurable reductions in cortisol and allostatic load. Digital CBT programs are increasingly available and accessible without specialist referral.

Mindfulness-based stress reduction. Mindfulness-based stress reduction (MBSR) is evidence-supported as a complement to CBT rather than an alternative. A 2024 systematic review in Neurology International found significant cortisol changes following mindfulness-based interventions in 25 of 35 studies examined. MBSR primarily enhances cortisol recovery after stress activation; CBT additionally reduces the anticipatory response. Combined approaches outperform either alone.

Yoga, Tai Chi, and mind-body practice. The most comprehensive head-to-head comparison of exercise modalities for cortisol reduction, a 2025 network meta-analysis of 44 randomized controlled trials (RCTs) published in MDPI Sports, found yoga demonstrated the greatest cortisol reduction effect across all exercise modalities, with a standardized mean difference (SMD) of -0.59 and a surface under the cumulative ranking curve (SUCRA) score of 93%. A 2023 Tai Chi RCT found significantly reduced salivary cortisol and measurable brain structural changes after 12 weeks. The mechanism across both practices is parasympathetic nervous system activation through breath-focused movement, simultaneously reducing HPA axis activity and increasing vagal tone.

Regular exercise. Chronic regular exercise produces HPA axis habituation, meaning a blunted cortisol response to both physical and psychological stressors compared to sedentary individuals. The 2025 network meta-analysis confirmed moderate cortisol reductions across exercise modalities generally, with yoga the most effective specific form. Any sustained exercise program contributes to stress biology regulation, independent of its direct metabolic effects.

Social connection. Physical social contact triggers oxytocin release and parasympathetic activation, reducing cortisol and attenuating the HPA axis response to subsequent stressors. The Heinrichs et al. foundational study (Biological Psychiatry, 2003) confirmed that social support combined with oxytocin suppressed both cortisol and subjective stress responses to a standardized psychosocial stressor. A 2024 World Psychiatry comprehensive review confirmed robust evidence for social connection as an independent predictor of mental and physical health, with the strongest evidence concentrated on mortality outcomes.

Practical pathways to meaningful in-person contact include work relationships, religious or spiritual community, hobby groups, family investment, and community activities.

Relationship and family counseling. Couples therapy and family therapy have documented evidence bases for reducing relationship conflict and resolving the dynamics that sustain chronic HPA activation.

Media and news consumption boundaries. Setting deliberate limits on news and social media consumption removes chronic low-grade HPA activators from your daily environment. The 2023 Health Psychology study confirmed that reduction in problematic news consumption was independently associated with reduced stress, anxiety, and functional impairment. Screen-free periods in the two hours before bed address both stress and sleep mechanisms simultaneously.

Financial literacy. For stress driven by voluntary overconsumption and perceived financial disorder, financial literacy directly reduces the magnitude of the stressor rather than modifying the response to it. A 2024 analysis using Panel Study of Income Dynamics (PSID) data found that borrowers with high financial literacy were 60.3% less likely to experience mortgage stress than those with low financial literacy. A longitudinal study confirmed that favorable changes in financial strain over three years were associated with reduced ambulatory blood pressure and lower cortisol awakening response, directly linking financial stress resolution to neuroendocrine normalization.

Financial distress from inability to meet basic necessities requires solutions that individual financial literacy cannot substitute for.

Time in natural environments. A meta-analysis of 22 studies including 8 RCTs found statistically significant cortisol reductions from “forest bathing” (mean difference -0.08 micrograms per deciliter before and -0.05 after, p less than 0.01). A 2024 Frontiers in Psychology review confirmed cortisol reductions, improved heart rate variability (HRV), and enhanced parasympathetic dominance. A 2025 narrative review confirmed associations with enhanced natural killer cell activity and shifts toward parasympathetic autonomic dominance.

Americans spend approximately 90% of their time indoors, intentional daily time in natural environments is available to most readers at no cost. A park, a garden, or any natural setting delivers a meaningful component of the effect.

Pharmacological support. Medications for stress-related symptoms are bridges, not treatments. Anxiolytics reduce acute anxiety symptoms but carry tolerance, tachyphylaxis, dependence, and sleep architecture disruption risks. Antidepressants have evidence for stress-related anxiety and depression meeting clinical thresholds but do not address the stressor or modify the appraisal pattern driving HPA activation. Combined CBT and pharmacotherapy, where both are clinically indicated, produces stronger outcomes than either alone: the medication reduces the physiological noise that makes CBT difficult to engage with, while CBT builds the durable cognitive architecture that makes eventual discontinuation of medication possible.

If you are experiencing stress-related symptoms that meet clinical threshold, discuss pharmacological options with your physician as part of a broader treatment plan. Prescribing medication without simultaneously initiating behavioral intervention addresses the symptom while leaving the cause unchanged.

The Combinatorial Principle

No single intervention transforms chronic stress biology. The most effective approach combines stressor reduction with response modulation: counseling, financial literacy, media boundaries, social investment, and time in natural environments on one side; CBT, mindfulness, yoga, and exercise on the other. The degree of implementation determines the degree of benefit.

The complete framework addresses the cause and the response, that is how biology works.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

Berberine is a plant alkaloid, a class of nitrogen-containing compounds that plants produce not for human benefit but as chemical defense mechanisms against insects, herbivores, and microbial pathogens. It is found in the roots, bark, and stems of several plant species, including Berberis vulgaris (barberry), Coptis chinensis (goldenseal’s Asian relative), and Hydrastis canadensis (goldenseal itself).

Its history of human use spans approximately 3,000 years in traditional Chinese medicine and Ayurvedic practice, almost entirely as an antimicrobial. It was used for gastrointestinal infections, wound treatment, and diarrheal illness. The metabolic applications are entirely modern, and they were discovered accidentally: Chinese physicians treating diabetic patients with berberine-containing herbal preparations in the 1980s noticed unexpected improvements in fasting glucose. That observation eventually prompted systematic investigation.

The Bioavailability Problem

Oral bioavailability is under 1% in humans (Expert Opinion on Drug Metabolism and Toxicology, 2023). Following a standard 300mg dose, peak plasma concentration reaches approximately 0.33 micrograms per liter. Approximately 99.5% of an oral berberine dose is eliminated during gastrointestinal first-pass processing, through a combination of P-glycoprotein-mediated efflux, extensive intestinal and hepatic first-pass metabolism by cytochrome P450 (CYP) enzymes, and low membrane permeability.

Because berberine is poorly absorbed, it accumulates at very high concentrations in the gastrointestinal (GI) tract before the small fraction that survives first-pass metabolism enters systemic circulation. High local concentrations act directly on intestinal enzymes involved in carbohydrate digestion, on enteroendocrine cells that secrete gut hormones, and on the gut microbiome.

Metformin, the best-characterized oral diabetes medication available, works through a strikingly similar model. Metformin accumulates in intestinal epithelial cells at concentrations far exceeding plasma levels, stimulates GLP-1 secretion from enteroendocrine L-cells in the distal gut, alters bile acid metabolism, and remodels the gut microbiome, particularly increasing Akkermansia muciniphila (McCreight et al., Diabetologia, 2016). A delayed-release metformin formulation achieves comparable glycemic control to immediate-release with significantly less systemic exposure, a finding that supports the gut as a primary site of action rather than systemic circulation. Berberine and metformin share this gut-predominant profile and produce overlapping microbiome changes.

Dihydroberberine and phytosome-complexed berberine products claim improved bioavailability. The problem is that improved systemic absorption does not come with clinical outcome evidence demonstrating better results. The formulation claims are ahead of the evidence and the safety implications of enhanced bioavailability are genuinely unknown.

What the Science Actually Shows

Glucose Lowering

Multiple meta-analyses demonstrate significant reductions in fasting plasma glucose (weighted mean difference of approximately -0.515 mmol/L) and two-hour oral glucose tolerance test (OGTT) glucose (weighted mean difference of approximately -1.606 mmol/L) compared to placebo in metabolic syndrome and type 2 diabetes mellitus (T2DM) populations.

The most frequently cited head-to-head trial compared berberine directly to metformin in 116 patients with T2DM over 13 weeks (Yin et al., Metabolism, 2008). Both produced approximately 2 percentage point reductions in glycated hemoglobin (HbA1c). A 2023 meta-analysis in JAMA Network Open confirmed comparable glucose lowering across multiple trials.

The evidence comes overwhelmingly from Chinese populations with established T2DM who were simultaneously implementing lifestyle modification. The contribution of concurrent lifestyle change to the observed outcomes cannot be cleanly separated from berberine’s pharmacological effect. Western, non-diabetic populations are not adequately represented in the evidence base.

The head-to-head trials are open-label, small-sample, and short-duration. The glucose-lowering effect is a real finding in a specific population under specific conditions.

Lipid Modulation

Berberine produces consistent reductions in low-density lipoprotein cholesterol (LDL-C) (weighted mean difference approximately -0.495 mmol/L), total cholesterol (approximately -0.451 mmol/L), and triglycerides (approximately -0.367 mmol/L) compared to placebo. High-density lipoprotein cholesterol (HDL-C) is not significantly affected.

The mechanism responsible for LDL-C reduction includes upregulation of LDL receptor expression through inhibition of proprotein convertase subtilisin/kexin type 9 (PCSK9). PCSK9 is the same target as evolocumab and alirocumab, two injectable monoclonal antibodies that represent some of the most expensive cholesterol medications available (Kong et al., Nature Medicine, 2004). Berberine achieves PCSK9 inhibition through a different mechanism than these biologics.

A 2023 meta-analysis of 44 randomized controlled trials (RCTs) found that berberine alone showed no significant lipid benefit compared to statins or standard care, with very high heterogeneity across trials (I-squared of 76-96%) (Yang et al., Phytomedicine, 2023). Berberine reduces lipids compared to placebo.

Weight and Body Composition

A 2025 meta-analysis of 23 RCTs found statistically significant reductions in body weight (mean difference -0.88 kg), body mass index (BMI) (mean difference -0.48 kg per square meter), and waist circumference (mean difference -1.32 cm), but no significant reduction in waist-to-hip ratio, suggesting minimal specific effect on visceral fat (International Journal of Obesity, 2026).

The most plausible interpretation is that the modest weight effect is secondary to metabolic improvement rather than a primary fat-loss mechanism. Berberine is not acting on appetite regulation, energy expenditure, or adipose tissue biology in any way that resembles GLP-1 receptor agonism.

Gut Microbiome

Berberine increases certain bacterial species in the gut, particularly Akkermansia muciniphila, through an indirect mechanism involving gut mucin secretion and alterations in the intestinal environment produced by its antimicrobial activity and metabolic effects (Xie et al., Microbiology Spectrum, 2025). Akkermansia muciniphila is associated with metabolic health in observational data. The human evidence for clinically meaningful microbiome benefit from berberine supplementation remains limited. The marketing extrapolation from a specific mechanistic finding to a general wellness claim is not supported.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Cancer Claims

Almost all of berberine’s marketed cancer claims are based on cell culture experiments using concentrations that cannot be achieved in human tissue at standard oral doses. Given that less than 1% of berberine reaches the bloodstream, the plasma concentrations that might be relevant to systemic tumor biology simply do not materialize.

Colorectal adenoma chemoprevention is the strongest evidence berberine has in any clinical application, and the mechanism is coherent. A multicenter, double-blind RCT enrolled 1,100 Chinese post-polypectomy patients and found that berberine 0.3g twice daily reduced adenoma recurrence by 23% relative risk reduction at two years compared to placebo (Chen et al., Lancet Gastroenterology and Hepatology, 2020). A 2025 six-year follow-up study of the same cohort found durable protection persisting after treatment cessation: adenoma recurrence occurred in 34.7% of the berberine group versus 52.1% in the placebo group, with neoplasm occurrence also lower in the berberine arm (Tan et al., Lancet Regional Health, Western Pacific, 2025).

The compound does not need systemic absorption to act on colonic mucosa. The bioavailability problem that undermines systemic cancer claims is the same pharmacokinetic feature that makes colorectal adenoma chemoprevention biologically plausible.

The Logical Comparison, Metformin

Berberine and metformin share mitochondrial respiratory complex I inhibition in intestinal epithelium as a core mechanism for glucose lowering. Berberine’s glucose-lowering effect includes both AMP-activated protein kinase (AMPK)-dependent and AMPK-independent pathways: complex I inhibition drives glycolysis stimulation directly, with AMPK activation as a consequence rather than the primary mechanism (Liu et al., Journal of Cellular and Molecular Medicine, 2018). Both compounds work predominantly in the gut. Both increase Akkermansia muciniphila. Both reduce fasting glucose and HbA1c in T2DM populations. Short-duration head-to-head trials show comparable surrogate endpoint effects.

Metformin has decades of cardiovascular outcome data, including the United Kingdom Prospective Diabetes Study (UKPDS), which demonstrated reduction in macrovascular endpoints in overweight T2DM patients. No equivalent hard outcome data exists for berberine. No myocardial infarction, stroke, or mortality endpoint trial has been completed. A Mendelian randomization study using UK Biobank data found that a berberine biological response was associated with reduced risk of ischemic heart disease (odds ratio 0.85, 95% CI 0.79-0.91) and diabetes (odds ratio 0.88, 95% CI 0.80-0.96) (Zhao et al., npj Cardiovascular Health, 2026). Mendelian randomization provides stronger causal inference than standard observational data, but it does not substitute for a randomized outcome trial.

Metformin is manufactured under Food and Drug Administration (FDA) regulatory oversight to standardized pharmaceutical specifications, berberine supplements are not. Metformin is frequently covered by insurance when prescribed, berberine supplements are not. Metformin is available as a generic for under $10 per month.

For every metabolic indication where berberine is being marketed, metformin is a thoroughly characterized, FDA-regulated, generically available alternative that any physician will readily prescribe if clinically indicated. The comparison between them is not close.

Adverse Effects and Drug Interactions

Gastrointestinal Effects

GI side effects are the most common adverse effects of berberine: nausea, constipation, diarrhea, abdominal cramping, and flatulence. They are usually dose-dependent and self-limiting, and they parallel the GI side effect profile of metformin. For most people, they are manageable.

A Theoretical Concern Grounded in Mechanism

Berberine, metformin, and phenformin, a biguanide withdrawn from clinical use in the 1970s, all inhibit mitochondrial complex I as a shared mechanism. Phenformin was withdrawn because it produced unacceptable rates of lactic acidosis, a life-threatening complication of impaired lactate clearance when mitochondrial function is suppressed. Metformin produces lactic acidosis at a far lower rate, which is why it remains in use, but the FDA mandates contraindication in patients with renal impairment, hepatic insufficiency, or conditions associated with tissue hypoperfusion, precisely because these states reduce the safety margin around complex I inhibition.

Berberine produces dose-dependent lactate elevation consistent with complex I inhibition (Oncotarget, 2018). No documented human case of berberine-associated lactic acidosis exists in the literature. This is a theoretical concern grounded in mechanism but it is a concern that demands specific attention for patients with renal impairment, hepatic insufficiency, or tissue hypoperfusion, and for anyone considering high-bioavailability formulations whose systemic exposure profile has not been safety-characterized. These patients are not candidates for self-directed berberine supplementation.

The Real Health Concern

Berberine is a potent inhibitor of several cytochrome P450 (CYP) liver enzymes, the enzyme family responsible for metabolizing the majority of pharmaceutical drugs in common use. When these enzymes are inhibited, medications that depend on them for clearance accumulate to higher plasma concentrations than intended. Depending on the drug involved, that accumulation can range from clinically inconsequential to life-threatening.

A randomized crossover study in healthy volunteers receiving berberine 300mg three times daily for two weeks demonstrated a ninefold increase in the urinary dextromethorphan/dextrorphan ratio, a validated measure of CYP2D6 inhibition, and a twofold increase in the losartan/E-3174 ratio, a validated measure of CYP2C9 inhibition (Guo et al., European Journal of Clinical Pharmacology, 2012). P-glycoprotein inhibition and CYP3A4 inhibition have been demonstrated at doses as low as 300mg per day in cyclosporine interaction studies (Xin et al., 2006).

The clinical implications depend on which medications are involved:

Warfarin and anticoagulants. Berberine inhibits the CYP2C9-mediated metabolism of warfarin, the primary route of warfarin clearance. When CYP2C9 is inhibited, warfarin plasma levels rise and anticoagulant effect intensifies. The consequence is elevated bleeding risk, including intracranial hemorrhage. Direct oral anticoagulants (DOACs) including rivaroxaban and apixaban are metabolized through CYP3A4 and P-glycoprotein pathways, both of which berberine inhibits. Any patient on anticoagulation therapy who takes berberine without physician oversight is accepting an unquantified and potentially serious bleeding risk.

Immunosuppressants. Cyclosporine and tacrolimus, the cornerstone immunosuppressants used after organ transplantation, have narrow therapeutic windows and are metabolized through CYP3A4. Berberine’s CYP3A4 inhibition raises their plasma concentrations, increasing the risk of nephrotoxicity and other dose-dependent toxicities.

Psychiatric medications. A large proportion of antidepressants and antipsychotics, including fluoxetine, paroxetine, haloperidol, risperidone, and aripiprazole, are metabolized primarily through CYP2D6. Berberine’s potent CYP2D6 inhibition raises their plasma concentrations in ways that cannot be predicted without therapeutic drug monitoring. The consequences range from intensified side effects and cardiac arrhythmia.

Antiarrhythmics and beta-blockers. Metoprolol, carvedilol, propafenone, and flecainide are among the cardiac medications metabolized through CYP2D6. Concentration increases in this drug class carry direct cardiac risk, particularly in patients with underlying structural heart disease.

Statins. Several statins, including simvastatin and atorvastatin, are metabolized through CYP3A4. Berberine’s CYP3A4 inhibition raises statin concentrations and increases the risk of statin-associated myopathy and, at high concentrations, rhabdomyolysis.

Insulin and insulin secretagogues. Berberine’s own glucose-lowering effect, combined with the blood-glucose-lowering effect of insulin or sulfonylureas, creates additive hypoglycemic risk. A patient on a sulfonylurea who adds berberine without dose adjustment is at increased risk for hypoglycemic episodes.

The interaction profile is additive. A patient on warfarin, a statin, metoprolol, and an antidepressant, a combination that describes millions of Americans with metabolic and cardiovascular disease, who adds berberine faces simultaneous inhibition of the clearance pathways for all four medications. The cumulative pharmacokinetic effect is not predictable without clinical monitoring (International Journal of Molecular Sciences, 2025;26(11):5188).

A Hard Contraindication

Any pregnant woman, or anyone who may become pregnant, should not take berberine. Any breastfeeding person should not take berberine. This applies to berberine from any source, including traditional herbal preparations that contain it.

Berberine displaces bilirubin from albumin, the protein that normally keeps unbound bilirubin in check (Chan E., Biological Neonate, 1993). Chronic administration produces persistent elevation of unbound serum bilirubin in animal models. Berberine crosses the placenta, the neonatal liver lacks the enzymatic maturity to conjugate bilirubin efficiently, making the fetus and neonate specifically vulnerable to bilirubin-induced neurological damage. Case reports associate berberine-containing herbal preparations with neonatal jaundice and kernicterus risk. Berberine also has documented uterotonic properties.

Hepatotoxicity

Isolated case reports associate berberine use with hepatotoxicity. Causality is difficult to establish from case reports, and the evidence base here is limited. This is important for patients with pre-existing hepatic disease.

Who Should Not Take Berberine Without Physician Review

The following people are not candidates for self-directed berberine supplementation. If you are in any of these categories and are considering berberine, that decision requires a conversation with your physician before any purchase.

• Anyone taking warfarin or any anticoagulant

• Anyone on immunosuppressants following organ transplantation

• Anyone taking insulin or any insulin secretagogue, including sulfonylureas

• Anyone on antidepressants or antipsychotic medications, particularly those metabolized by CYP2D6

• Anyone taking antiarrhythmics or beta-blockers

• Anyone with renal impairment

• Anyone with hepatic insufficiency or active liver disease

• Anyone who is pregnant, breastfeeding, or may become pregnant

• Anyone taking any medication with a narrow therapeutic window

• Anyone on multiple medications simultaneously, because the interaction profile is additive and unpredictable

This list describes a substantial proportion of the American adults who are most likely to be interested in berberine based on its marketed metabolic indications.

What Should You Take From This Article

First. This piece makes no recommendation for berberine use in any indication. The evidence for glucose lowering and lipid modulation is real, but it comes from selected populations under specific conditions and does not generalize to the broad metabolic wellness market where berberine is primarily sold. The drug interaction profile documented above is a genuine public health concern. Whether berberine’s potential benefits outweigh its risks in any individual patient is a clinical question that requires physician involvement, not a decision made in the supplement aisle.

Second. Almost all of berberine’s cancer-related marketing claims lack human clinical evidence and are implausible at standard oral doses. It is the central pharmacokinetic fact that makes systemic cancer claims incoherent. The one narrow exception where credible clinical evidence exists is colorectal adenoma chemoprevention in post-polypectomy patients, where high luminal concentrations act directly on colonic mucosa and where a well-designed RCT with six-year follow-up data demonstrates durable protective effect (Tan et al., Lancet Regional Health, Western Pacific, 2025). This is not an endorsement, any decision in that specific area belongs with the treating physician.

Third. If you are considering berberine for any reason, the first step is a conversation with your physician about all current medications. Given the drug interaction profile documented in this piece, that conversation is the minimum responsible precaution.

The “natural equals safe” equation is one of the most consequential errors in contemporary health culture. Berberine is a biologically active compound with real pharmacological effects and real pharmacological risks. Biological activity and safety are not the same thing.

Berberine deserves honest evaluation: neither dismissing it because it comes from a plant nor endorsing it because wellness marketing. The science supports specific benefits, but the risks are a real concern.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

Wind-Down Is a Biological Requirement

The 30 to 60 minutes before sleep is the time to wind-down before sleep. The pre-sleep environment is important to support sleep.

The single strongest non-pharmacological pre-sleep intervention with randomized controlled trial support is a warm bath or shower taken approximately 90 minutes before your target sleep time. A 2019 systematic review and meta-analysis by Haghayegh et al. in Sleep Medicine Reviews found a 36% reduction in sleep onset latency with this approach. The mechanism is peripheral vasodilation: warm water draws blood toward the skin, accelerating the drop in core body temperature that the circadian system uses to initiate sleep. The timing of 90 minutes is when the vasodilation effect on core temperature is strongest.

Room temperature works through the same mechanism. Across datasets including an analysis of 3.75 million nights by Rifkin et al. and a 2025 synthesis of 134 studies in Indoor Air, the consistent finding is that cooler sleeping environments improve sleep quality. The evidence suggests 64 to 68 degrees Fahrenheit (18 to 20 degrees Celsius) as optimal. Bedrooms running warmer than 70 degrees Fahrenheit are associated with poorer sleep quality in the Rifkin data.

Lighting in the hour before sleep matters for two reasons: photonic suppression of melatonin and conditioned arousal from screen content. The practical standard for pre-sleep lighting is warm-spectrum illumination below 2700K at low intensity, positioned as indirect or shaded rather than direct task lighting. Television in bed compounds both problems: retinal photon dose, content-driven cognitive arousal, and disruption of the conditioned association between your bed and sleep onset.

On blue light blocking glasses and Night Shift mode: both are appealing in theory and underwhelming in evidence. A 2025 systematic review and meta-analysis of three double-blind crossover RCTs in Frontiers in Neurology (Luna-Rangel et al.) found non-significant effects across all four sleep parameters for commercially available blue light blocking glasses. The Lighting Research Center’s evaluation of Apple’s Night Shift concluded that turning devices off two hours before bed remains the evidence-supported recommendation. Night Shift produces a partial spectral shift insufficient to eliminate melanopsin activation at typical screen brightness; screen brightness contributes as much to the problem as spectral content. Neither technology substitutes for device removal.

For pre-sleep activity in the wind-down window, the evidence favors passive engagement over active. Passive narrative fiction, reduces cognitive arousal without generating sympathetic nervous system activation. Progressive muscle relaxation, discussed in the CBT-I section below, is also effective here. A 2026 meta-analysis of 31 RCTs involving 2,277 participants confirmed measurable sleep quality improvement and anxiety reduction across population groups, and a 2022 PSG study by Simon et al. confirmed that PMR specifically increases slow-wave sleep.

Wake Time Is the Anchor

Consistent scheduling is the behavioral foundation of circadian entrainment. Most people who struggle with sleep focus on bedtime; biology points to wake time.

The suprachiasmatic nucleus (SCN) is primarily entrained by the morning light signal. Homeostatic sleep pressure then accumulates across the waking day, reaching its peak as bedtime approaches. Trying to control bedtime without anchoring wake time works against this sequence.

Fix the wake time first, bedtime follows from it.

Morning light exposure is the most potent daily entraining tool available and requires nothing more than going outside. Outdoor light ranges from 10,000 lux on an overcast day to 100,000 lux in direct sun. Indoor light through a window typically falls below 500 lux. Ten minutes of outdoor exposure in the first hour after waking delivers the phase-advancing signal the SCN requires. For those who cannot go outside regularly, a 10,000 lux light therapy box used in the morning is an effective alternative with robust evidence, particularly relevant for northern latitudes in winter and for people with mobility limitations.

A 2023 meta-analysis by Bouman et al. in the Journal of Sleep Research found that social jet lag, defined as the discrepancy between biological sleep timing on work days versus free days, is independently associated with metabolic syndrome and type 2 diabetes. Sleeping in by 90 minutes or more on Saturday and Sunday initiates a measurable circadian phase delay physiologically equivalent to mild westward jet lag. The fatigue that accumulates by Monday morning is not sleep debt, is circadian misalignment produced by the weekend phase shift. Maintaining wake time within one hour of weekday timing on weekends prevents it.

For those who work shift schedules, a 2025 umbrella review of meta-analyses by Cho et al. in the Journal of Sleep Research compared fixed versus rotating shift work through December 2024. Fixed night shift workers carry higher cardiovascular and obesity risk; rotating shift workers carry higher cancer and pregnancy complication risk, because rotating shift workers never achieve stable entrainment in either direction. Forward rotation (morning to afternoon to night) was substantially better tolerated than backward rotation, with nearly double the odds of poor sleep quality for backward rotation in a study of 4,750 workers. Where shift schedules are unavoidable, consistent timing on days off and forward rotation direction reduce circadian disruption without eliminating it.

Shortened winter photoperiod at higher latitudes produces progressive circadian phase delay in susceptible individuals as the SCN receives insufficient morning light to maintain entrainment. Seasonal affective disorder (SAD) is not simply a mood disorder with seasonal timing, is a circadian disorder in which hypersomnia, carbohydrate craving, weight gain, and profound fatigue are the metabolic manifestations. The carbohydrate craving specifically runs through serotonin: reduced winter sunlight decreases serotonin synthesis, and carbohydrate consumption transiently increases brain serotonin availability through insulin-mediated tryptophan uptake. Morning light therapy is the first-line treatment and works through the identical mechanism as the morning light recommendation above.

The circadian clock shifts at approximately one to two hours per day under optimal entraining conditions. Full re-entrainment following significant disruption requires days to weeks. A 2024 study in Sleep on simulated night-shift work found incomplete circadian adjustment even after 96 hours under controlled conditions. Accurate expectations prevent premature abandonment of an intervention that is working.

Exercise As Sleep Intervention

A 2025 network meta-analysis of 86 RCTs involving 7,276 participants published in BMC Public Health found that combined aerobic and resistance training produced the strongest sleep quality improvements of any exercise modality examined. A separate 2025 comparative efficacy analysis of 18 studies involving 1,214 adults found exercise interventions improved sleep efficiency by a mean of 2.85%, reduced wake after sleep onset by an average of 10 minutes, and extended slow-wave sleep by an average of 2.19 minutes on polysomnography (PSG).

For aerobic exercise specifically, a 2025 meta-analysis by Rubio-Valles and Ramos-Jimenez found moderate-intensity aerobic exercise reduced sleep onset latency by 55%, reduced wake time by 30%, and increased total sleep time by 18%, with a 13% improvement in sleep efficiency. The anti-inflammatory mechanism is direct: aerobic exercise reduces IL-6 and TNF-alpha, connecting the intervention explicitly to systemic inflammation. The optimal dose from the 2025 network meta-analysis is three sessions per week of 45 to 60 minutes at moderate intensity for 8 to 12 weeks.

Resistance training contributes through a different but complementary mechanism. The Souza et al. 2022 RCT using PSG in sarcopenic older adults (IJERPH, PMC9736460) reduced sleep onset latency from 30 to 16 minutes and increased N3 percentage. The mechanism involves growth hormone secretion during recovery, which is concentrated in slow-wave sleep. Combined aerobic and resistance training consistently outperforms either modality alone across the network meta-analysis literature.

Scheduled exercise at consistent times shifts melatonin onset timing and reinforces circadian alignment through core body temperature changes, adrenergic activation, and neuroendocrine output. Morning exercise specifically lowers post-waking cortisol and produces sustained circadian reinforcement across the day.

A real-world analysis of 150,000 nights (PMC8599432) found no meaningful association between evening physical activity and sleep quality in free-living adults. A 2025 Nature Communications analysis of 4,084,354 person-nights established the practical threshold: exercise bouts ending four or more hours before sleep onset are not associated with any sleep impairment regardless of intensity. Within that four-hour window, higher intensity produces more disruption than moderate intensity. Vigorous exercise ending within one hour of bedtime impairs sleep onset latency, total sleep time, and efficiency across multiple studies.

The hierarchy in plain terms: morning exercise is optimal. Evening moderate-intensity exercise ending more than two hours before bed produces no meaningful disruption. Evening vigorous exercise more than four hours before bed is safe. Evening vigorous exercise within one hour of bed causes modest, acute disruption. Exercise at any realistic time is vastly superior to no exercise for both sleep quality and metabolic health.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

The Most Effective Insomnia Treatments

Cognitive behavioral therapy for insomnia (CBT-I ) is the gold-standard first-line treatment for chronic insomnia according to the American Academy of Sleep Medicine, the American College of Physicians, and the European Sleep Research Society.

A component network meta-analysis by Furukawa et al. published in JAMA Psychiatry in 2024, encompassing 241 trials and 31,452 participants, identified the active ingredients: cognitive restructuring (incremental OR for remission 1.68), third-wave components (iOR 1.49), sleep restriction (iOR 1.49), and stimulus control (iOR 1.43). Sleep hygiene education alone was not essential (iOR 1.01). A separate 2024 network meta-analysis by Furukawa et al. in Psychiatry and Clinical Neurosciences found CBT-I produced superior long-term remission compared to pharmacotherapy. A 2023 systematic review (PMC10244489) confirmed CBT-I reduces HbA1c and CRP compared to controls, connecting the behavioral intervention directly to metabolic outcomes.

Stimulus control rebuilds the conditioned association between bed and sleep. The rules: bed only for sleep and sex; leave bed after approximately 20 minutes of wakefulness at night and return only when sleepy; consistent wake time regardless of the previous night’s sleep duration; no daytime napping. The mechanism is classical conditioning. The bed becomes a stimulus that reliably predicts sleep, and expectation shapes the physiological response. This is the most foundational component.

Sleep restriction therapy temporarily limits time in bed to actual sleep time, creating controlled sleep pressure that consolidates fragmented sleep and rebuilds efficiency. It is counterintuitive and among the strongest individual components. It is not appropriate for self-administration without guidance in bipolar disorder or seizure disorders, and warrants a conversation with a physician or sleep specialist in those populations.

Cognitive restructuring identifies and challenges automatic negative thoughts about sleep: catastrophic predictions, rigid beliefs about sleep requirements, hypervigilance toward sleep cues. The goal is accurate thinking, not positive thinking. “I cannot function without eight hours” activates pre-sleep cortisol. Examining that thought against actual evidence of prior functioning reduces the activation.

Constructive worry uses a designated 15 to 20 minute period earlier in the evening, at a desk and not in bed, to write down concerns with one concrete next step for each. When worry arises at bedtime, it is acknowledged and deferred. The bed is not the place for problem-solving.

Two relaxation techniques require no equipment, no training, and are available tonight:

The 4-7-8 breathing technique: inhale through the nose for four counts, hold for seven, exhale completely through the mouth for eight. Repeat four cycles. The extended exhale is the active ingredient, activating vagal tone and reducing sympathetic activity. Any ratio where the exhale is twice the inhale length achieves the same mechanism. A 2025 scoping review confirmed increased heart rate variability and decreased systolic blood pressure through parasympathetic activation.

Progressive muscle relaxation: systematic tension and release of muscle groups from feet upward. Five seconds of firm tension per group, ten seconds of complete release, attention directed to the contrast. Ten to 15 minutes for the full sequence. Many people fall asleep before completing it. The 2026 meta-analysis of 31 RCTs and the 2022 PSG study by Simon et al. provide the evidence base.

Behavioral sleep medicine specialists are scarce outside major metropolitan areas. Digital CBT-I resolves the access problem with a robust published evidence base. The 2025 SleepioRx RCT of 336 US adults with DSM-5 insomnia disorder found statistically and clinically significant improvements in insomnia severity at 10 weeks (Cohen’s d = 0.60), strengthening at 16 weeks (d = 0.65) and 24 weeks (d = 0.77). A 2023 PSG RCT of an online CBT-I program (Eigl et al., Clocks Sleep, PMC10594462) confirmed reduced wake after sleep onset from 58.6 to 42.5 minutes and improved sleep efficiency from 86.0% to 89.2% on objective measurement. Available platforms with published evidence: Sleepio (strongest published evidence base), CBTI Coach (free, developed by the VA, available on iOS and Android), and SleepioRx (FDA-regulated, available through healthcare providers). In-person CBT-I with a trained therapist remains the gold standard. Digital CBT-I is a genuine and effective intervention, not a compromise.

Melatonin, Not a Sleeping Pill

Melatonin is a hormone that signals the timing of darkness to the suprachiasmatic nucleus. Its primary biological role is circadian phase shifting, not sedation. It does not induce sleep the way a sedative does. It repositions the internal clock relative to the external light-dark cycle.

Its clearest evidence-supported application is jet lag. The Cochrane review by Herxheimer et al. (PMC8958662) confirmed effectiveness for preventing and reducing jet lag across five or more time zones, with the strongest effects for eastward travel. Taken at the destination’s local bedtime on arrival day, melatonin initiates a phase advance, shifting the internal clock toward the new time zone faster than light exposure alone. Timing relative to the internal clock’s current phase determines the direction of effect entirely: evening administration produces a phase advance, morning administration produces a phase delay. The same mechanism applies to social jet lag and schedule disruption recovery, at lower magnitude.

A secondary and real effect is modest reduction in sleep onset latency, documented consistently across the meta-analysis literature and produced without disrupting sleep architecture.

The dose problem is worth understanding directly. Commercial supplements typically contain 5 to 10 mg. Endogenous nocturnal melatonin peaks at approximately 100 to 200 picograms per milliliter, a concentration that 0.3 to 0.5 mg of exogenous melatonin approximates. A 5 mg dose produces blood levels 10 to 30 times the physiological nocturnal peak. At the receptor level, MT1 and MT2 affinity is calibrated to physiological concentrations: the pKi values for human melatonin receptors indicate half-saturation well below 1 nM, meaning supraphysiological doses saturate and desensitize receptors rather than producing proportionally greater effects (Reiter et al., PMC8006026). A 2024 dose-response meta-analysis by Cruz-Sanabria et al. in the Journal of Pineal Research, evaluating 26 RCTs and 1,689 observations, found that administration timing matters as much as dose in determining efficacy, with effects on sleep onset latency and total sleep time optimized when melatonin is taken two to three hours before the target sleep time rather than 30 minutes. The morning grogginess experienced by many current users of 5 to 10 mg tablets is the predictable consequence of supraphysiological dosing and its persistence into the morning phase-delay zone. Reducing to 0.5 mg and shifting administration to 90 minutes before bed resolves this in most cases.

Melatonin is not FDA-approved for any indication in the United States. It is a dietary supplement not subject to pharmaceutical manufacturing standards. Independent testing has found substantial discrepancies between labeled and actual content. Third-party certification (USP or NSF) reduces but does not eliminate labeling accuracy risk.

About White Noise

A white noise machine or a free app set to low volume is an inexpensive, immediately available tool with real evidence behind it. A 2025 systematic review and meta-analysis of 12 controlled trials involving 1,301 participants published in Sleep confirmed that white noise improves sleep efficiency and reduces nighttime awakenings, with the strongest benefits in noisy environments.

A simpler and equally effective variation requires nothing more than a pair of soft silicone earplugs. By sealing the ear canal, they amplify the sound of your own breathing into a steady, rhythmic background, a self-generated masking sound that crowds out both external noise and the mental chatter that delays sleep onset. Soft silicone earplugs are preferable to foam for overnight use: they conform to the ear canal without the sustained pressure that makes foam uncomfortable after a few hours.

Sedation Is Not Sleep

Every medication below produces sedation, but none produces sleep in the biological sense, with its staged architecture of NREM and REM cycling, slow-wave consolidation, and glymphatic clearance. The question is what it does to the sleep you have while unconscious.

A phenomenon experienced by most people using sleep aids chronically is reduced efficacy overtime: this is secondary to two mechanisms, tachyphylaxis and tolerance. Tachyphylaxis is rapid reduction in receptor-level response following repeated administration, through acute desensitization, receptor internalization, or uncoupling of signaling. Tolerance is broader: receptor downregulation, altered neurotransmitter synthesis, and compensatory upregulation of opposing pathways. Remove the drug and the excitatory upregulation is unopposed, producing rebound insomnia and anxiety that are frequently worse than the original complaint. Any sleep medication is not for continued use, but only for occasional use when needed.

Benzodiazepines enhance GABA-A receptor activity, reducing sleep onset latency and nocturnal awakenings in the short term. The PSG consequences work directly against the architecture of restorative sleep: increased N2, decreased N3 slow-wave sleep, and dose-dependent REM reduction. A 2024 review by Jupe et al. in European Psychiatry (PMC11862261) and a 2025 PSG study by Barbaux et al. in Sleep confirmed both the architectural disruption and the suppression of slow oscillation and spindle coupling that underlies memory consolidation. Long-term consequences include a 65% higher risk for dementia in a 2025 Canadian case-control study (Journal of the Neurological Sciences), doubled risk with long half-life agents, and documented cognitive decline across multiple domains. A 2023 US survey of 1,207 benzodiazepine users found 76.6% reported discontinuation symptoms persisting one year or longer. Benzodiazepines are indicated for two to four weeks maximum in acute situational insomnia. They are contraindicated for chronic insomnia management.

Z-drugs (zolpidem and related agents) act on the same GABA-A receptor complex with greater alpha-1 subunit selectivity, introduced as architecturally superior to benzodiazepines. The 2025 PSG study by Barbaux et al. confirmed that chronic Z-drug use disrupts slow oscillations and spindle coupling comparably to benzodiazepines. Tachyphylaxis and rebound insomnia on discontinuation are documented. The American Geriatrics Society Beers Criteria lists Z-drugs as medications to avoid in older adults due to fall risk, cognitive impairment, and motor vehicle accident risk. Indicated: short-term acute situational use with explicit duration limits.

Trazodone at 25 to 100 mg is among the most commonly prescribed sleep medications in the United States despite no FDA approval for insomnia. The 2022 PSG meta-analysis by Zheng et al. in Scientific Reports (PMC9402537), encompassing 11 RCTs, found trazodone reduces sleep onset latency, reduces wake after sleep onset, increases total sleep time, increases N3 slow-wave sleep, and improves sleep efficiency. The N3 finding is architecturally favorable, the opposite of benzodiazepines. No dependence liability comparable to GABAergic agents. The evidence base is smaller and weaker than approved sleep medications, no long-term controlled insomnia trials exist, and adverse effects include orthostatic hypotension with fall risk in older adults, morning sedation, priapism at higher doses, and cardiac conduction effects. A 2024 CNS Drugs systematic review concluded the adverse effect profile requires careful individual risk-benefit assessment.

Low-dose doxepin at 3 to 6 mg is FDA-approved specifically for sleep maintenance insomnia, functioning through selective histamine H1 receptor antagonism at these doses, a fundamentally different pharmacological profile from antidepressant doses. It improves sleep maintenance, reduces wake after sleep onset, and carries a safety profile comparable to placebo in clinical trials. No dependence liability. The architectural cost is REM reduction. In older adults, anticholinergic effects become relevant even at low doses given reduced cholinergic reserve with aging.

Orexin receptor antagonists (DORAs) are the most architecturally favorable pharmacological option currently available. Suvorexant, lemborexant, and daridorexant are FDA-approved. The mechanism is selective blockade of orexin neuropeptide signaling at OX1R and OX2R removes the drive to wakefulness rather than imposing sedation. A 2025 MDPI International Journal of Molecular Sciences review (PMC12429101) confirmed DORAs facilitate sleep onset and maintenance without disrupting natural sleep architecture. Suvorexant increases both REM and NREM sleep. A network meta-analysis of 20 medications for primary insomnia (Yue et al., Sleep Medicine Reviews, 2023) found DORAs had the highest values across all sleep parameters with the second-best safety profile behind placebo. In the SUNRISE 1 Phase 3 trial, lemborexant demonstrated superior efficacy to zolpidem extended-release with better next-morning cognitive and psychomotor performance. A 2023 RCT by Lucey et al. in Annals of Neurology found acute suvorexant reduced CSF amyloid-beta and phosphorylated tau. That finding requires longer-term replication before clinical interpretation. Tolerance and rebound profiles are more favorable than GABAergic agents. Practical access barriers: DORAs are Schedule IV controlled substances and substantially more expensive than generic alternatives.

No pharmacological agent replaces CBT-I for chronic insomnia. Medications address the symptom. CBT-I addresses the mechanism. The appropriate use of pharmacotherapy is short-term bridging while behavioral treatment is being established, or adjunctive support when behavioral intervention alone is insufficient. Any medication change or discontinuation should be managed with your physician.

Where to Begin

Sleep quality is cumulative. The degree of benefit is proportional to the degree of implementation, and implementation does not require reorganization of your life.

The behavioral interventions are the foundation. Melatonin, used correctly at physiological doses and appropriate timing, is a targeted tool for specific circadian applications, not a nightly supplement. Pharmacotherapy, when genuinely indicated, is a short-term bridge while behavioral treatment is established.

Every tool in this piece is available to you immediately. No prescription is required for the behavioral interventions. No specialist appointment is required to begin CBT-I via CBTI Coach tonight, free of charge, on your phone. Start with the change most accessible to your current life and build from there.

Sleep is not something that happens to you. It is something you can learn to protect.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

The question this series has build toward is whether or not the American healthcare system is worth saving. The honest answer is: it depends. Let’s first compare the strengths and weaknesses of our system with the rest of the civilized world. Then present some proposals to correct some of the problems we have analyzed over the course of this series.

Where Our System Fails

The United States ranks last among ten high-income nations on four of five health outcome measures, according to the Commonwealth Fund’s Mirror, Mirror 2024 report, the most comprehensive international health system comparison available, drawing on OECD data, WHO data, and standardized survey methodology across peer nations.

• Life expectancy in the US stands at 78.4 years, compared to a ten-country peer average of 82.5 years, a gap of 4.1 years that has widened over the past two decades (Commonwealth Fund, Mirror Mirror 2024, September 2024).

• Maternal mortality sits at 18.6 deaths per 100,000 live births, more than three and a half times the peer average of 5.1. This gap holds across every racial, ethnic, socioeconomic, and age group in the country (KFF, International Comparison of Health Systems, October 2025).

• Infant mortality is the highest among peer nations.

• Preventable and treatable death rates are the highest among peer nations.

• The US spends $14,885 per capita on healthcare, more than double the peer average of $7,371, and nearly 50% more than second-place Switzerland at $9,963 (Peterson-KFF Health System Tracker, October 2025). US healthcare expenditure represents 17.6% of GDP against a peer average of approximately 10%. The primary driver is price (PGPF, How Does the US Healthcare System Compare to Other Countries, October 2025).

Where Our System Leads

• The US all-cancer five-year survival rate is approximately 70%, compared to 55% in the UK and 57% in Spain (American Action Forum, Cancer Care in the United States Is Unrivaled, April 2025). Cancer death rates have declined 33% since 1991 translating to approximately 3.5 million lives saved. US cancer mortality rates rank among the lowest of twelve comparable OECD countries.

• Thirty-day mortality after heart attack, hemorrhagic stroke, and ischemic stroke is lower in the US than in many peer nations (Peterson-KFF Health System Tracker, October 2025). The FDA approved 50 novel drugs in 2024 alone.

• Americans gain access to new therapies significantly faster than European and Canadian counterparts.

• The US hosts a disproportionate share of global biomedical research, clinical trial infrastructure, and pharmaceutical innovation output (American Action Forum, April 2025; PMC10317843, 2023).

The Case for Saving Our System

The US market’s premium pricing, patent protection, and private sector R&D investment incentives produce approximately half of the world’s new drug approvals and host a disproportionate share of global biomedical research output. No peer system has demonstrated the capacity to generate comparable biomedical innovation at comparable scale.

This innovation engine is the one component of the US healthcare system the world cannot afford to lose.

How I Got Here

I opened this series unable to see a solution. The problems turned out to be more severe than I suspected, but also more precisely documented.

What changed was the framing. The failures are not random, they are identifiable points where financial conflict of interest drives decision-making processes. That specificity is what makes structural correction possible.

The proposals below are the product of this framework. I present them as coherent structural solutions, not as an ultimate ones.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

The Reform Framework

Insurance Architecture

Creation of a new federal agency with a narrow mandate to establish uniform minimum coverage standards and standardized disclosure requirements nationally, enabling plan comparison at point of purchase. This will encourage increased insurance provider competition on all markets by removing state regulatory entry barriers in existence today.

Transition from direct to insurer government subsidies to a direct consumer one. Placing subsidy dollars on individual’s hands forces insurers to earn the customer with competitive offerings as precondition to accessing the subsidy.

When internal insurance appeal procedures are exhausted without resolution, the case proceeds to an independent review board composed exclusively of physicians with zero affiliation to the insurance industry. The board adjudicates on medical merit alone, decisions carry binding arbitration force.

The board’s aggregate reversal data feeds directly into the regulatory agency, where high reversal rates triggers company’s scrutiny of authorization practices. This becomes a new accountability process for repeat offenders.

Delivery Incentive Realignment

The AMA’s Relative Value Scale Update Committee is replaced by a fully independent government board with no institutional affiliations of any kind.

Primary care, preventive medicine, psychiatry, endocrinology receives reimbursement reflecting its actual clinical value and its demonstrated capacity to interrupt disease progression at lowest system cost.

A defined portion of existing Medicare Graduate Medical Education funding is reoriented toward primary care, preventive medicine, and psychiatry residency positions. GME reorientation and RVU re-weighting are explicitly linked interventions supporting the same goal.

Hospital Readmissions Reduction Program realignment applying a modest bonus for discharges within established length-of-stay parameters and more steep penalties for unjustified readmissions where the institution’s own discharge decision is the proximate cause.

Price Transparency With Enforcement

Mandatory publication of actual transaction prices for all elective and planned services, prescription drugs, and routine care, combined with financial penalties plus Medicare and Medicaid participation consequences for persistent non-compliance.

This will create the preconditions required for functional market competition in planned and elective care.

Pharmaceutical System Integrity

Upon FDA approval process request, the research budget transfers to an industry independent board which funds research development and completion by fully independent research teams. This applies across the entire drug lifecycle: pre-approval trials, post-market surveillance, and all required post-approval studies.

A foreign drug equivalent certification for identical products sold by the same manufacturer at lower prices in foreign markets, making them allowable for US insurance coverage.

Pharmacy Benefit Manager System

PBMs are compensated by transparent, per-transaction fees for clearly defined services eliminating the rebate system.

Only two members on a P&T committee are permitted to have any industry financial relationship. The rest are fully independent.

Mandatory PBM divestiture from any other healthcare related company that could create an operational conflict of interest.

Research Integrity and Clinical Standards

Medical society clinical practice guidelines derive validity from their adoption by CMS as the standard of care. As condition for adoption of new guidelines, CMS will require complete independence from any industry financial relationships from all clinical practice guidelines committee members.

CME Reform

CME accreditation requires that organizers and all presenters have no financial relationships with any healthcare industry entity. Unrestricted educational grants from industry to accredited CME organizations remain permissible.

Anti-Polypharmacy Initiative

A federally funded structured medication review program for Medicare beneficiaries delivers pharmacist-led, physician-supervised review with the explicit goal of identifying and safely reducing inappropriate polypharmacy burden.

Structured medication review reduces emergency department presentations by 27% (Christensen M et al., Cochrane Database of Systematic Reviews, 2016), is not associated with increased mortality in randomized trials and is associated with improved mental health and frailty outcomes (Page AT et al., British Journal of Clinical Pharmacology, 2016; PMC11182547, PLOS One, 2024).

Long-Term Care Infrastructure

A dedicated public long-term care benefit financed through defined payroll contribution during working years that activates on clinical need without the Medicaid spend-down requirement existing today.

Washington State’s WA Cares Fund represents the first domestic proof-of-concept for this model: implementation is ongoing, actuarial sustainability questions remain unresolved, and the experiment has not been in operation long enough to evaluate long-term outcomes (Washington State WA Cares Fund, official program documentation and actuarial analysis). The federal design should be informed by its results, not modeled on its current state.

The Food Environment

Metabolic disease dominates US healthcare expenditure. Its current trajectory will exhaust the healthcare budget if left unaddressed.

The FDA’s self-affirmation mechanism currently allows manufacturers to designate their own ingredients as generally recognized as safe (GRAS), a glaring conflict of interest. All GRAS designations will now require mandatory independent FDA review.

A defined portion of existing Farm Bill commodity subsidies can be reoriented toward whole food production from their current concentration in corn, soy, wheat, and sugar. This subsidy reorientation will contribute to lower whole food prices at the consumer level.

The Political Obstacle

Every proposal in this framework is legal, and feasible within existing governmental structures. All are achievable if the appropriate political will exists.

The political environment is not immovable. Whether it produces different political demands is outside any author’s control. What is within every reader’s control is whether or not they demand different behavior from the people who seek their vote.

Where This Ends

These proposals are not presented as the only possible answers. I do not hold them as correct answers in any final sense. They are meant to be the starting point for an open and constructive dialog.

I have now shared what forty years of observation and honest inquiry taught me.

Is the United State healthcare system worth saving? In my opinion… Yes! Provided changes addressing existing inadequacies are implemented.

The rest is up to you!

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

Why the Guidance Changed

For most of the 1980s and 1990s, large observational studies consistently found that moderate drinkers had lower rates of cardiovascular disease than non-drinkers. When researchers plotted the relationship between alcohol consumption and heart disease risk on a graph, the curve bent downward at low doses before rising steeply at high doses. The cardioprotective effect of moderate drinking became one of the most cited findings in nutritional epidemiology, and it gave scientific credibility to what many people already wanted to believe: that the glass of wine at dinner was not just pleasurable but beneficial.

Observational studies measure what people do and what happens to them over time. That limitation left the moderate-drinker group quietly contaminated by two systematic errors that made abstainers look sicker than they actually were.

• Sick quitter bias: many people who appear in the abstainer category of these studies are not lifetime non-drinkers, they are former drinkers who stopped because of illness.

• Healthy user bias: in wealthy Western populations, moderate drinkers tend to cluster with other health-protective behaviors: regular exercise, higher income, better access to healthcare, lower rates of smoking. These factors independently reduce cardiovascular risk.

A 2024 review of 95 cohort studies on alcohol and cardiovascular disease found that the sick quitter problem was the most serious methodological weakness in this literature, identified in the majority of studies reviewed but addressed with highly variable rigor. More telling are the results from Mendelian randomization studies, a methodological approach that uses inherited genetic variants affecting alcohol metabolism as a natural experiment to estimate the effect of consumption without the behavioral confounding that plagues observational research. A 2024 nested case-control study in more than 250,000 participants from the Million Veteran Program, using both observational and Mendelian randomization methods, found that the two approaches produced divergent results: the observationally apparent protective effect for coronary heart disease and type 2 diabetes was not supported by the genetic analysis (Kember et al., Alcohol: Clinical and Experimental Research, 2024).

The Red Wine Carve-Out

The argument runs as follows: wine, particularly red wine, contains resveratrol, a polyphenol compound found in grape skins. Laboratory studies have shown that resveratrol activates certain cellular pathways associated with longevity and metabolic regulation. Therefore, red wine is different from other alcoholic beverages, and its benefits outweigh its harms.

The reality paints a different picture.

Resveratrol is present in red wine, but the concentration is low. A standard glass of red wine contains somewhere between 0.2 and 2 milligrams of resveratrol. The laboratory studies that produced excitement about this compound used doses in the range of hundreds of milligrams per day, applied to cell cultures or animal models. The gap between what a glass of wine delivers and what a study requires to show a biological effect is several orders of magnitude.

The supplement industry responded to this gap by producing purpose-formulated resveratrol capsules at doses far exceeding anything achievable through wine consumption. A 2024 systematic review and meta-analysis of resveratrol supplementation trials found no statistically significant overall effect on glucose metabolism and an increase in triglycerides in some subgroups (Zahoor et al., Obesity Pillars, 2024). A companion 2024 systematic review and meta-analysis examining resveratrol’s effects across metabolic syndrome components reached similarly null conclusions (Endocrines, 2024).

The cellular mechanisms that made resveratrol compelling in the laboratory have not translated into clinical outcomes in humans, even at pharmacological doses that no amount of wine drinking could approach.

The red wine exception also fails on a more basic chemical point. Blood pressure data from a large Danish cohort study, published in the American Journal of Medicine in 2024, found consistent blood pressure effects across wine, beer, and spirits, with no meaningful difference between beverage types (Copenhagen General Population Study, 2024). Ethanol is the same molecule regardless of what surrounds it.

What Alcohol Actually Does

With the cardioprotective claim set aside, the evidence on alcohol’s biological effects points consistently in one direction.

Blood Pressure

A 2024 systematic review and dose-response meta-analysis of 23 cohort studies published in Hypertension found a positive, nearly linear association between alcohol intake and the risk of developing high blood pressure across the full range of consumption, with no evidence of a threshold below which the effect disappears (Cecchini et al., Hypertension, 2024). A companion meta-analysis confirmed the same linear relationship for both systolic and diastolic pressure over time (di Federico et al., Hypertension, 2023).

Cessation data reinforces the causal interpretation. A 2025 longitudinal Japanese cohort study published in the Journal of the American College of Cardiology found dose-dependent blood pressure reductions when participants reduced or stopped drinking, and dose-dependent increases when new drinkers started, with consistent findings across all beverage types.

High blood pressure is a core component of the metabolic syndrome cluster, and alcohol is contributing to it in a dose-responsive fashion starting from the first drink.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Visceral Fat and Liver Function

Alcohol provides 7 calories per gram, placing it just below fat in caloric density. Ethanol is preferentially oxidized over both fat and carbohydrates, meaning the body burns it first. While alcohol is being processed, fat oxidation is suppressed, de novo lipogenesis (the conversion of excess energy into fat) is promoted, and insulin signaling is disrupted.

The fat that accumulates as a result is not distributed randomly. An Oxford Biobank study using dual-energy X-ray absorptiometry (DXA) scanning in 5,761 participants found that alcohol consumption increased visceral fat mass in both men and women (International Journal of Obesity, 2022). Visceral fat, the metabolically active fat surrounding the abdominal organs, carries substantially greater cardiometabolic risk than subcutaneous fat.

In patients with pre-existing metabolic dysfunction-associated steatotic liver disease (MASLD), moderate alcohol intake has been found to increase the risk of type 2 diabetes and advanced liver fibrosis, with a synergistic interaction with insulin resistance that accelerates disease progression (Clinical and Molecular Hepatology, 2022). The National Academies of Sciences, Engineering, and Medicine reviewed the available evidence on alcohol and weight-related outcomes in 2025 and reached consistent conclusions about alcohol’s role in promoting visceral adiposity and worsening hepatic disease in vulnerable populations (National Academies Press, 2025).

Sleep Architecture

Alcohol is widely used as a sleep aid and at higher doses it can shorten the time it takes to fall asleep. That is where the benefit ends.

A 2024 systematic review and meta-analysis found that even low-dose alcohol suppresses rapid eye movement (REM) sleep in a dose-dependent fashion, with impairment proportional to consumption across the full range studied (Gardiner et al., Sleep Medicine Reviews, 2024). REM sleep is the stage most closely associated with memory consolidation, emotional regulation, and metabolic recovery. A 2024 study examining consecutive nights of pre-sleep alcohol consumption confirmed cumulative disruption to sleep architecture with repeated use, meaning the problem compounds rather than adapts (McCullar et al., Sleep, 2024).

REM disruption drives the same hormonal cascade that worsens metabolic syndrome independently: cortisol dysregulation, elevation of ghrelin (the hunger-stimulating hormone), and suppression of leptin (the satiety hormone). The nightcap that appears to ease sleep onset is compounding the metabolic burden rather than relieving it.

Gut Microbiome

Is well established that chronic, heavy alcohol consumption is associated with gut dysbiosis, increased intestinal permeability, reduction in beneficial bacterial populations including Lactobacillus species, elevation of pathogenic species, and endotoxemia that drives systemic inflammation and contributes to liver injury (Koutromanos et al., World Journal of Methodology, 2024; Frontiers in Microbiology, 2024). These effects have been documented consistently across multiple research groups and study designs.

For social drinking at lower doses, the data points in same direction but is less certain. Current evidence does not permit a precise threshold statement for this population. The best conclusion for now is that the gut microbiome appears sensitive to alcohol in a dose-dependent fashion, with the clearest findings at higher consumption levels and an emerging but not yet fully quantified picture at moderate intake.

The Cancer Question

The International Agency for Research on Cancer (IARC) has classified alcoholic beverages as Group 1 carcinogens since 1988. Group 1 means sufficient evidence of causality in humans, the highest classification available. Ethanol and acetaldehyde, its primary metabolite, are each independently classified Group 1. Seven cancer sites are causally linked: oral cavity, pharynx, larynx, esophagus, liver, colorectum, and female breast. The World Health Organization (WHO) reaffirmed in 2023 that no safe threshold for cancer risk can be established and that the dose-response relationship begins at zero (WHO/IARC joint statement, 2023).

The case for causality rests on several lines of evidence. Epidemiological consistency is one: the association between alcohol and these seven cancer sites has been replicated across populations that differ substantially in diet, genetics, healthcare access, and environmental exposures. The cellular mechanism is another. Acetaldehyde, the first breakdown product of ethanol, causes direct damage in the DNA and inhibition of the repair enzymes that would normally correct this damage (Lachenmeier and Salaspuro, Nature Reviews Cancer, 2007; Clinical and Translational Discovery, 2024). Additional mechanisms include induction of the CYP2E1 enzyme generating reactive oxygen species, disruption of DNA methylation patterns, interference with retinoid metabolism, and elevation of circulating estrogen contributing to breast cancer risk.

The most compelling single line of evidence comes from genetics. A common variant in the ALDH2 gene, found predominantly in East Asian populations, impairs the enzyme that clears acetaldehyde after ethanol is metabolized. People carrying this variant who drink accumulate acetaldehyde at substantially higher concentrations than normal metabolizers. Their rates of upper respiratory and digestive tract cancers are dramatically elevated compared to both non-carriers who drink and non-drinkers of any genotype. This natural experiment provides strong support for the acetaldehyde-mediated mechanism because it isolates the variable, acetaldehyde clearance capacity, while holding consumption behavior relatively constant. Cessation data add further weight: stopping drinking reduces the risk of oral and esophageal cancer, with the reduction proportional to duration of abstinence (Freisling et al., IARC Handbooks Working Group, New England Journal of Medicine, 2023).

In evaluating the strict conclusions expressed by these health organizations, in my personal opinion the evidence is not conclusive enough to support them. Let me explain why:

Cancer studies require observation windows measured in years to decades. Over those timescales, study participants are simultaneously exposed to a large and varied landscape of other carcinogens: environmental pollutants, dietary factors, occupational exposures, and the background carcinogenic burden of modern industrial life. Fully accounting for those exposures is genuinely difficult, and in long-duration cancer epidemiology the confounding burden is substantial. The IARC Group 1 classification addresses a specific question: is there sufficient evidence that alcohol causes cancer in humans? The answer to that question is yes. It does not address a separate question: at social drinking levels, in a population already carrying meaningful background carcinogenic exposure from other sources, what is the precise incremental cancer risk attributable to alcohol?

What This Means for You

We can say with confidence that there is no identified dose of alcohol that confers a net health benefit: the cardioprotective story was a methodological artifact, and the resveratrol story was a laboratory finding that never survived clinical testing. What the evidence consistently shows, across blood pressure, visceral fat, liver function, sleep architecture, and cancer biology, is a dose-dependent pattern of harm without a protective floor.

Abstinence is the single best recommendation, if you do not drink there is no reason to start. For those unwilling to adopt abstinence, the evidence clearly supports aggressive reduction of total alcohol intake.

The case for elimination is particularly strong if you are already managing metabolic syndrome, elevated blood pressure, or hepatic steatosis. In each of those conditions, alcohol is synergizing with existing disease processes in ways that compound the risks.

The official position changed because better research tools revealed what earlier tools could not: the protection was never real, and the harm was always present.

Found this article useful? Share your thoughts. Join the conversation below.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

If you haven’t, then this article is for you.

What Normal Sleep Actually Does

The American Heart Association and AASM both recommend 7 to 9 hours of sleep per night for adults (AHA, 2022). The American Academy of Sleep Medicine classifies sleep as four distinct stages cycling four to six times per night in approximately 90-minute ultradian cycles (AASM, ICSD-3-TR, 2023).

• N1 is the transition from wakefulness, lasting one to five minutes. It has no significant restorative function. It is the entry stage.

• N2, consolidated light sleep, is where the heart rate slows and core body temperature begins its descent. Sleep spindles appear here: bursts of oscillatory neural activity responsible for transferring memories from the hippocampus to the neocortex for long-term storage. N2 constitutes approximately 45 to 55 percent of total sleep time and is the most abundant stage in the adult sleep architecture.

• N3, slow-wave sleep, is the most metabolically critical stage. The majority of nightly growth hormone secretion is concentrated in the first slow-wave episode of the night. Brain glucose utilization drops substantially. Tissue repair, immune cytokine release, and cellular restoration are concentrated here. Glymphatic clearance, the brain’s waste removal system, is maximally active during slow-wave sleep. Slow-wave sleep constitutes approximately 15 to 20 percent of total sleep time in young adults and declines substantially with age.

• REM sleep produces a brain electrical pattern nearly indistinguishable from wakefulness, with skeletal muscle atonia preventing the body from acting out the activity of a near-waking brain. Brain glucose utilization returns to near-waking levels. REM is when the brain processes emotional experience, consolidates emotional memory, and performs synaptic homeostasis. The autonomic variability that occurs during REM is part of normal cardiovascular conditioning. REM episodes lengthen progressively toward morning. The final episode of a full night can last 45 to 60 minutes.

Slow-wave sleep dominates the first half, REM dominates the second. Cutting the night short at the back end disproportionately eliminates REM, while fragmenting the first half disproportionately eliminates slow-wave sleep and its attendant growth hormone secretion and glymphatic activity.

Five Factors That Disrupt Sleep Quality

Psychological Stress

Work pressure, family conflict, and occupational demand activate the hypothalamic-pituitary-adrenal axis, producing cortisol elevation and central nervous system hyperarousal that is directly incompatible with sleep initiation and maintenance. Slow-wave sleep normally exerts an inhibitory influence on the HPA axis, damping cortisol secretion. When sleep is disrupted, that inhibitory brake is removed: cortisol rises further, hyperarousal deepens, and the cycle propagates independently of the original stressor. Acute psychosocial stress increases sleep onset latency and reduces early slow-wave activity. Chronic stress sustains HPA hyperactivation associated with metabolic dysfunction, obesity risk, and cognitive impairment (Vgontzas et al., PMC2902103; PLOS Mental Health 2025 review; American Journal of Medicine 2025, doi:10.1016/j.amjmed.2025.05.044).

Irregular Sleep Scheduling

The suprachiasmatic nucleus, the brain’s master circadian clock, requires consistent sleep-wake timing to maintain biological alignment. Irregular scheduling produces social jet lag: chronic misalignment between the biological clock and socially imposed schedules. Bouman and colleagues, in a 2023 meta-analysis in the Journal of Sleep Research, found social jet lag significantly associated with metabolic syndrome parameters and type 2 diabetes risk across multiple cohort studies (Bouman et al. J Sleep Res. 2023;32:e13770). A human crossover trial demonstrated that circadian misalignment alone, independent of caloric intake and physical activity, reduced insulin sensitivity by 32% (Sládek et al. Sleep. 2023. PMC10262187). A 2024 prospective cohort study by Windred and colleagues in Sleep found sleep regularity to be a stronger predictor of mortality risk than total sleep duration, a finding with substantial implications for the widespread practice of sleeping inconsistently through the week and attempting to recover on weekends (Windred et al. Sleep. 2024;47:zsad253).

Alcohol

Alcohol is widely used as a sleep aid: alcohol shortens sleep onset latency through its effects on GABA receptors, glutamate, and adenosine pathways. The trade-off is severe and operates directly on the architecture described above. In the first half of the night, alcohol increases slow-wave sleep beyond its normal proportion while simultaneously suppressing REM. As alcohol is metabolized in the second half, its sedative effect reverses. Rebound sympathetic activation produces increased arousals, fragmented sleep, and disproportionate elimination of second-half REM, the portion of the night where REM is already most abundant and most consequential.

A 2025 systematic review and meta-analysis of 27 studies by Gardiner and colleagues confirmed a dose-response relationship: REM disruption occurs following even low doses, defined as two standard drinks or fewer, and worsens with increasing intake (Gardiner et al. Sleep Med Rev. 2025;80:102030). McCullar and colleagues demonstrated in Sleep (2024) that consecutive nights of pre-sleep alcohol produce cumulative architectural disruption that does not recover night-to-night (McCullar et al. Sleep. 2024;47:zsae003). Alcohol produces sedation while systematically dismantling the architecture that makes sleep restorative.

Late Meal Timing

Three mechanisms converge when the last meal is taken late in the evening.

• First, postprandial thermogenesis generates heat that works against the core body temperature drop required for sleep initiation and slow-wave sleep maintenance.

• Second, insulin sensitivity follows a circadian rhythm, peaking in the morning and declining through the evening: eating late activates insulin secretion at a point of reduced peripheral sensitivity, producing larger glycemic excursions and greater insulin demand than the same meal consumed earlier.

• Third, melatonin secretion begins in the evening and suppresses insulin release from pancreatic beta cells via MT1 and MT2 receptors. A large late meal taken close to melatonin onset creates direct competition between a rising melatonin suppressing insulin and a postprandial glucose load demanding it.

A 2024 NHANES-based study in PLOS One by Yan and colleagues found that late initial, midpoint, and final meal timing were each independently associated with poor sleep quality (Yan et al. PLoS One. 2024;19(8):e0308172. PMC11293727). A 2024 systematic scoping review in Sleep Medicine Reviews confirmed the association between late eating patterns and disrupted sleep across multiple study designs (Saidi et al. Sleep Med Rev. 2024;76:101953).

Evening Blue Light Exposure and Screens

Blue light in the 460 to 480 nanometer range activates photosensitive retinal ganglion cells containing melanopsin. These cells signal directly to the suprachiasmatic nucleus, which in turn suppresses pineal melatonin secretion. The circadian system shows meaningful sensitivity to light levels below 30 lux, well within the range of a standard phone or tablet screen. Even brief evening screen use reduces melatonin and shifts its onset, delaying sleep initiation and shortening total sleep time.

A 2025 systematic review and meta-analysis in Frontiers in Neurology by Luna-Rangel and colleagues confirmed that evening blue light suppresses melatonin, delays circadian phase, and prolongs sleep onset latency (Luna-Rangel et al. Front Neurol. 2025. PMC12668929).

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

The Metabolic Consequences of Chronic Poor Sleep

Insulin Resistance and Glucose Dysregulation

Sleep deprivation activates the sympathetic nervous system and elevates cortisol, reducing peripheral insulin sensitivity by diminishing muscle glucose uptake while simultaneously enhancing hepatic glucose output. This metabolic cascade mirrors early type 2 diabetes: reduced glucose tolerance, impaired insulin-stimulated glucose disposal, and inadequate glucose-induced insulin secretion.

A 2022 meta-analysis of 21 randomized controlled trials by Sondrup and colleagues found significant reductions in insulin sensitivity across all included sleep restriction studies (Sondrup et al. 2022). One RCT found the acute insulin response during sleep restriction to be 30% lower than in well-rested conditions, a magnitude comparable to the insulin resistance associated with aging and gestational diabetes. Insomnia is associated with increased in HbA1c (Schipper et al. Diabetologia. 2021). Sleep extension of one to two weeks improved blood glucose control and insulin sensitivity in both healthy and diabetic participants across seven eligible RCTs (Kanaley et al. Exerc Sport Sci Rev. 2024;52(3):77-86. PMC11168896).

The metabolic impairment compounds across consecutive nights of restriction and is not fully reversed by a single recovery night. The person sleeping poorly across a working week is not returning to metabolic baseline on the weekend. Recovery is partial and slow.

Appetite Dysregulation and Weight Gain

Sleep deprivation disrupts hormonal appetite regulation through two documented mechanisms. Leptin, the satiety-signaling adipokine, declines with sleep restriction, removing the central inhibitory effects on appetite. Ghrelin rises, increasing appetite drive and food-seeking behavior.

Spiegel and Van Cauter demonstrated that four hours of sleep for two consecutive nights decreased leptin and increased ghrelin with quantifiable increase in self-reported hunger (Spiegel K, Tasali E, Penev P, Van Cauter E. Ann Intern Med. 2004). A controlled crossover study in 19 lean men confirmed that sleep restriction elevated 24-hour ghrelin profiles and increased snack calorie intake by 328 kcal, primarily from carbohydrates. Van Egmond and colleagues found in a 2023 Obesity study that the ghrelin response after acute sleep loss was more pronounced in individuals with obesity (Van Egmond et al. Obesity. 2023;31(3):635-641).

A 2025 meta-analysis of six RCTs found no statistically significant population-level changes in leptin or ghrelin following sleep deprivation in all studies, suggesting that central reward pathway effects are equally or more important than peripheral hormone shifts alone (Rosenberg et al. Obesity Reviews. 2026). This connects directly to the emotional dysregulation section below.

Cortisol Elevation and the Self-Perpetuating Cycle

Chronic poor sleep produces sustained HPA (hypothallamic-pituitary-adrenal) axis activation and elevated cortisol, particularly in the evening hours when cortisol should be at its lowest. Elevated evening cortisol directly impairs slow-wave sleep, the stage that normally exerts inhibitory feedback on the HPA axis, creating a self-sustaining cycle that propagates independently of the original stressor. The metabolic effects of sustained cortisol elevation are well-established: cortisol is catabolic for muscle, directly promotes hepatic gluconeogenesis, and contributes to both insulin resistance and visceral adiposity.

One RCT found that controlling for cortisol and testosterone statistically eliminated 50% of the insulin resistance induced by sleep deprivation, directly implicating hormonal dysregulation as a primary mechanism (Vgontzas et al. PMC2902103). What begins as a cause of poor sleep becomes, once chronic, a mechanism that perpetuates the disruption without any continued external stressor.

Cardiovascular Disease

Sleep deprivation and poor sleep quality are independently associated with hypertension, coronary heart disease, heart failure, atrial fibrillation, stroke, and cardiovascular mortality through converging biological mechanisms. Sustained sympathetic nervous system activation elevates resting heart rate and blood pressure. HPA-mediated cortisol elevation promotes systemic inflammation and endothelial dysfunction. Reduced slow-wave and REM sleep attenuates the normal nocturnal blood pressure dipping that protects vascular integrity. Even a single night of sleep deprivation is associated with increased arterial stiffness in healthy adults.

A 2025 PLOS One analysis found that both shorter and longer sleep durations increase the risk of heart failure, myocardial infarction, and hypertension, with optimal cardiovascular protection in the 7 to 9 hour range (PLOS One. July 2025. doi:10.1371/journal.pone.0326499). The pro-atherogenic mechanism includes sympathetic nervous system driven bone marrow release of monocytes and progenitor cells, elevated inflammatory cytokines, and endothelial adhesion molecule upregulation, all documented in human sleep deprivation studies (Franceschini et al. Nature Communications Biology. 2021. PMC8602722).

Glymphatic Failure and Dementia Risk

The glymphatic system is a brain-wide network of perivascular channels through which cerebrospinal fluid and interstitial fluid exchange, serving as the brain’s primary waste clearance mechanism. Identified by Nedergaard and colleagues in 2012 and named for its dependence on glial aquaporin-4 water channels, glymphatic activity is dramatically higher during sleep than during wakefulness, driven by reduced brain parenchymal resistance to fluid flow, reduced noradrenergic tone, and the slow oscillatory neural activity characteristic of slow-wave sleep. The primary waste products cleared include amyloid-beta and tau, the proteins whose accumulation defines Alzheimer’s disease pathology (Xie et al. Science. 2013;342(6156):373-377).

In animal models, acute and chronic sleep deprivation increase interstitial amyloid-beta levels and accelerate plaque deposition, with tau seeding and spread worsening with sleep loss. A 2024 randomized crossover trial in 39 humans directly demonstrated that overnight glymphatic clearance during normal sleep increased morning plasma levels of Alzheimer’s disease biomarkers compared to sleep-deprived conditions, confirming that the system actively clears amyloid-beta and tau to plasma in humans during sleep (PMC12847902).

The Framingham Heart Study data are the most sobering finding in this area. Himali, Pase, and colleagues followed 346 adults over 60 for 17 years and found that each percentage decrease in slow-wave sleep per year was associated with a 27% higher risk of incident all-cause dementia, adjusted for age, sex, smoking, medication use, and genetic risk (Himali et al. JAMA Neurol. 2023;80(12):1326-1333. doi:10.1001/jamaneurol.2023.3889). While only a prospective longitudinal association, is among the strongest evidence linking a modifiable sleep parameter to dementia risk over a clinically relevant time horizon. APOE e4 carrier status was independently associated with accelerated slow-wave sleep loss, suggesting that genetic Alzheimer’s risk operates partly through disruption of the very sleep stage responsible for clearing the pathological proteins.

The 2025 SLEEP Annual Meeting included formal discussion of emerging data suggesting glymphatic clearance may not be strictly sleep-dependent and may occur to some degree during wakefulness. This is an evolving area of scientific discussion. The preponderance of evidence across animal models, human RCTs, and longitudinal cohort data still supports slow-wave sleep as essential to glymphatic function and amyloid clearance (Corbali and Levey. Front Neurol. 2025. PMC11835678).

Systemic Inflammation — The Convergent Downstream Pathway

Every consequence described above shares a common amplifier: persistent low-grade systemic inflammation produced by chronic sleep deprivation.

A 2025 meta-analysis in the Journal of Sleep Research by Ballesio and colleagues, covering 35 studies and 887 participants, found that multiple nights of partial sleep deprivation, approximately 4.5 hours for three or more consecutive nights, produced significant increases in IL-6 and CRP (Ballesio et al. J Sleep Res. 2025. PMC12856123). Critically, a single night of deprivation did not produce measurable inflammatory changes. This establishes a threshold effect: the inflammatory consequence requires sustained disruption, not acute disruption. The pro-inflammatory mechanism operates through sympathetic nervous system activation increasing monocyte and neutrophil production from bone marrow, HPA-driven cortisol dysregulation altering cytokine balance, and impaired immune homeostasis across innate and adaptive compartments. Sustained inflammation is the pathway through which poor sleep accelerates insulin resistance, cardiovascular disease, and neurodegeneration simultaneously.

Acute Cognitive Impairment and Emotional Dysregulation

The prefrontal cortex is disproportionately sensitive to sleep loss. Even modest sleep restriction selectively impairs sustained attention, executive function, working memory, impulse control, and decision-making before other cognitive domains are measurably affected. A 2025 study in Frontiers in Neuroscience confirmed that sleep deprivation selectively impairs attention networks and executive function first (Ren et al. Front Neurosci. 2025. PMC12014645). A 2025 narrative review confirmed higher error rates, impaired decision-making, and reduced cognitive control across all tested domains following chronic sleep deprivation (PMC12168795).

The emotional dysregulation mechanism is the most personally recognizable consequence. REM sleep is when the brain processes and integrates emotional experience through coordinated theta-frequency oscillatory activity between the amygdala, hippocampus, and prefrontal cortex. During REM, the prefrontal cortex exerts top-down regulatory control over amygdala reactivity, allowing emotionally charged experiences to be consolidated. A 2023 Journal of Neuroscience computational modeling study confirmed that rhythmic prefrontal-amygdala interaction during REM is the basis for emotional memory processing and fear consolidation (Stickgold R, Bhatt DL, et al. Journal of Neuroscience. 2023;43(3):433-446. doi:10.1523/JNEUROSCI.1020-22.2022).

Sleep deprivation severs this regulatory circuit. Yoo and colleagues’ neuroimaging work demonstrated a prefrontal-amygdala disconnect following sleep deprivation: amygdala reactivity to emotionally provocative stimuli increased by approximately 60% while prefrontal inhibitory control over that response was simultaneously weakened (Yoo SS et al. Curr Biol. 2007;17(20):R877-8). The result is a brain operating with a hyperreactive emotional processing center and a compromised regulatory governor, producing the irritability, emotional lability, impulsivity, and heightened stress reactivity that anyone who has worked through a night shift or come off a long stretch of inadequate sleep recognizes immediately.

After a poor night, ghrelin rises and leptin falls. Simultaneously, amygdala hyperreactivity drives reward-seeking behavior while prefrontal inhibitory control is too compromised to override it. Sleep deprivation also reduces striatal dopamine D2 receptor availability, increasing the reinforcing value of food stimuli in direct parallel to the neurochemistry of substance craving (Rexrode et al. Front Sleep. 2023. PMC10624159). The person reaching for pastries at 7 a.m. after a sleepless night is not exercising poor judgment. Their brain’s regulatory architecture has been temporarily dismantled by a biological process with documented, measurable neurochemical consequences.

Now you have a better understanding of what sleep is, normal architecture and functions and the metabolic consequences of chronic poor sleep. Now that you understand the mechanisms, how can you actually improve sleep?

Part Four addresses exactly that.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

Money drives behavior is the proposition running through this series. Today we explore the reverse: when money drives the changes. Will take a look of how money shapes healthcare policy.

Lobbying Is Not the Problem

Lobbying is a constitutionally protected right.

In principle is the mechanism by which the people can voice their positions to elected representatives. The problem is when money is the one making the petition instead.

Total healthcare sector lobbying expenditures grew from $358 million in 2000 to $714 million in 2020, a 70% increase over two decades (Wouters OJ et al., JAMA Health Forum, 2022). In 2021, the sector spent nearly $700 million, the highest ever recorded in a single year. The breakdown by subsector in 2020: pharmaceutical and health product manufacturers led at $308 million, providers at $287 million, and payers at $81 million. Spending is highly concentrated, the top 10% of firms account for 70% of payer lobbying expenditures and 69% of manufacturer expenditures. The healthcare sector has ranked among the top five lobbying spenders in the United States consistently for decades. In 2009 alone, more than $1.1 billion was spent lobbying the initial version of what would become the Affordable Care Act (Center for Public Integrity, 2010).

The Industry is Party Agnostic

The overall health sector has shifted its giving between parties multiple times over the past three decades, favoring Republicans in some cycles, Democrats in others, always consistently following power rather than ideology (OpenSecrets, Health Sector Summary).

The insurance industry has historically favored Republicans. The pharmaceutical industry historically favored Republicans as well, then flipped toward Democrats in 2020, and has distributed nearly evenly since. In the 2023-2024 election cycle, pharmaceutical PACs gave $5.2 million to Democrats and $6.6 million to Republicans (PharmaVoice, October 2024). Individual major companies split their contributions deliberately across both parties’ congressional and senatorial committees. Novo Nordisk gave 49% to Democrats and 51% to Republicans. Eli Lilly divided its giving evenly between both parties’ committees (BioSpace, August 2024).

Seven of the top ten organizations registered to lobby on the Inflation Reduction Act were pharmaceutical or health insurance companies (OpenSecrets, 2022).

Both parties have been recipients of healthcare industry money across every administration and every Congress for fifty years, and both parties have consistently failed to enact structural reform of the system that funds them.

Who Represents Patients?

According to peer-reviewed analysis of federal tax disclosures and organizational reporting, 67.3% of patient advocacy organizations receive industry funding (Rose SL et al., JAMA Internal Medicine, 2017). Nearly 12% receive more than half their total funding from industry. More than one third have pharmaceutical, biotech, or medical device executives on their boards of directors. Only 12% have published conflict of interest policies. A separate analysis published in the New England Journal of Medicine found that of 104 large patient advocacy organizations examined, one stated plainly that it accepted no industry funding (McCoy MS et al., NEJM, 2017). One.

Between 2010 and 2022, the pharmaceutical industry distributed at least $6 billion in grants to more than 20,000 organizations, more than it spent on direct lobbying and campaign contributions combined during the same period (KFF Health News, December 2023). Funding concentrates in disease categories where the contributing company has commercial products, not in areas where patients most need advocacy.

The answer to the original question “who represents patients in the policy process?” is sadly, nobody.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

The ACA: What Happened, What It Produced

The Affordable Care Act produced real coverage gains. The uninsured rate fell from 14.5% in 2013 to a record low of 7.7% in 2023. The number of uninsured Americans dropped from 45.2 million to 26.4 million. Twenty million previously uninsured Americans gained coverage (KFF, October 2025; CBPP, March 2024).

What is also true is the cost trajectory. The gross federal cost of ACA marketplace subsidies grew from $18 billion in 2014 to $92 billion in 2023 and an estimated $138 billion in 2025 (Committee for a Responsible Federal Budget, November 2025). The Congressional Budget Office projects total federal subsidies for health insurance will reach $25 trillion over the 2024-2033 decade (CBO, September 2023). Out-of-pocket costs for insured Americans rose 77% over the decade despite expanded coverage. The individual mandate was effectively eliminated in 2019 when the tax penalty was reduced to zero, altering the legislation’s economic architecture without repealing the legislation itself.

As of 2022, 26.4 million Americans remained uninsured. Thirty percent of providers deny Medicaid patients, limiting access to the coverage that was expanded. The structural incentives driving healthcare cost growth were not altered by the ACA’s passage.

But Who Shaped It?

When the Senate Finance Committee took the lead in drafting the ACA the legislation was primarily written by Elizabeth Fowler, Senator Max Baucus’s chief health policy counsel. Before joining his office, Fowler had served as Vice President for Public Policy and External Affairs at WellPoint, at the time the nation’s largest health insurance provider. After the ACA passed, she moved to the White House to oversee its implementation. She subsequently left for a senior-level position in Johnson & Johnson’s government affairs and policy group (The Guardian, December 2012).

The pharmaceutical industry, through PhRMA, supported the ACA publicly while lobbying specifically to exclude Medicare drug price negotiation authority. The insurance industry, through AHIP, publicly supported the ACA while internally spending approximately $100 million to limit its most disruptive provisions. (ProPublica; OpenSecrets, June 2021). The version of the ACA that passed preserved the employer-sponsored insurance system, prohibited Medicare from negotiating drug prices, and did not include a public option. Each of these outcomes aligned precisely with the financial interests of the industries that lobbied most heavily during the drafting process.

The COVID Era

Beginning in March 2020, the federal government and state governments implemented economy-wide business closures of a scale and duration without precedent in American peacetime history. Schools closed, affecting tens of millions of children, with documented multi-year consequences for academic achievement and developmental outcomes. Mask mandates were implemented at federal, state, and local levels with varying legal authority, enforcement mechanisms, and durations. Vaccine mandates were implemented for specific employment categories, one of the best examples was the military mandate.

On August 24, 2021, the Secretary of Defense issued a memorandum requiring all members of the US Armed Forces to receive COVID-19 vaccination. Approximately 17,000 service members refused. More than 8,400 were involuntarily discharged: 3,717 Marines, 2,041 Navy sailors, 1,841 Army soldiers, and 834 Air Force and Space Force members.

Legal challenges were filed on First Amendment, Religious Freedom Restoration Act, and informed consent grounds. Congress directed rescission through Section 525 of the 2023 National Defense Authorization Act. The mandate was rescinded on January 10, 2023. On January 27, 2025, President Trump signed an executive order directing reinstatement of those discharged, as of mid-2025, fewer than 200 of the 8,400 discharged had returned to service (Executive Order, January 27, 2025; EANGUS; New Civil Liberties Alliance; Military Times, February 2026).

During the same period, federal health agencies were involved in directing social media content moderation of COVID-related information. The House Select Subcommittee on the Coronavirus Pandemic documented communications between federal health officials and social media platforms regarding the moderation of COVID-related content. Federal courts addressed related First Amendment questions through the Missouri v. Biden litigation. The specific communications are part of the public congressional record (House Select Subcommittee on the Coronavirus Pandemic, Final Report, 2024). The scope, intent, and justification of that involvement remain actively contested in legal and political proceedings.

The COVID era is the most extreme illustration of what happens when government assumes authority over individual healthcare decisions at scale. Any honest evaluation of proposals to expand governmental control over individual healthcare decisions should account for that record.

The Architecture That Sustains the Failures

Across this series we examined what is wrong with the American healthcare system through the behavior of its major players. The political architecture documented in this piece, while not the only cause of all those failures, is the mechanism by which they are sustained.

The concluding piece in this series will bring all these pieces together and offer several coherent proposals to address some of the structural problems identified throughout this series.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

On June 22, 2026, Nature Medicine published a study from a team at Washington University School of Medicine in St. Louis reporting that younger adults are aging biologically faster than older adults born decades earlier, and this accelerated aging is linked to the rising incidence of early-onset solid cancers (Tian et al., 2026). The WashU press release described the finding as a possible biological explanation for why cancer is increasingly striking people under 50, treating “accelerated aging” as the new headline phenomenon.

When I read the paper carefully and against the broader literature on metabolic disease, inflammation, and aging biology, I came away with a very different impression of what is actually being measured. What follows is my interpretation of the evidence, not the conclusions the authors expressed on the original paper. I think the standard framing misses what may be the most important thing about this finding.

What the Paper Actually Shows

The Tian study analyzed 154,169 participants in the United Kingdom (UK) Biobank and 10,262 participants in the United States National Institutes of Health (NIH) All of Us Research Program. The team used three biological aging metrics: PhenoAge, the Klemera-Doubal Method (KDM), and a metabolomic age score. They calculated each participant’s “age gap,” the difference between biological and chronological age, and then prospectively linked the age gap to incident early-onset solid cancers in people under 55.

Each one standard deviation increase in PhenoAge gap was associated with an 8% increase in early-onset cancer risk (hazard ratio 1.08), and people in the highest tertile of biological aging had a 15% higher risk than those in the lowest tertile. The three aging metrics produced directionally consistent but variable results. Organ-specific analyses linked immune-system aging to lung cancer risk and adipose-tissue aging to colorectal cancer risk. The All of Us cohort produced partial replication based on only 104 incident cases over an average follow-up of 2.4 years. The authors appropriately acknowledged that an observational design cannot establish causation.

Two independent senior investigators commented on the paper through the United Kingdom (UK) Science Media Centre on the day of publication. Dr. Jyoti Nangalia of the Wellcome Sanger Institute raised the central methodological question directly: are these biological age measurements capturing processes that drive cancer, or are both the aging changes and the cancer being driven by other shared upstream factors (Science Media Centre, 2026)? That question, posed at the moment of publication by a senior cancer geneticist, is the question this article addresses.

What PhenoAge Is Built From

PhenoAge, the aging clock most central to the Tian analysis, is built from nine blood biomarkers: albumin, alkaline phosphatase, creatinine, C-reactive protein (CRP), glucose, mean cell volume (MCV), red cell distribution width (RDW), white blood cell count (WBC), and lymphocyte percentage (Levine et al., 2018). Look at that list and ask the diagnostic question a clinician asks every day: what conditions move these numbers?

CRP is the prototypical marker of chronic low-grade inflammation, and it is elevated in obesity, metabolic syndrome, and type 2 diabetes. Fasting glucose is, by definition, the variable that defines dysglycemia. Albumin falls in chronic inflammatory states and in hepatic dysfunction associated with metabolic-associated steatotic liver disease. Alkaline phosphatase is elevated in fatty liver disease. WBC count rises with chronic inflammation. RDW rises with metabolic and cardiovascular dysfunction. Lymphocyte percentage shifts with chronic immune activation. MCV moves with nutritional status and chronic disease.

Every single one of these nine biomarkers is directly moved by metabolic disease and its inflammatory consequences. PhenoAge is not measuring some abstract aging biology, is measuring a composite of inflammation, glycemic dysregulation, and the visceral footprint of metabolic dysfunction, packaged as a single number and labeled “biological age”.

If you accept that framing, the question is no longer if younger generations are aging faster? The question becomes; are younger generations carrying a higher metabolic-inflammatory burden than their parents and grandparents did at the same age, and is that burden showing up in the biomarkers we use to estimate aging? The literature answers that question with a clear yes.

Metabolic Disease Moves the Aging Clock

The published literature on metabolic syndrome and biological aging is large and remarkably consistent across cohorts, aging clocks, and age ranges.

McCarthy and colleagues, working in the Irish Longitudinal Study on Ageing (TILDA), examined 469 participants and found that metabolic syndrome was associated with accelerated epigenetic aging as measured by the GrimAge clock. Critically, the team performed a mediation analysis and found that CRP, the inflammatory marker, mediated approximately one-third of the metabolic-syndrome-to-aging association (McCarthy et al., 2024).

Föhr and colleagues conducted a twin study published in the International Journal of Obesity, examining 268 participants in the discovery cohort with replication in 1,857 additional participants across ages 23 to 69. Metabolic syndrome was associated with acceleration on both the GrimAge clock and the DunedinPACE clock. The twin design is what makes this study particularly informative. By comparing twins discordant for metabolic syndrome, the investigators could partially separate genetic susceptibility from the metabolic exposure itself. Shared genetic factors explained much of the GrimAge association, but the DunedinPACE association persisted within twin pairs (Föhr et al., 2024). Some of what aging clocks detect is genetic susceptibility shared with metabolic disease, the rest is the metabolic process itself.

Lemke and colleagues, working in the Coronary Artery Risk Development in Young Adults (CARDIA) cohort, conducted a longitudinal analysis directly relevant to the age range of the Tian paper. Metabolic syndrome severity prospectively predicted epigenetic age acceleration in young adults. The authors framed accelerated epigenetic aging as a potential early-detection tool for emerging metabolic syndrome (Lemke et al., 2019). In other words, the people studying aging clocks in young adults already proposed, in 2019, that what the clocks are reading is essentially the metabolic process.

Davis and colleagues examined 273 children aged 8 to 14 and found that higher body mass index (BMI) was associated with accelerated epigenetic aging (Davis et al., 2022). Salech and colleagues, working in a Chilean cohort, reported that persistent obesity since childhood and adolescence was associated with accelerated biological aging in young adults (Salech et al., 2024). The metabolic-to-aging association is detectable before adolescence and tracks forward through the young adult years where the Tian paper finds its strongest evidence.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Chronic Inflammation as the Connector

The biological link between metabolic dysfunction and accelerated aging is chronic low-grade inflammation. This pathway is well documented. Tam and colleagues, in a 2024 review in Immunity & Ageing, traced the chain: obesity drives adipocyte senescence; senescent adipocytes propagate the senescence-associated secretory phenotype (SASP) to immune cells; chronic low-grade inflammation results; this inflammation feeds back to worsen metabolic dysfunction and accelerates the cellular processes that aging clocks detect (Tam et al., 2024).

Liu and colleagues, in a 2025 review in Cell Death Discovery, catalogued ten overlapping mechanisms between obesity and aging: systemic inflammation, telomere depletion, epigenetic alterations, mitochondrial dysfunction, stem cell exhaustion, deregulated nutrient sensing, genomic instability, loss of cellular homeostasis, accumulation of senescent cells, and gut dysbiosis (Liu et al., 2025). Obesity essentially recapitulates the hallmarks of aging at the molecular level. The 2014 foundational review by Park and colleagues in Inflammation Research had already established the reciprocally reinforcing relationship between age-related inflammation and insulin resistance (Park et al., 2014).

The inflammaging literature, beginning with Franceschi’s foundational 2000 paper in the Annals of the New York Academy of Sciences and extending forward for two decades, has established that chronic low-grade inflammation is itself a fundamental driver of aging biology (Franceschi et al., 2000). What is new is the recognition that the generational rise in metabolic disease has loaded younger cohorts with this inflammatory burden earlier in life than their parents carried it.

The Same Mechanism Drives Early-Onset Cancer

The metabolic-inflammatory axis is independently established as a driver of early-onset cancer, particularly early-onset colorectal cancer.

Liu and colleagues, in a 2024 review in Frontiers in Oncology, argued explicitly that obesity-induced low-grade inflammation may play a more important role in early-onset colorectal cancer than in late-onset disease (Liu et al., 2024). Schumacher and colleagues, in a 2024 paper in Cancers, identified tumor-associated macrophage metabolism, leptin and adiponectin signaling, and the PI3K/AKT pathway as the specific biology linking obesity to early-onset colorectal cancer (Schumacher et al., 2024). Kühn and colleagues, in a 2017 nested case-control analysis using prediagnostic samples from the Västerbotten Intervention Programme, showed that the association between metabolic syndrome and colorectal cancer is substantially mediated by inflammatory proteins, with visceral adiposity as the driving exposure (Kühn et al., 2017).

The clearest statement comes from a paper the Tian team cites in their own reference list. Du and colleagues, in a 2025 review in Nature Reviews Endocrinology, reframe early-onset colorectal cancer explicitly as a disease of metabolic dysregulation (Du et al., 2025). The Tian authors cite this paper to explain why their adipose-aging-to-colorectal-cancer finding is biologically plausible.

Younger birth cohorts carry higher rates of obesity, metabolic dysfunction, and chronic inflammation than their parents and grandparents did at the same age. These conditions move the biomarkers that aging clocks are built from. These same conditions independently drive early-onset cancer through documented mechanisms. The accelerated aging finding and the early-onset cancer finding are not two separate phenomena requiring two separate explanations. They are the same epidemiologic phenomenon observed through two different windows.

The Osteoarthritis Parallel

I find it useful to think about this through a parallel to a disease most readers know. Osteoarthritis (OA) of the elderly is conventionally understood as a wear-and-tear phenomenon. The articular cartilage that lines joint surfaces has bounded capacity to repair the microscopic damage that ordinary mechanical loading produces over a lifetime. Repair keeps pace with damage for decades, until late in life, when accumulated microscopic damage finally exceeds repair capacity and the clinical picture of OA emerges.

In some populations, the timeline collapses. The competitive runner with thirty years of high-mileage training presents with OA in their forties, not their seventies. The patient who has carried 100 extra pounds for two decades presents with knee OA in their fifties. Same disease, same mechanism, different timeline, driven entirely by the rate of damage accumulation relative to the bounded rate of repair.

The same logic applies to systemic biology. The body’s cellular repair systems operate at roughly bounded rates. Chronic metabolic-driven inflammation produces continuous low-grade damage across multiple systems simultaneously. When the rate of accumulation chronically exceeds what ongoing repair can keep up with, the failure modes ordinarily associated with old age, including cancer, appear earlier.

This is a conceptual frame, not a documented pathway. It aligns with established theoretical work: the disposable soma theory of aging, the inflammaging framework, the cumulative damage model. I offer it as a useful lens for thinking about what is happening, not as a finding.

The Integrative Principle

Modern biomedical science studies aging in one discipline, metabolic disease in another, oncology in a third, and inflammation in a fourth. Press coverage and clinical practice tend to inherit this fragmentation; the Tian paper is a case in point. It is excellent aging-epidemiology work that, viewed through the wider lens of metabolic medicine and inflammation biology, reveals something other than what its framing suggests.

Aging is not an independent, autonomous process happening on its own clock. It is the integrated consequence of how every other system in the body is functioning over time. The aging researchers are not wrong to study aging as an independent phenomenon, this is useful for the organization of research itself. They become misleading when imported into public understanding of how the body actually works. A finding that the same nine inflammatory and metabolic biomarkers move with both “accelerated aging” and early-onset cancer should not surprise anyone. It is the same biology, named differently in different disciplines.

This recognition transforms the conversation about metabolic health. Improving metabolic health is not merely about getting the glucose, blood pressure, and weight on the scale into normal range, important as those targets are. It is about reducing the cumulative inflammatory burden that is reshaping the trajectory of biological aging itself and increasing susceptibility to the diseases conventionally associated with old age.

The Impact in Real Numbers

The numbers that frame this for the United States are clinically sobering. According to the Centers for Disease Control and Prevention (CDC), approximately 38% of American adults have prediabetes and another 11% have diagnosed or undiagnosed diabetes, meaning roughly half the adult population is somewhere on the dysglycemia spectrum (CDC, 2024). The American Heart Association reports that more than one in three American adults meet the criteria for metabolic syndrome (American Heart Association, 2024). The economic burden is comparably large. The American Diabetes Association estimates the total annual cost of diabetes in the United States at $413 billion as of the most recent national accounting (American Diabetes Association, 2024).

The early-onset cancer trend that the Tian paper attempts to explain is real and accelerating. Early-onset colorectal cancer incidence in particular has been rising for three decades, and Berrington de Gonzalez and colleagues, in a 2025 international comparative analysis published in the Annals of Internal Medicine, documented similar trends across multiple high-income countries (Berrington de Gonzalez et al., 2025). These are the same countries in which the metabolic-disease curve has been climbing for the same period. The temporal correlation does not prove causation, but it is the kind of correlation a metabolic-inflammatory explanation predicts and the kind a sealed-off “accelerated aging” explanation does not.

What This Means For You

The same lifestyle modifications this publication has covered repeatedly, and will continue to cover, are not just about preventing the diseases of metabolic dysfunction. They are about reducing the rate at which the cumulative damage that accelerates biological aging accumulates. The action steps are familiar, and they are the right ones:

• Reduce ultraprocessed food consumption, which independently drives inflammation, dysglycemia, and weight gain. The single highest-yield change in the contemporary American food environment is reducing the share of calories coming from industrially formulated foods.

• Eat a dietary pattern centered on whole foods, with abundant vegetables, legumes, intact whole grains, nuts, fish, and olive oil, in the Mediterranean tradition. This pattern has the strongest evidence base for reducing inflammatory and metabolic markers.

• Move daily: both aerobic activity and resistance training independently improve insulin sensitivity, reduce inflammatory markers, and preserve the metabolic flexibility that decays with age and metabolic disease.

• Sleep seven to nine hours per night on a regular schedule. Sleep restriction directly impairs glucose tolerance and raises inflammatory markers within days.

• Address chronic psychological stress, which directly elevates cortisol and inflammatory cytokines and indirectly drives the behaviors that worsen metabolic health.

• Eliminate tobacco and treat alcohol intake as a metabolic exposure to be minimized, not a neutral social variable.

None of this is new information, what may be new is the reason to take it seriously.

Aging is not something that simply happens to us on a clock we do not control. It is in substantial part something we accelerate or decelerate through how we live, beginning earlier than most of us realize and continuing through every decade that follows.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

This piece teaches you to use the right part of the label, recognize the ingredients that disqualify a product immediately, understand what each one does to your metabolism in plain language, and apply a simple three-question framework before anything goes in your cart. It also covers artificial sweeteners: what the current evidence shows about their metabolic consequences so you can make informed choices.

The Right Part of the Label

Ingredients are listed by weight in descending order, that is the information you need. The nutrition facts panel still has four numbers worth checking, but the ingredient list is the primary tool.

A large prospective cohort study of 108,643 adults linked specific additive combinations to significantly higher incidence of type 2 diabetes (Lancet Series on Ultra-Processed Foods, Touvier M et al., November 2025). A separate 2025 laboratory study found that mixtures of additives caused toxic effects in human colon, liver, kidney, and neuron cell models that were not observed when the same substances were tested individually.

The Worst Offenders: What to Look for and Why It Matters

Industrial Sweeteners

High fructose corn syrup and its aliases: high fructose corn syrup (HFCS) bypasses the regulatory steps that normally govern glucose metabolism and is processed almost entirely in the liver, where it drives de novo lipogenesis, elevates triglycerides, and contributes to insulin resistance through a pathway that glucose does not share.

On ingredient lists, HFCS may appear as: corn syrup, corn syrup solids, glucose-fructose syrup, isoglucose, or high fructose maize syrup. If any of these aliases appears in the first five ingredients, the product is built on cheap industrial sweetener.

The sugar fragmentation problem: sugar has more than sixty names on ingredient lists. Manufacturers distribute it across multiple entries to prevent any single form from appearing prominently enough to alarm a scanning reader. Dextrose, maltose, maltodextrin, fruit juice concentrate, cane sugar, brown rice syrup, and agave nectar are all sugar by other names.

The one place the nutrition facts panel is genuinely useful is the added sugars line, which aggregates every form of added caloric sweetener into a single gram count, regardless of how many names they appear under. The World Health Organization (WHO) recommends staying below 50 grams of added sugar per day on a 2,000-calorie diet. A single serving of many breakfast cereals, flavored yogurts, or condiments can consume a substantial fraction of that budget.

Industrial Fats

Partially hydrogenated oils: partially hydrogenated oils are the source of artificial trans fats, and they are a disqualifying finding regardless of what the nutrition facts panel claims. Under current US labeling rules, a product with less than 0.5 grams of trans fat per serving can legally declare zero grams on the panel. A product consumed in two or three servings, as many packaged snacks are, can deliver meaningful trans fat exposure under a zero trans fat claim.

Fully hydrogenated oils and interesterified fats: these are the industrial replacements developed after the 2015 FDA determination that partially hydrogenated oils were no longer generally recognized as safe. They are not technically trans fats by regulatory definition, but they are present for the same industrial purpose: extending shelf life and modifying texture in ways that real food fats cannot match as cheaply. The long-term human metabolic evidence on these substitutes is limited.

Seed oils in the first five ingredients: soybean oil, corn oil, cottonseed oil, and sunflower oil appearing in the first five ingredients is a clear marker of industrial manufacturing independent of the omega-6 to omega-3 ratios.

Emulsifiers: The Most Important New Evidence

Carboxymethylcellulose (CMC) and polysorbate 80 (P80) have the strongest documented harm evidence. They thin the intestinal mucus layer that protects epithelial cells, increase gut permeability, elevate lipopolysaccharide (LPS) translocation into the bloodstream, and activate NF-kB inflammatory pathways with upregulation of TNF-alpha and interleukin-6 (IL-6). These are the mechanisms that drive chronic low-grade inflammation and propagate insulin resistance.

Chassaing B et al. demonstrated direct impact of CMC and P80 on human gut microbiota (Microbiome, 2021). A 2024 Communications Biology study confirmed that CMC and P80 induce intestinal inflammation and metabolic syndrome markers through gut permeability elevation and LPS translocation. The most recent and highest-quality human data comes from a 2025 placebo-controlled randomized controlled trial (RCT) of 60 healthy participants published in Clinical Gastroenterology and Hepatology: CMC consumption produced reduced short-chain fatty acid (SCFA) concentrations, and carrageenan produced significantly increased transcellular intestinal permeability compared to placebo.

On ingredient lists, emulsifiers appear as: carboxymethylcellulose, cellulose gum, polysorbate 80, carrageenan, mono and diglycerides, soy lecithin, xanthan gum, and guar gum.

Artificial Colors and Preservatives

Artificial colors: Red 40, Yellow 5, Yellow 6, Blue 1, and Blue 2 are petroleum-derived dyes added to make industrially manufactured products visually appealing. Their presence on an ingredient list is an unambiguous marker of industrial manufacturing. The regulatory landscape is shifting: in 2025, the FDA announced plans to phase out some petroleum-derived dyes from the US food supply, and California signed a law in 2025 legally defining UPF and phasing out the most harmful additives from public school meals.

Sodium benzoate and potassium benzoate: when combined with ascorbic acid in the same product, they can form benzene under certain conditions. Ascorbic acid used alone as a preservative is safe: it is vitamin C. The issue is specific to its combination with benzoate preservatives.

Butylated hydroxyanisole (BHA) and butylated hydroxytoluene (BHT): are petroleum-derived antioxidant preservatives added to extend shelf life. They provide no nutritional benefit to the consumer. Their safety profiles remain contested in the scientific literature. Their presence on a label tells you the product required industrial chemistry to remain stable on a shelf.

Flavor Manipulation Ingredients

Natural flavors: covers a wide range of industrial flavor extracts derived from natural sources and processed through methods that bear little resemblance to home cooking. When natural flavors appear in the first five ingredients, the product’s flavor character is being engineered rather than delivered by the actual food ingredients.

Monosodium glutamate (MSG): the sodium salt of glutamic acid, an amino acid naturally abundant in fermented foods, aged cheeses, and many vegetables. In UPF, it functions as a palatability amplifier designed to make a product taste better.

The First Five Rule

Ingredients are listed by weight in descending order, the first five ingredients are the main ones. If any of the worst offenders described above appear in the first five positions, look for an alternate product.

Real food does not need a paragraph to explain itself. A product with twenty-two ingredients, half of them unpronounceable, is very likely not good for your metabolic health.

What to Actually Use on the Nutrition Facts Panel

Added sugars: aggregates every form of added caloric sweetener, including HFCS, corn syrup, dextrose, maltose, fruit juice concentrates, and all other forms, into a single gram count. The WHO recommendation is below 50 grams per day on a 2,000-calorie diet. Check this number against the serving size actually consumed, not the labeled serving.

Dietary fiber: a grain-based product delivering less than 1 gram of fiber per serving has been heavily refined. More than 3 grams represents a meaningful contribution.

Sodium: check against the potassium amount further down on the label. Ideally potassium should be higher or at least roughly equal to the sodium amount.

Serving size: manufacturers define serving sizes to produce numbers that look favorable. Every number on the nutrition facts panel multiplies by actual consumption. The calorie count that looked reasonable was calculated for a portion nobody eats.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Artificial Sweeteners: What They Are, Where They Hide, and What the Evidence Shows

Sucralose (Splenda)

Sucralose is the most widely used sweetener in commercially available diet products and carries the most concerning evidence profile of the sweeteners covered here.

A 2025 triple-blind RCT by Romo-Romo A et al., published in Clinical Nutrition ESPEN, found that 30 days of sucralose consumption at just 30% of the acceptable daily intake (ADI) produced a 20.3% reduction in insulin sensitivity in healthy lean adults, accompanied by reduced microbial diversity, shifts in bacterial populations, and decreased butyrate. A separate 10-week open-label RCT found altered gut bacterial abundance and associated changes in glucose and insulin levels on tolerance testing at 48mg daily sucralose (Mendez-Garcia LA et al., Microorganisms, 2022). The landmark Suez J et al. 2022 RCT of 120 healthy adults published in Cell found that sucralose significantly impaired glycemic responses through microbiome-mediated mechanisms confirmed in mouse transfer experiments (Cell, 2022;185(18):3307-3328).

A 2025 brain imaging RCT from the University of Southern California found that sucralose increased hunger sensation by approximately 17% and increased connectivity in brain regions controlling motivation, leading the researchers to conclude that sucralose interferes with normal appetite regulation in ways that could adversely affect weight control (Page KA et al., Nature Metabolism, 2025).

The appetite disruption evidence across all non-caloric sweeteners remains heterogeneous in the broader human literature. For sucralose specifically, multiple independent RCTs are consistent in direction across microbiome disruption, insulin sensitivity reduction, and appetite dysregulation.

Saccharin (Sweet’N Low)

A large case-control study of 3,010 bladder cancer patients and 5,783 controls found no association with saccharin use. Saccharin was removed from the US National Toxicology Program’s (NTP) list of potential carcinogens in 2001. A 2024 meta-analysis in Minerva Surgery concluded the carcinogenic risk of saccharin is not proven in humans (Balint IB et al., Minerva Surg, 2024;79(1):92-99). The European Food Safety Authority’s (EFSA) 2024 reassessment raised the ADI and concluded the cancer risk in humans is low.

Saccharin’s legitimate metabolic concern in this series is gut microbiome disruption. The Suez et al. 2022 Cell RCT found saccharin significantly impaired glycemic responses through microbiome-mediated mechanisms, comparable in effect to sucralose.

Aspartame (NutraSweet, Equal)

Among the most extensively studied sweeteners, it has the least concerning acute metabolic profile in RCT data. The Suez et al. 2022 Cell RCT found aspartame produced less pronounced microbiome and glycemic effects than saccharin or sucralose.

The 2023 International Agency for Research on Cancer (IARC) Group 2B “possibly carcinogenic” classification reflects limited human evidence and has not changed the safety positions of the FDA or EFSA. EFSA’s comprehensive risk assessment concluded aspartame does not pose a cancer risk at current intake levels.

One critical warning for Phenylketonurics: CONTAINS PHENYLALANINE. Phenylketonuria (PKU) is a rare genetic disorder in which the body cannot metabolize phenylalanine.

Acesulfame-K (Ace-K, Sweet One, Sunett)

It appears in combination with aspartame or sucralose in the majority of products where it is present, used to enhance sweetness while reducing aftertaste. It appears wherever aspartame or sucralose appear, often without consumer awareness that a second sweetener is present.

Acesulfame-K is understudied as an isolated ingredient. Its effects at typical human consumption levels are less well characterized than the other sweeteners on this list, which is itself important given how widely it is consumed. Its co-use with sucralose in particular places it in the same products as the sweetener with the most concerning evidence profile.

Stevia (Truvia, PureVia)

It currently carries the most benign metabolic profile among commonly used sweeteners in the available evidence. The Suez et al. 2022 Cell RCT found stevia produced less pronounced microbiome and glycemic effects than saccharin or sucralose. A large multi-cohort study of 47,910 adults reviewed by Harrold JA et al. found stevia was not associated with obesity risk, unlike sucralose, saccharin, and aspartame, which showed positive associations (PMC, 2024).

The evidence base for stevia is smaller than for older sweeteners. Its benign profile is supported by available data, not established by the same volume of research.

Monk Fruit (Luo Han Guo, Monk Fruit in the Raw)

Monk fruit extract is increasingly present in premium and health-positioned products. The evidence base is limited compared to any of the above, but no significant adverse metabolic findings have emerged to date. It is currently considered alongside stevia as the least concerning option when a non-caloric sweetener is being used.

The Sweetener Hierarchy: Current Evidence Summary

Based on the available evidence, from most to least metabolically concerning:

• Sucralose and saccharin: strongest microbiome disruption evidence and most consistent adverse effects on glycemic responses in RCT data

• Aspartame and acesulfame-K: mixed or limited evidence; aspartame less concerning in head-to-head RCT comparisons; acesulfame-K understudied in isolation

• Stevia and monk fruit: most benign profiles in currently available evidence

This hierarchy reflects the state of the science as of 2025-2026. The human evidence on appetite disruption across all sweetener types remains heterogeneous, and individual variation appears substantial. For a full discussion of the sweetener evidence and its implications for diet sodas, see the Diet Soda: Zero Calories, Not Zero Consequences article on The Metabolic Archives.

The Three Questions at the Shelf

Before anything goes in the cart, ask these in order.

One: Read the ingredient list, not the nutrition label. Are the first five ingredients things you would cook with?

Two: Do any of the worst offenders appear in those first five positions? HFCS or its aliases. Partially hydrogenated oils. Sugar as the first or second ingredient. Industrial emulsifiers. Artificial colors.

Three: How many ingredients are there in total? More than five or six begins to tell a story. A paragraph of ingredients tells the whole story.

For readers who want the complete label-reading methodology, the companion piece Do You Know The One Part of the Food Label That Actually Matters covers the full framework.

The Regulatory Landscape Is Shifting

In 2025, California signed the first law in the United States legally defining ultra-processed food and phasing out the most harmful additives from public school meals. The FDA announced plans in 2025 to phase out certain petroleum-derived artificial dyes from the US food supply. In early 2026, San Francisco filed the first government lawsuit against major UPF producers. The 2025 Lancet Series on Ultra-Processed Foods, authored by 43 international experts, called for stronger regulatory action. Legislators in dozens of US states have introduced or passed bills targeting harmful chemicals in the food supply.

When governments begin to act, the science has typically reached the threshold where the evidence is no longer deniable. You are learning to read a label in a moment when regulators are arriving at the same conclusions.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

This series has examined every major participant in the American healthcare system. Each has been held accountable in proportion to their contribution to what American healthcare has become. One participant has not been examined yet: the patient.

Intellectual honesty and scientific rigor demands we take a look to every player on the system, and that includes the patients. Before you turn the anger against me, I ask you to evaluate the arguments and evidence presented herein with an open mind and be willing to accept we, as the users of the system, share some portion of the responsibility as well.

The Copay Is Not the Price

Employer-sponsored insurance covered approximately 159 million Americans in 2023. The average employer contribution to family coverage was $16,357 annually or roughly 73% of the total premium (KFF Employer Health Benefits Survey, 2023). Medicare and Medicaid together covered approximately 140 million Americans at a combined federal and state expenditure exceeding $1.5 trillion annually (CMS National Health Expenditure Data, 2023).

The person who believes the copay is their entire financial participation in the healthcare transaction is mistaken. They are paying for everyone else’s avoidable consumption, and everyone else is paying for theirs in return.

When Patients Ask For That They Do Not Need

Approximately 30% of all outpatient antibiotic prescriptions, 47 million annually, are unnecessary, written primarily for viral respiratory ailments (Fleming-Dutra KE et al., JAMA, 2016). Sinusitis is the single diagnosis generating the most antibiotic prescriptions in American outpatient medicine: 56 per 1,000 population annually. Inappropriate prescribing for sinusitis and pharyngitis alone cost the privately insured system $69 million in excess spending in a single study year (Pew Charitable Trusts, 2023). The ultimate consequence is 2 million antibiotic-resistant infections and 23,000 deaths annually at a system cost of $30 billion (CDC, Antibiotic Resistance Threats, 2019).

Direct-to-consumer pharmaceutical advertising influences patient behavior as well. It encourage patients on stable treatment to ask (in some cases demand) a switch to a newer, heavily marketed equivalent with no demonstrated clinical superiority. The cost difference falls on the insurer and ultimately on all premium payers.

Physician shopping, seeking additional opinions until the desired outcome is obtained, compounds both problems. It circumvents the clinical judgment the system depends on, generates costs at every consultation, and creates a documented market incentive for the physician willing to provide the desired answer. This does not apply to patients rightfully seeking second opinions for serious or unexpected conditions, those are legitimate and most competent physicians will encourage them.

The professional consequence for the physician who fails to comply is swift. The patient leaves, posts a negative review, and usually transfers care to a physician who will comply. This ends penalizing the original physician’s clinical integrity, while financially incentivizing unprofessional behavior.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

Brand Name Over Generic

Generic drugs are required by the FDA to be bioequivalent to their brand name counterparts: identical in active ingredient, dosage form, route of administration, strength, and therapeutic effect. A review of bioequivalence data from more than 2,000 FDA-approved clinical pharmacokinetic trials found no significant difference in therapeutic effect between branded and generic drugs (Califf RM et al., PMC5417581). Generics cost approximately 80 to 85% less than their brand name equivalents. Between 2009 and 2019, generic drug use saved the US healthcare system nearly $2 trillion (FDA, Generic Drugs: Questions and Answers).

Despite this, more than one-third of patients report a preference for branded products over generics, and 46% have asked their physician to prescribe a brand name drug over an available generic alternative (Shrank WH et al., PMC1852907). Patient requests for brand name drugs over generically equivalent alternatives cost the Medicare Part D program $673 million in 2017 alone, and cost Medicare patients themselves an additional $109 million in unnecessary out-of-pocket spending in the same year (Bai G et al., JAMA Network Open, 2021). Across the entire healthcare system, unnecessary brand name dispensing when generic equivalents are available generates an estimated $8.8 billion in excess expenditure annually.

The Motorized Scooter Bubble

Medicare covers power wheelchairs and motorized scooters as durable medical equipment for beneficiaries with documented severe mobility impairment who cannot operate a manual wheelchair. The Scooter Store, the largest power wheelchair supplier with approximately 80% of its revenue derived from Medicare patients, launched a television campaign in late 1990s and 2000s telling elderly viewers they needed a power scooter to live an independent life, they were entitled to one, and Medicare would pay for it. This campaign created a growing demand from medicare beneficiaries seeking their own motorized scooter benefits from physicians oftentimes without identifiable medical need.

Physician who found no qualifying mobility impairment were positioned by the company as the obstacle, fostering an adversarial relationship between patient and physician. Former Scooter Store employees testified that the company ranked physicians by their willingness to prescribe and operated programs specifically designed to pressure physicians who had declined to certify patients as qualifying (DePaul Journal of Health Care Law; Washington Post, August 2014).

The Department of Health and Human Services Inspector General found that 80% of Medicare payments for power wheelchairs industry-wide were made in error, the majority to people who did not need the equipment or lacked documentation of need (HHS OIG Report OEI-03-02-00600, 2004). Since 1999, Medicare made more than $8 billion in payments for 2.7 million wheelchairs and scooters. The prescription rate for power wheelchairs increased 33-fold between 1994 and 2001 — a trajectory tracking precisely with the expansion of direct-to-consumer durable medical equipment advertising during the same period (Kessler D et al., PMC1850931). The government was aware of the fraud pattern as early as 1998 and did not act substantively until 2003 to 2004.

When Patients Stop Treatment

Medication non-adherence costs the US healthcare system between $100 billion and $300 billion annually in avoidable spending (Iuga AO, McGuire MJ, Risk Management and Healthcare Policy, 2014; Cutler RL et al., BMJ Open, 2018). It is associated with 125,000 preventable deaths annually and accounts for up to 25% of hospitalizations (Bosworth HB et al., Duke Health, 2018).

A portion of non-adherence episodes are attributable to populations at significant socioeconomic disadvantage making it often impossible to maintain medical compliance. While they do contribute to the figures cited above, their lack of medical compliance is certainly non-malicious. A different group of patients are willfully non-compliant, seeking care and stopping it for no excusable reasons. In my experience the latter group is significantly smaller, but no official numbers to distinguish these populations are available for review.

The well defined consequences from patient non-adherence are quality penalties and negative readmission metrics that fall on physicians and institutions alike. The Hospital Readmissions Reduction Program penalizes hospitals for readmissions without adjustment for whether the patient discharged against medical advice, stopped their medications the day after discharge, or returned directly to the lifestyle that produced the original admission.

What Patients Do Not Change

Chronic diseases consume approximately 90% of the nation’s $4.9 trillion annual healthcare spending (CDC, Fast Facts, 2025). The majority are significantly preventable or modifiable through behavioral change.

The specific cost figures:

• Smoking-related disease exceeds $240 billion.

• Obesity costs the healthcare system approximately $173 billion annually (Biener A et al., Health Affairs, 2010).

• Physical inactivity costs $192 billion (NHLBI, 2019).

• Poor diet accounts for approximately $50 billion in cardiometabolic disease costs (Pearson-Stuttard J et al., PLOS Medicine, 2019).

I acknowledge behavioral change is difficult, and socioeconomic conditions make it more difficult for some more than others. However it does not change what the behaviors cost society at large.

The physician who has repeated the goals-of-care conversation, adjusted medications to accommodate behaviors that do not change, ordered tests required by progressive deterioration, often find the patient and family attribute the lack of improvement to inadequate medical care instead.

What Families Do

End-of-life care (depending on how end-of-life is defined) consumes approximately 25% of all Medicare spending (Riley GF, Lubitz JD, Health Services Research, 2010; Aldridge MD, Kelley AS, American Journal of Public Health, 2015). The median Medicare expenditure in the last six months of life exceeds $28,000 per beneficiary. This is exacerbated by families that, purely out of grief, request every available life-sustaining intervention for patients with terminal diagnoses and no realistic prognosis for recovery. While I don’t condemn their motivations, their actions do contribute to the increasing financial stress of our healthcare system.

On the other hand, I have directly experienced families that actively undermine inpatient care by delivering contraband; the most common being food and cigarettes, although in rare instances, it can also include alcohol and even street drugs. Whether this stems from misguided love or loyalty, this behavior directly prevents the clinical outcomes the care team is being held accountable for producing, often leading to prolonged hospital stays with the increased costs and penalties already discussed elsewhere.

What Patients Do Not Disclose

Dietary supplements generate approximately 23,000 emergency department visits and 2,000 hospitalizations annually in the United States, based on nationally representative surveillance data from 63 emergency departments collected between 2004 and 2013 (Geller AI et al., NEJM, 2015). Disclosure rates for supplement use to treating physicians are estimated at 25 to 33% (Awortwe C et al., Frontiers in Pharmacology, 2025).

The problem here is not the patient decision to use a supplement, is the undisclosed supplement use along with prescription medications.

A patient on warfarin or a direct oral anticoagulant using a supplement with known antiplatelet or anticoagulant properties — Ginkgo biloba, fish oil at high doses, vitamin E, nattokinase — without disclosing it, is unknowingly creating a bleeding risk. The resulting hemorrhagic event requires hospital care for management of both the bleeding and associated complications. That episode was preventable by a single conversation that did not happen.

The Honest Close

This series demands addressing the public conversation society avoids. Patients are participants in the system, and participation carries rights and responsibilities.

Our healthcare system has an obligation to every patient regardless of the choices they make. That obligation is not conditional on behavior and it should not be. Healthcare resources are finite, that is an unavoidable fact. If we want the resources to meet the needs of society we need to hold all parties equally accountable for the efficient allocations of such resources.

One of those parties, is the patient.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

What Ultra-Processed Food Is

The accepted scientific standard is the NOVA classification system, developed by Carlos Monteiro at the University of Sao Paulo in 2009 and adopted by the UN Food and Agriculture Organization as its preferred framework for dietary analysis. NOVA divides food into four groups based on the extent and purpose of processing.

• Group 1 is unprocessed or minimally processed food: vegetables, fruit, meat, fish, eggs, plain grains, legumes.

• Group 2 is processed culinary ingredients: oils, flours, salt, sugar: things used to prepare food at home.

• Group 3 is processed food: canned fish, cured meats, simple cheeses, fermented foods: recognizable ingredients combined in recognizable ways.

• Group 4 is ultra-processed food.

NOVA Group 4 products are industrial formulations manufactured primarily from substances extracted or derived from food: refined starches, hydrogenated oils, protein isolates, high-fructose corn syrup. These are combined with additives not found in any home kitchen: emulsifiers, artificial flavors, colorants, humectants, anti-caking agents, preservatives.

They are designed for palatability, shelf stability, and profit, not nourishment.

A useful field test: read the ingredient list. If it contains substances you would not find in a kitchen or if the list runs longer than a paragraph, you are almost certainly looking at a Group 4 product.

How We Got Here

In the 1950s and 1960s, two competing hypotheses existed for the dietary driver of coronary heart disease. John Yudkin, a British physiologist, identified added sugars. Ancel Keys, an American physiologist, identified dietary fat. What resolved the debate was not science, was money.

The Sugar Research Foundation identified an existential commercial threat in Yudkin’s work. Internal documents later obtained by researchers at UCSF showed that the Foundation recognized as early as 1954 that a low-fat dietary environment would increase per-capita sugar consumption by more than one third.

The Foundation funded Harvard nutrition researchers in the mid-1960s to produce a literature review on dietary fat and coronary heart disease. The result was published in the New England Journal of Medicine in 1967 without disclosure of industry funding, a standard that did not yet exist. The review dismissed Yudkin’s sugar hypothesis and elevated Keys’s fat hypothesis.

A 2016 analysis of the Sugar Research Foundation’s own internal correspondence, published in JAMA Internal Medicine by Kearns, Schmidt, and Glantz, documented this sequence with primary source evidence. The scientific consensus that emerged from the 1960s and 1970s reflected what the industry had paid to produce.

The 1977 Policy Moment

The Senate Select Committee on Nutrition and Human Needs, chaired by Senator George McGovern, issued Dietary Goals for the United States in January 1977. The goals recommended reducing fat, cholesterol, and refined sugars while increasing complex carbohydrates and fiber. Three of eight senators on the committee dissented, arguing the evidence more strongly implicated refined carbohydrates than fat.

The food industry faced an immediate commercial problem. Fat provides palatability, texture, mouthfeel, and satiety; remove it and the product fails on the shelf. The solution was systematic substitutions. Sugar was added to restore taste, salt was increased to restore flavor, partially hydrogenated vegetable oils (trans-fats) were expanded to restore texture and extend shelf life. A growing toolkit of industrial additives restored the sensory qualities that whole-food fat had provided naturally.

The Low-Fat Era in a Single Product

No product illustrates the period more clearly than margarine.

Margarine was originally introduced in the nineteenth century as a cheap butter substitute for military and lower-income populations. By the 1980s, it had been rebranded as the heart-healthy alternative to saturated animal fat. It contained no cholesterol, medical societies endorsed it, a public primed to fear butter adopted it widely.

The mechanism that made liquid vegetable oil semi-solid at room temperature was partial hydrogenation: the industrial introduction of hydrogen bonds into unsaturated fatty acid chains. Partial hydrogenation produces trans-fatty acids as a byproduct. Trans fats raise LDL cholesterol, lower HDL cholesterol, and promote systemic inflammation.

A 2006 review in the New England Journal of Medicine by Mozaffarian and colleagues estimated that trans fat consumption was responsible for up to one in five myocardial infarctions per year in the United States. The FDA banned partially hydrogenated oils from the food supply in 2018, nearly four decades after margarine’s heart-healthy marketing era began.

Modern margarines have replaced partial hydrogenation with inter-esterification: a different chemical rearrangement of fatty acids on the glycerol backbone that achieves comparable physical properties without producing the same trans-fat profile. Animal data has demonstrated glucose intolerance and insulin resistance with inter-esterified fat consumption. A 2016 review by Mensink and colleagues in Advances in Nutrition concluded that the potential metabolic health risk of long term inter-esterified fat human consumption warrants serious concern.

The Obesity Timeline

The national obesity rate in the United States was approximately 13–14% through the mid-1970s (CDC NHANES data). The rise began between 1976 and 1980, coinciding precisely with the low-fat mandate’s translation into the documented rise in UPF consumption tracked in NHANES surveys. The largest increases through the 1980s and 1990s were in sugar-sweetened beverages, salty snacks, refined grain products, and fast food. By 2022, the adult obesity rate had reached 41.9%.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

What the Industry Knew

Ultra-processed food was not accidentally engineered to override appetite. The peer-reviewed evidence establishes that it was deliberately engineered using strategies directly imported from tobacco science.

Beginning in 1963, major tobacco companies began acquiring large segments of the US food industry. R.J. Reynolds and Philip Morris eventually owned brands including Del Monte, Nabisco, General Foods, Kraft, and 7UP. Peer-reviewed research published in Obesity in 2019 by Fazzino and colleagues, using the public tobacco industry archive, found that foods owned by tobacco companies between 1988 and 2001 were 29% more likely to be classified as fat-and-sodium hyperpalatable and 80% more likely to be classified as carbohydrate-and-sodium hyperpalatable than foods produced by non-tobacco-owned companies during the same period.

A 2026 review in the Milbank Quarterly, authored by researchers from Harvard, Duke, and the University of Michigan, concluded that ultra-processed foods are not simply natural products but highly engineered delivery systems designed specifically to maximize biological and psychological reinforcement and habitual overuse, sharing key engineering strategies with the tobacco industry including dose optimization and hedonic manipulation (Gearhardt, Brownell, and Brandt, 2026).

Industry trade publications in their own words described the goal as “turning consumer cravings into commercial wins” and acknowledged that “for decades, indulgence has been the profit engine.”

With US, UK, and EU markets saturated, the industry pushed into South America, Africa, Eastern Europe, China, and India. According to the November 2025 Lancet Series on Ultra-Processed Foods, authored by 43 international experts, UPF consumption has doubled in Brazil, Canada, and Mexico and tripled in China, South Korea, and Spain within a period of a few years. More than 50% of the $2.9 trillion distributed to food corporation shareholders between 1962 and 2021 was paid out by UPF manufacturers alone.

What Processing Does to Food

Before examining what ultra-processed food does to your body is worth examining what industrial processing does to food itself.

Food matrix destruction. Whole food has physical structure: fiber networks, cell walls, the spatial arrangement of macronutrients within intact cellular architecture. That structure governs digestion rate, glucose release kinetics, and the gut-brain satiety signaling that tells you when to stop eating. Industrial processing destroys it. The result is food that is digested faster, absorbed more rapidly, produces sharper glycemic excursions with corresponding insulin responses, and fails to engage the satiety mechanisms that intact food reliably triggers.

Refined fat, sugar, and salt at non-natural concentrations. The combinations of fat, sugar, and salt found in ultra-processed products are calibrated to maximize hedonic response and drive consumption beyond what your satiety system would otherwise permit. The reward pathway engagement produced by these combinations exceeds what any whole food can generate.

Industrial additives. Emulsifiers, artificial sweeteners, preservatives, colorants, and flavor enhancers serve industrial functions: shelf stability, texture restoration, appearance, and palatability amplification. They are not in your food to nourish you. Several additives have documented effects on gut microbiome composition and intestinal barrier integrity independent of their caloric content.

What Ultra-Processed Food Does to Your Body

Gut microbiome disruption. Ultra-processed food is deficient in dietary fiber, the primary substrate for beneficial gut bacteria, and rich in refined sugars, artificial sweeteners, and emulsifiers that directly alter microbial composition. Higher UPF consumption is associated with decreased microbial diversity, depletion of beneficial species including Akkermansia muciniphila and Faecalibacterium prausnitzii, increased pro-inflammatory microorganisms, elevated intestinal permeability, and systemic endotoxemia via lipopolysaccharide translocation, all of which propagate the chronic low-grade inflammation that sustains and advances insulin resistance (Zinöcker and Lindseth, 2018; Nutrients, 2025).

Disrupted appetite and satiety signaling. The Hall randomized controlled trial, published in Cell Metabolism in 2019, is the only inpatient RCT that has directly tested whether UPF drives overconsumption independently of nutrient content. Twenty adults were randomized to two-week periods of ultra-processed or unprocessed diets matched for presented calories, energy density, sugar, fat, fiber, and macronutrient composition. Ad libitum intake was approximately 500 kcal per day higher on the ultra-processed diet. Body weight changes tracked directly with caloric intake differences. The only variable that differed between conditions was the degree of processing. This is proof-of-concept evidence from a controlled experiment: small sample size (n=20), short duration (two weeks), primarily younger adults.

Addictive overconsumption. Hyperpalatable ultra-processed food engages the brain’s reward system in ways that structurally parallel addictive substances: rapid delivery of reinforcing stimuli, short-lived reward driving repeated consumption, tolerance effects requiring increasing quantity to achieve the same hedonic response. The published addiction science literature now explicitly frames UPF as addictive.

Displacement. Approximately 70% of packaged food on US grocery shelves is ultra-processed. Americans overall derive 55% of their daily calories from UPF. Children derive 61.9%, with children aged 6–11 at 64.8% the highest intake of any age group (CDC Data Brief No. 536, August 2025, NHANES 2021–2023). The fiber, phytonutrients, intact food matrix, and prebiotic substrates of whole food are simply absent from the diet.

The epidemiological evidence. A systematic review and meta-analysis of 207,291 participants across seven prospective cohort studies found UPF consumption associated with a 21% increased risk of all-cause mortality, a 50% increased risk of cardiovascular disease mortality, and a 66% increased risk of heart disease mortality. Separate meta-analyses found UPF consumption associated with a 15–53% higher risk of developing type 2 diabetes and a significantly elevated risk of metabolic syndrome across cross-sectional and cohort study designs. All large-scale outcome evidence is strictly observational.

Your First Step Out

The rest of this series will address dietary patterns in detail. For now, three simple substitutions to start with today.

Instant mashed potatoes, replaced by potatoes. The food matrix remains intact, industrial starch, flavoring agents, emulsifiers, and sodium phosphates in the packet are gone.

Instant oatmeal, replaced by old-fashioned or steel-cut oats. Instant oats are pre-cooked and rolled thin to accelerate cooking and digestion. Steel-cut oats require 20 minutes; old-fashioned rolled oats require five. Add your favorite natural flavoring yourself.

Flavored fruit yogurt, replaced by plain Greek yogurt with fresh or frozen fruit. A standard flavored yogurt contains 12–20 grams of added sugar per serving. Plain Greek yogurt contains none, and the fruit you add provides the food matrix that the fruit puree concentrate in the cup has already destroyed.

These substitutions are meant as illustrative examples of how you can start moving away from UPF. Each one reduces your daily UPF exposure, preserves food matrix, and consume food your biology was originally built to process.

That is how lifestyle modification works: not a complete overhaul in one day, instead one substitution at a time, sustained over months and years.

On future articles in the series we visit diet modification in detail, for now cutting back on ultra-processed foods is the first strategy you can start implementing today.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.

This piece is an account of decades spent inside the profession witnessing our collective failures. This indictment is self-inclusive, treated with the same intellectually honest standard I have strived for elsewhere.

Nothing that follows changes a fundamental truth: the majority of physicians entered medicine to serve patients and continue doing so despite increasing constraint, diminishing authority, and mounting personal cost. It provides accountability the profession at large.

The Original Sin

Cost-plus reimbursement, the dominant payment model through much of the postwar period, rewarded volume, duration, and expenditure without reference to outcome. A portion of the profession responded with excess: extended hospital stays, procedures without clear indications, frequency of follow-up appointments for stable conditions. The payment reforms that followed were institutional responses to physician-driven cost inflation.

Cesarean Section Explosion

The cesarean section rate climbed from approximately 5% in 1970 to over 32% today. The mechanism is documented in peer-reviewed literature: when fertility declined through the 1970s and early 1980s, reducing obstetricians’ volume of vaginal deliveries, cesarean rates increased in direct proportion. A nationally representative dataset shows a strong within-state correlation between fertility decline and cesarean rate increase during this period, consistent with an induced demand model (Gruber and Owings, RAND Journal of Economics, 1996). Women delivering at hospitals generating higher profit per cesarean procedure were significantly more likely to undergo cesarean delivery than women at lower-profit hospitals (JAMA Network Open, 2021, PMC7980096).

The American College of Obstetricians and Gynecologists has itself stated that the rapid increase in cesarean rates without concomitant improvement in maternal or neonatal outcomes raises significant concern about cesarean delivery overuse.

Multiple drivers beyond profit operate simultaneously: liability fear, patient preference, scheduling convenience.

If you enjoy evidence-based medical information, subscribe to receive these articles delivered to your mailbox every week.

Subscribe now

The Reactive Response

When reimbursement model changed, the profession adapted. The RVU architecture undervalued primary care rewarding procedures instead. The response in many practices was to compress encounter time and increase daily patient throughput. This “assembly-line” practice was a choice made by physicians responding to financial pressures.

The consequence for patients was abbreviated encounters with reduced depth of clinical engagement, and the erosion of the therapeutic relationship.

The Ownership Conflict

Other practices adopted a different model in response to the financial pressures.

Physician ownership of ancillary services creates a direct and financial conflict of interest. The physician who owns in-house laboratory equipment, imaging technology, stress testing facilities, DEXA scan units, or ECG and X-ray equipment has a financial incentive to order more of these services. Physician-owned facilities order significantly more ancillary services than non-physician-owned ones for identical patient populations (Medicare Payment Advisory Commission, MedPAC, 2005; Iglehart, New England Journal of Medicine, 2005).

The federal government recognized this conflict of interest as consequential enough to require legislative response. The Stark Law was the result: it prohibits physician self-referrals for Medicare and Medicaid designated health services.

As a result other arrangements were developed for continued capture of economic benefits from self-referral while technically complying with the law. Some of those include: management services organizations, indirect compensation arrangements, and space and equipment rental structures. Those represent legally creative efforts pushing the limits of the law.

Defensive Medicine Costs

The threat of liability for failing to order a test, to refer, or to pursue an intervention a patient demanded, contribute to measurable costs increases through over utilization.

The most conservative peer-reviewed estimate puts defensive medicine costs at approximately $46 billion annually, representing roughly 2.9% of total healthcare spending at the time of measurement (Mello et al., Health Affairs, 2010). Nine out of ten physicians in a national survey reported practicing defensive medicine (Jackson Healthcare, 2010). In a Massachusetts study of internists, 27% of CT scans, 16% of laboratory tests, and 14% of hospital admissions were reported as ordered due to concerns about liability rather than clinical indication (BMJ Quality and Safety, 2014, PMC4231873).

Defensive medicine takes two forms:

• Assurance behavior: ordering additional services to document clinical thoroughness and reduce liability exposure. I admit being guilty of this practice.

• Avoidance behavior: declining high-risk procedures or clinical situations where liability exposure is elevated, producing access problems in obstetrics, neurosurgery, and emergency medicine.

Fragmentation as Professional Culture

The expansion of subspecialty referral has contributed to patient care fragmentation. The drivers are multiple: liability fear, the RVU undervaluation of primary care work, time pressure, and, in some cases, the financial architecture of referral relationships within physician networks.

The result: complex patient accumulates multiple specialists, medication lists grow, testing is duplicated across specialties with no coordinating clinician tracking the entire picture.

The Continued Medical Education Industry

Approximately 28,000 to 46,000 active peer-reviewed medical journals now exist worldwide. Collectively they publish between 1.8 and 3 million articles annually. PubMed adds approximately 800,000 to 1 million new citations per year. A physician attempting to maintain current knowledge across even a single specialty would need to read dozens of relevant articles daily, across hundreds of distinct journals.

Many busy physicians, myself included, depend on formal CME programs and digest publications to maintain professional competency. Many of these are partially or totally funded by device manufacturers, pharmaceutical companies or healthcare systems. They usually concentrate on education promoting drugs over non-financially viable treatments, and limit discussion of emerging non-commercial alternatives. They drive physician behavior and become the basis for the accepted standards of care that effectively govern the practice of medicine.

CME industry sponsorship accounts for approximately 50–65% of total CME revenue in the United States, representing more than $1 billion annually from pharmaceutical and device manufacturers (Lexchin, Canadian Family Physician, 2006, PMC2231419; Lexchin and Sekeres, Canadian Family Physician, 2014, PMC4131951). The industry estimates it recoups $3.56 in increased sales for every dollar invested in CME.

Sponsored CME increases prescribing rates for the sponsoring company’s products. In one analysis, positive clinical effects of the sponsoring drug were mentioned 2.5 to 3 times more often than competitor drugs during sponsored educational sessions (Bowman and Pearle, Journal of Continuing Education in the Health Professions, 1988). Physicians who interact more frequently with industry sponsored CME have poorer prescribing habits and lower rates of evidence-based guideline adherence (Avorn and Shostack, Circulation, 2010).

The Case of Oxycontin

Between 1996 and 2002, Purdue Pharma sponsored more than 20,000 educational programs disseminating information that misrepresented OxyContin’s addiction risk. These programs were funded by the pharmaceutical company, led by industry-sponsored physicians, and accredited by professional bodies. OxyContin sales grew from $48 million in 1996 to $1.1 billion in 2000.

The educational programs were a covert promotional strategy, the epidemic that followed was the public health consequence.

Accountability Without Absolution

The majority of physicians choose medicine to serve patients despite existing systemic limitations. Nothing in this piece is meant to diminish the genuine dedication and sacrifices most of them bring to patient care.

Is meant as an intellectually honest acknowledgment of the profession’s failures, as well as my own. A well overdue reckoning of our collective participation in the healthcare system’s failures.

Found this article useful? Share your thoughts. Join the conversation below.

Educational content on The Metabolic Archives is free, because medical information should be accessible to everyone. If you find value and want to support the work, a paid subscription is available and genuinely appreciated. Visit the About Page for additional information.

Subscribe now

© 2026 The Metabolic Archives. All rights reserved.